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INTEGRATIVE ANALYSIS OF OMICS DATA IN ADULT GLIOMA AND 
OTHER TCGA CANCERS TO GUIDE PRECISION MEDICINE 
 
Xin Hu, M.S. 
Supervisory advisor: Roel Verhaak, Ph.D. 
Transcriptomic profiling and gene expression signatures have been widely applied as 
effective approaches for enhancing the molecular classification, diagnosis, prognosis or 
prediction of therapeutic response towards personalized therapy for cancer patients. Thanks 
to modern genome-wide profiling technology, scientists are able to build engines leveraging 
massive genomic variations and integrating with clinical data to identify “at risk” individuals 
for the sake of prevention, diagnosis and therapeutic interventions. In my graduate work for 
my Ph.D. thesis, I have investigated genomic sequencing data mining to comprehensively 
characterize molecular classifications and aberrant genomic events associated with clinical 
prognosis and treatment response, through applying high dimensional omics genomic data 
to promote the understanding of gene signatures and somatic molecular alterations 
contributing to cancer progression and clinical outcomes. Following this motivation, my 
dissertation has been focused on the following three topics in translational genomics. 
 
1) Characterization of transcriptomic plasticity and its association with the tumor 
microenvironment in glioblastoma (GBM). I have integrated transcriptomic, genomic, protein 
and clinical data to increase the accuracy of GBM classification, and identify the association 
between the GBM mesenchymal subtype and reduced tumor purity, accompanied with 
increased presence of tumor-associated microglia. Then I have tackled  the sole source of 
microglial as intrinsic tumor bulk but not their corresponding neurosphere cells through both 
transcriptional and protein level analysis using a panel of sphere-forming glioma cultures 
and their parent GBM samples. Furthermore I have demonstrated my hypothesis through 
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longitudinal analysis of paired primary and recurrent GBM samples that the phenotypic 
alterations of GBM subtypes are not due to intrinsic proneural-to-mesenchymal transition in 
tumor cells, rather it is intertwined with increased level of microglia upon disease recurrence. 
Collectively I have elucidated the critical role of tumor microenvironment (Microglia and 
macrophages from central nervous system) contributing to the intra-tumor heterogeneity and 
accurate classification of GBM patients based on transcriptomic profiling, which will not only 
significantly impact on clinical perspective but also pave the way for preclinical cancer 
research. 
 
2)  Identification of prognostic gene signatures that stratify adult diffuse glioma patients 
harboring 1p/19q co-deletions. I have compared multiple statistical methods and derived a 
gene signature significantly associated with survival by applying a machine learning 
algorithm. Then I have identified inflammatory response and acetylation activity that 
associated with malignant progression of 1p/19q co-deleted glioma. In addition, I showed 
this signature translates to other types of adult diffuse glioma, suggesting its universality in 
the pathobiology of other subset gliomas. My efforts on integrative data analysis of this 
highly curated data set using optimized statistical models will reflect the pending update to 
WHO classification system of tumors in the central nervous system (CNS). 
 
3) Comprehensive characterization of somatic fusion transcripts in Pan-Cancers. I have 
identified a panel of novel fusion transcripts across all of TCGA cancer types through 
transcriptomic profiling. Then I have predicted fusion proteins with kinase activity and hub 
function of pathway network based on the annotation of genetically mobile domains and 
functional domain architectures. I have evaluated a panel of in frame gene fusions as 
potential driver mutations based on network fusion centrality hypothesis. I have also 
characterized the emerging complexity of genetic architecture in fusion transcripts through 
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integrating genomic structure and somatic variants and delineating the distinct genomic 
patterns of fusion events across different cancer types. Overall my exploration of the 
pathogenetic impact and clinical relevance of candidate gene fusions have provided 
fundamental insights into the management of a subset of cancer patients by predicting the 
oncogenic signaling and specific drug targets encoded by these fusion genes.   
 
Taken together, the translational genomic research I have conducted during my Ph.D. study 
will shed new light on precision medicine and contribute to the cancer research community. 
The novel classification concept, gene signature and fusion transcripts I have identified will 
address several hotly debated issues in translational genomics, such as 
complex interactions between tumor bulks and their adjacent microenvironments, prognostic 
markers for clinical diagnostics and personalized therapy, distinct patterns of genomic 
structure alterations and oncogenic events in different cancer types, therefore facilitating our 
understanding of genomic alterations and moving us towards the development of precision 
medicine. 
 
 
KEYWORDS 
Cancer genomics, Omics data mining, Transcriptomics profiling, Gene signature, Risk 
prediction, Tumor microenvironment, Precision medicine, Glioma, Pan-cancer, Fusion 
transcripts, Genomic rearrangement, Next-generation sequencing, Prediction model    
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CHAPTER 1 
INTRODUCTION 
1.1 Promise of next generation sequencing (NGS) data applied in precision medicine  
1.1.1 Big (NGS) data brings the promise of precision medicine to clinical oncology 
The molecular classification of cancer based on next generation sequencing (NGS) has built 
the foundation for more precision drug development. Taking advantage of genomic 
sequencing technologies, scientists are able to decipher complex features of an individual’s 
cancer genome, determine the risk factors for prognosis and tailor targeted therapies based 
on gene signatures and genomic variants. In the genomic era, the paradigm of clinical 
oncology is largely shifting from empirical, retrospective diagnosis with uniform treatment 
strategies to mechanism-based diagnosis and treatment driven by molecular diagnostics 
and risk based individualized regimens. For instance, a meta-analysis of 570 phase II 
clinical trials involving 32,149 patients demonstrated that patients whose treatment was 
selected based on the molecular characteristics of their tumor exhibit significantly better 
outcomes.(Schwaederle, Zhao et al. 2015)  Applying advanced genomic sequencing, the 
Oncotype DX® breast cancer test has efficiently identified patients with higher likelihood of 
response to chemotherapy in both pre-invasive stage (DCIS) and invasive breast cancer 
with 600,000 cases examined across more than 90 countries, demonstrating the power of 
personalized medicine by taking account of genomics as a critical part of clinical decision 
making for oncologist. The Cancer Genome Atlas (TCGA) network has sequenced more 
than 11,000 tumors across 34 cancer types, including the identification of germ-line and 
somatic aberrations (SNVs), DNA copy number alterations, fusion events, differential DNA 
methylation, and transcriptomic classification. (Martinez-Ledesma, de Groot et al. 2015)  
 
1.1.2 The challenge of leveraging cancer genomics in personalized medicine 
1 
 
Regarding profiling based assignment of cancer therapeutics, while stratifying patients and 
developing targeted therapies based on genomic biomarkers, scientists and clinicians still 
face challenges regarding specimen acquisition and heterogeneity. Somatic mutation, clonal 
selection and genetic drift are the basic processes shaping cancer evolution, the 
relationships between sample sizes, mutation frequency / rate and predictability create a 
complex and non-monotonic milieu. Time-to-event predictability is more difficult in tumors 
with limited mutational burdens due to stochastic mutation generation and drift events. The 
development of an integrative cancer evolutionary framework using refined computational 
modeling is of critical importance in order to obtain accurate predictions. The predictive 
models need to incorporate the spatial constraints in tumor samples with optimal sampling 
approaches and input parameters dependent on the variability of the tumor, such as growth, 
metastasis and driver events. Nevertheless, cancer evolution processes influenced by 
stochastic effects on the entire clonal composition will still influence the predictive power in 
clinical scenario. (Lipinski, Barber et al. 2016) In addition, passenger mutations are 
“collateral damage” resulting from genomic instability and are not required for maintaining 
the transformed phenotype, therefore are “noise” in the predictive system, and since most 
cancers are rapidly evolving biologic entities, major challenges remain to sort out “drivers” 
from “passengers”, and these events may change over time. Driver mutations in the 
signaling pathways affect highly integrated “wiring” comprised of multiple signal transduction 
flows. Perturbation of a single component of a regulatory network will lead to activation of 
other components due to feedback activation or loss of feedback repression, which can 
contribute to drug resistance. It should be noted that many novel epigenetic drivers are not 
currently targetable with available drugs. Determining trial designs and endpoints are also 
challenges aspects for precision medicine. Other practical challenges for moving precision 
oncology into cancer care include, improving sequencing platforms, designing clinical utility, 
and exploring novel perspectives. There are also ethical and social issues, such as patients’ 
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consent for cancer genetic testing, genomic/genetics test result confidentiality and 
disclosure, insurance costs for pharmaco-genomic testing, and combined targeted 
therapeutic regimens for cancer patients. (McGowan, Settersten et al. 2014) 
 
1.2 NGS technology promoted advances in our understanding of cancer genomes  
Over the last decade, rapid advances in cancer genomics have shed new lights on cancer 
biology, promoting comprehensive understanding at a systematic level of the disease and 
unraveling the multi-dimensional landscapes of aberrant genomic structures that contribute 
to cancer progression, which has led to novel perspectives for managing the disease 
(Samantarrai, Dash et al. 2013). NGS has been broadly applied for genome, epigenome 
and transcriptome sequencing. NGS outperforms traditional genetic test for its accuracy, 
sensitivity and efficiency, and it has proven mature enough for routine diagnostic use in 
many laboratories. Next-generation sequencing encompasses worldwide collaborative 
efforts, such as The Cancer Genome Atlas (TCGA) and International Genome Consortium 
(ICGC) projects, to characterize the genomic landscape and transcriptomic subtypes of 
thousands of cancer genomes across various cancer types. These discoveries lead to new 
fundamental understanding of disease pathogenesis. Molecular profiling has also been 
established for the identification of unique somatic mutations and gene signatures that 
accrue in cancer cells. Cancer genomic technology in turn has evolved to facilitate 
molecular profiling, enabling the assessment of all potential causative or predictive genes in 
panels using targeted sequencing, especially using circulating tumor ctDNA to noninvasively 
identify cancer biomarkers for early detection (Cortesi, Palleschi et al. 2015). Since most 
common clinical oncology phenotypes show diverse responses to the same therapy 
regimens in patients with equivalent diagnose, it is conceivable to have both their germline 
and cancer genomes sequenced for each patient to facilitate rationally guided molecular 
therapies, thanks to the updated NGS technology, allowing several genomes to be 
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sequenced simultaneously using one affordable instrument run by one scientist within 10 
days. Thus, by integrating traditional pathologic diagnosis with other approaches such as 
molecular imaging, NGS technology allow us to treat each genetic abnormality as an 
independent variable. Given thousands of variables for each patient, we can 
comprehensively integrate genomic information and clinical phenotypes with new trial 
designs and statistical methods (Meldrum, Doyle et al. 2011, Gagan and Van Allen 2015) 
(Katsios, Ziogas et al. 2012) (Boerno, Grimm et al. 2010) (Barbieri, Demichelis et al. 2012) 
(Roukos 2010, Roychowdhury and Chinnaiyan 2016) Moreover, with revolutionized NGS 
technology, emerging advances in cancer genomics may change the strategy for current 
surgical oncology practice as well (Roukos 2011). Since treatment decisions such as 
complete tumor resection with or without adjuvant radio/chemo therapy depends on cancer 
type and stage, genome sequencing in cancer patients could systematically assess the 
complex nature of cancer initiation and metastasis, with widespread variability of somatic 
mutations, genomic rearrangements and copy-number changes, and these alterations in 
turn deregulated signaling pathways. Therefore the genomic features will ultimately 
determine the molecular classification of patients associated with their clinical-pathologic 
status.  
 
1.3 Molecular classification and potential clinical implications in cancer   
Cancer is a biologically heterogeneous disease, which is reflected by complex etiological 
pathways that drive tumor evolution, and the network of signaling pathways could be 
potentially modulated by distinct genetic/ epigenetic and transcriptional / translational 
alterations. Therefore understanding of molecular heterogeneity could facilitate clinical 
management and cancer prognosis, and intra-tumor heterogeneity of genetic aberrations 
could classify discrepancies in the validation of oncologic biomarkers, and treatment 
resistance (Eder and Kalman 2014). Cancer diagnosis is traditionally based on histological 
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examination and in the precision medicine era, it is crucial to accurately stratify patients by 
integrating genomic and histological diagnosis. A series of molecular diagnostic tests have 
been developed based on intrinsic gene signatures incorporated into the histopathological 
classification systems for different types of cancer. (Vitucci, Hayes et al. 2011) (Francis, 
Namlos et al. 2007) 
Scientists have made many efforts to characterize the correlation of molecular 
subtype and phenotypes for cancer, towards a better understanding of cancer development 
and individual risk prediction, and guiding early detection, clinical decisions and prevention 
from recurrence in more informative manners than the traditional “wait and see” approach. 
(Kocarnik, Shiovitz et al. 2015)  (Aine, Eriksson et al. 2015, Prat, Pineda et al. 2015, Chen, 
Xu et al. 2016) The profiling of cancer has yielded a number of genetic, epigenetics (DNA 
methylation), mRNA, microRNA expression, proteomic, metabolic, and imaging biomarkers 
for molecular classification, facilitated by next-generation sequencing. As a matter of fact, 
molecular classification has already been successfully implemented in many types of cancer, 
such as classification of EGFR / ALK positive non-small-cell lung cancers, subtyping of 
luminal A/B estrogen receptor-positive breast cancer, classification of WNT pathway and 
Sonic Hedgehog pathway medulloblastomas. The efficiency of molecular classification 
facilitating accurate diagnosis and combination chemo-radiation therapy for cancer is 
apparent, such as molecular classification of pheochromocytomas and gastrointestinal 
stromal tumors using 92-gene assay in metastatic lesions and primary patients (Greco 2013, 
Brachtel, Operana et al. 2016) Overall, previous studies suggest that molecular profiling 
based classification outperforms current pathology-based systems in terms of clinically 
relevance.(Hoadley, Yau et al. 2014) 
 
1.4 Linking the tumor microenvironment (TME) with cancer molecular classification 
5 
 
1.4.1 The tumor microenvironment (TME) is a pathological driver that modulates 
tumor evolution 
The tumor microenvironment (TME) plays critical roles in multiple 
spatial and temporal genomic alterations, particularly during immune-invasion and distal 
metastasis, which commonly lead to treatment resistance (Sun 2016). The essential 
functional components in the stroma from typical TME include neuroendocrine cells, 
fibroblasts, immune and inflammatory cells, myofibroblasts, blood /lymphatic vascular 
networks, adipose cells and extracellular matrix (ECM).(Razavi, Lee et al. 2016) The stroma 
could suppress tumorigenesis in its native status and is a predictor for favorable longevity 
(Elkhattouti, Hassan et al. 2015), yet when stroma was transformed into tumor-associated 
neighbor components by various  angiogenic and/or inflammatory stimuli, it exhibit adverse 
effects and significantly promote cancer progression, thereby the status and functionality of 
TME have substantial impacts on the clinical decision for frontline therapeutic 
interventions.(Chen, Zhuang et al. 2015) For example, stroma-mediated drug resistance 
through regulating innate immune response, tumor infiltration and vascular permeability 
were reported in animal models of breast cancer.  (Nakasone, Askautrud et al. 2012) And 
cancer-associated fibroblast (CAF) mediating the resistance to EGFR inhibitor erlotinib 
through inducing epithelial to mesenchymal transition (EMT) was previously reported in lung 
cancer. (Choe, Shin et al. 2015) In addition, stromal cell-mediated mitochondrial redox 
adaptation was described to regulate drug resistance in childhood acute lymphoblastic 
leukemia (ALL). (Liu, Masurekar et al. 2015) 
 
1.4.2 The immune classifications of tumors and precision immunotherapy targeting 
immune microenvironments (TME) 
Associations between the cellular composition of the tumor microenvironment and genomic 
features of the tumor are emerging. Dissecting the microenvironment of tumor molecular 
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subgroups could facilitate the prediction of disease progression or response to 
immunotherapies. Cancer cells are intertwined with a tumor microenvironment comprised of 
stromal cells (e.g. endothelial cells, fibroblasts and ectodermal stem cells) and immune cells 
in a complicated interactive manner. This interaction could determine the clinical outcome of 
cancer progression and response to therapy. For example, the adaptive immune system 
with high activity of cytotoxic and memory T cells could regulate tumor growth and 
metastasis, and this immune signaling could lead to favorable patient prognosis in colorectal 
cancer (CRC) (Markman and Shiao 2015). Other adaptive immune cells such as type I T 
helper (Th1) lymphocytes could activate both cytotoxic T cells and B-lymphocytes, 
which  secrete  antibodies attacking tumor (Fridman, Pages et al. 2012). Lymphocytes 
forming aggregates surrounding the tumor (Jiang, Mason et al. 2013, Ladanyi 2013) that 
mediate systemic immune responses have also been reported in non-small-cell lung cancer. 
These findings demonstrated the potential of immune response to translate into the clinics, 
such as immune checkpoint inhibitors stimulating cytotoxic T cells activity demonstrated 
favorable clinical responses in patients with advanced grade of malignancy. Bodies of 
evidence have demonstrated the association between the constitution of the tumor 
microenvironment and a patient’s prognosis, and more noteworthy, some of these 
components in the tumor microenvironment can be therapeutically targeted. With distinct 
correlation between tumor infiltrated cellular compositions and their genomic features, as 
well as response to immunotherapy, it is of paramount importance to analyze the 
microenvironment associated with tumor molecular subgroups and develop corresponding 
multi-dimensional tumor classification systems to select the responders and tailor the 
treatment regimens. Several types of cancer have been classified into molecularly 
homogeneous subgroups, such as GBM, LGG, colon cancer, breast cancer, and so on. 
Overall these subtypes are established through unsupervised classification of 'omics' data, 
based on the distinct molecular signatures that link genomic features and clinical 
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characteristics of the patients. This strategy was also applied to dissect the relationship 
between molecular subtypes and their associated immune microenvironment in diverse 
cancer types. For example, applying transcriptomic profiles from infiltration of immune and 
stromal cellular components identified molecular subgroups of clear-cell renal cell carcinoma 
(ccRCC) (Remark, Alifano et al. 2013) This study revealed that various immune cellular 
components in the tumor microenvironment are influenced by the metastasis derived 
malignant cells adjacent to the same surrounding pulmonary tissues and suggested 
essential roles of metastasis-deriving malignant cells in modulating the tumor immune 
microenvironment, and indicated significant correlation between the tumor molecular 
signature and their immunological features. This finding also implied that the originating anti-
tumor cells could exhibit suppressed activity accompanied with co-expression of checkpoint 
molecules in a highly inflammatory microenvironment, suggesting that the potential 
responders to PD-1 pathway inhibition are enriched in some molecular subgroup of ccRCC.  
It was also well documented that pro-tumorigenic inflammation signals could regulate 
the immune system to restore homeostasis disruption, such as infections or wound healing. 
Tumor cells acquired the innate capacity to decay inflammatory signals and produce 
excessive mutagens, angiogenic growth factors and activate  extracellular matrix 
remodeling and collagen turnover pathways (Candido and Hagemann 2013). Inflammation 
plays a critical role by suppressing acquired anti-tumor immune responses via stimulating 
MDSC (myeloid-derived suppressor cells), regulatory T cells, and immunosuppressive 
factors such as transforming growth factor (TGFß). One of the strategies of pharmaco-
genomic development of tailored immunotherapies is to simultaneously restore the adaptive 
immune response and dampen the pro-tumor inflammatory response, underscoring the 
translational value of dissecting the tumor microenvironment to integrate molecular 
classification of both immune and intrinsic tumors.  
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Another striking example was revealed by the stromal and immune classification of 
colorectal cancer, which was significantly correlated with established subtypes of the tumor. 
(Becht, Giraldo et al. 2015) A novel 'immune-high' subgroup of CRC, is in alignment with 
poor-prognosis mesenchymal subgroup that expressed the genes triggering adaptive 
immune response and checkpoint molecules. Tumors in this subtype were also infiltrated 
with macrophages, increased angiogenesis, high expression of inflammatory genes and 
fibroblast infiltration, plus abundant immunosuppressive factors such as TGFß. This study 
suggested that increased inflammation could break the cytotoxic cells activity in the 
colorectal cancer (CRC) mesenchymal subtype, therefore anti-angiogenic and anti-
inflammatory treatments, combined with checkpoint inhibitors, such as anti-PD-L1/2, could 
simultaneously damp inflammatory signaling and restore cytotoxic T-cell functionality. These 
treatment strategies will be beneficial for CRC patients in this subgroup.  
Noteworthy, another independent study showed that overall mutational load is 
associated with beneficial response to PD-1 blockage in non-small cell lung cancer (Rizvi, 
Hellmann et al. 2015, Van Allen, Miao et al. 2015). This further proved the antigenicity to 
trigger an adaptive immune response in the tumor microenvironment, which maybe a major 
driver in response to the checkpoint inhibitors, is tightly associated with somatic non-
synonymous mutations and cytotoxic orientation of the microenvironment. 
Taken together, these previous discoveries have proved the tight association 
between genomic features and immune classifications of tumors, and the relevance for 
precision immunotherapy targeting different immune microenvironments. 
 
1.5 The implications of cancer heterogeneity on molecular classifications 
A series of studies demonstrated both intra-tumor heterogeneity (cellular heterogeneity 
within individual tumors) and inter-tumor heterogeneity (cancer subtypes) have significant 
implications on the prognosis, response to therapy and progression with resistances. For 
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instance, a number of drugs for targeted therapy are conducted for clinical trials in patients 
diagnosed with metastatic colorectal cancer (mCRC), through stratifying the patients based 
on distinct intrinsic tumor subtypes of colorectal cancer while integrating the degree of intra-
tumor heterogeneity could provide optimal clinical outcomes. Several lines of evidence 
revealed that intra-tumor heterogeneity, both hierarchical and stochastic, cause various 
responses to chemoradio-therapy, yet intra-tumor heterogeneity was not examined by 
generally known biomarker-based approaches. The fate of a drug combination for an 
individual patient, responsive or resistant, is largely determined by the genetic and 
epigenetic background, along with its tumor microenvironment in the clonal populations. The 
spatial distribution and crosstalk between tumor and stromal cells within the tumor 
microenvironment could dramatically affect their interactions, which consequently impact 
differentiation, proliferation, morphology and a variety of biological functions during tumor 
progression. Therefore in order to accurately predict response to chemotherapy, it is rational 
to take into account this clinical ‘global’ heterogeneity in terms of genomic and epigenomic 
features, tumor microenvironment and cellular architectures. Therefore ideally classification 
of cancer patients should consider inter-individual heterogeneity with “unique tumor 
principles” including exogenous stimuli and endogenous factors in each patient, where the 
endogenous factors refer to patients’ epigenomic, genomic and metabolic background, and 
the exogenous factors refer to lifestyle, dietary intake and environmental exposure, which 
collectively act as external stimuli in signaling pathways and modulate the innate tumor 
properties.  
 
1.6 Towards personalized therapy for patients with glioma 
Glioma describes tumors that arise from the supportive glial tissue of the brain and spinal 
cord. Depending on the cell of origin, including oligodendrocytes, astrocytes and ependymal 
cells, glioma is categorized as astrocytoma, oligoastrocytoma (mixed gliomas) and 
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ependymoma. WHO grades of gliomas are based on their growth rate, with grade 1 showing 
slowest growth and grade 4 showing aggressive growth). Low-grade gliomas (WHO grade II) 
refer to those which are highly-differentiated (neither anaplastic nor benign) but exhibit 
favorable prognosis in general. In contrast, high-grade (WHO grade III-IV) glioma refer to 
undifferentiated (anaplastic) glioma with dismal prognosis. Grade IV glioma (or glioblastoma, 
GBM) is the most fatal glioma and the overall prognosis remains dismal, with a median 
survival time of only 12-15 months. 
Combined therapies with surgical resection, temozolomide (TMZ) and radiotherapy 
have been established as standard treatment and have improved clinical outcomes for 
patients diagnosed with glioblastoma. Optimal management requires a multidisciplinary 
approach with both in depth understanding of tumor progression and the mechanisms of 
actions in the treatment. Thanks to integrated sequencing and bioinformatics strategies, 
advances in the investigation of epigenomic and genomic alterations and molecular 
classifications of glioma have provided improved understanding of the genomic features and 
biological relevance of the disease. (Verhaak, Hoadley et al. 2010, Cancer Genome Atlas 
Research, Brat et al. 2015, Ceccarelli, Barthel et al. 2016) Molecular biomarker-driven 
strategies that modulate the function of “actionable molecular targets” have been used in 
clinical trials over the past several decades. Nevertheless, single “one size fits all” targeted 
treatment has yielded limited clinical efficacy in glioblastoma to date, due to lack of accurate 
tumor imaging, complex tumor heterogeneity, and pharmacodynamics / pharmacokinetic 
failures. For example, MGMT promoter methylation is significantly correlated with TMZ 
response and clinical benefit, yet other molecular biomarkers associated with therapeutic 
response remain to be explored in GBM.  
Given the phenotypic, genomic and clinical heterogeneity, it is necessary to conduct 
a biomarker -based selection of therapeutic regimens for GBM patients, and apply whole-
exome, transcriptome or gene expression profiles that collected from a patient's specimen to 
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build predictive models based upon multidimensional profiles, administrate with multiple 
agents that show better prognosis in prospective clinical trials. And importantly, it is 
important to collect multiple biopsies of GBM patients from different disease loci upon 
surgery dissections, including both infiltrative and non-infiltrative regions of tumor, and 
perform extensive genome-wide profiling and select individualized drug combinations with 
multiple agents that are predicted to eliminate actionable targets within the residual, diffused 
areas of malignant lesion. When feasible, matched samples from individual patients upon 
relapse should be collected to validate the strategy and assess the drug resistance.(Kim, 
Zheng et al. 2015) In addition, given the increasing options of clinical targets, a more rapid 
screening process is needed, along with larger patient population to design small, efficient 
trials to discern early efficacy signals. 
First, we should integrate genomic profiling including copy numbers, somatic 
mutations and transcriptomic profiling to deduce the molecular signatures of GBM, then 
create simulation-based model to predict rational combinations of FDA-approved targeted 
agents through incorporating comprehensive disease pathophysiological information with 
"actionable" genomics data, to generate personalized regimens and validate these 
responses in ex-vivo testing, which is proved to be an important step towards clinical 
translation to design rational, precision drug combinations for GBM. For instance, based on 
the molecular features of GBM from one patient, in-silico simulation could predict the 
inhibitors of PI3K and mTOR pathways to be effective against this tumor. 
 
1.7 Supervised learning for personalized medicine 
1.7.1 Supervised learning methods predicting output values from high-dimensional 
datasets  
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Supervised learning processes perform learning the relation between two variables: 
observed variable x and predicted variable y, usually uses a 1D array of n samples to fit a (x, 
y) model and given observations X, predict (X) method returns the predicted y.   
The simplest classification and regression rule is k nearest neighbors (KNN), as non-
generalizing machine learning methods, given a new observation X, search for the 
observations  in the training set with the closest feature vectors (e.g., Euclidean metric 
functions). The principle underlying nearest neighbor methods is to obtain an optimized 
number of training samples close to the new observation, and predict the new label. 
Linear regression is most common method that fits a linear model to the training 
dataset by optimizing the parameters to minimize the sum of squared residuals from the 
model. When there are few data points available in each dimension (small sample size), 
high variance will be induced by noise from the observations. One regularized solution is to 
shrink the regression coefficients to zero to prevent overfitting. When two sets of randomly 
selected observations are likely to be uncorrelated, ridge regression is used to decrease the 
contribution of non-informative features and return corresponding non-sparse coefficients. In 
contrast, Lasso (least absolute shrinkage and selection operator), as a sparse penalization 
approach, could set some coefficients to zero in regularization path for feature selection 
purposes.  
Support Vector Machines (SVM) belongs to the discriminant model family. The goal 
is to build a hyperplane that maximize the margin between the two subgroups by selecting a 
subset of samples. Regularization is fine-tuned by a parameter C, where small 
value indicates the margin is calculated using all or most observations around the separating 
line (heavy regularization); whereas large value C indicates the margin is estimated based 
on those observations approximate to separating line (weak regularization). When two 
classes could not be separated linearly in feature space, SVM can build a decision function 
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using polynomial kernel tricks to create decision energy by positioning kernels on the 
observations.   
 
1.7.2 Survival analysis of high-dimensional covariates from cancer genomics 
International organizations such as International Cancer Genome Consortium (ICGC) and 
the Cancer Genome Atlas (TCGA) have produced multiple dimensional analysis at a variety 
of genome-scales, aiming at identifying novel cancer biomarkers to enable clinical cancer 
researchers to tailor the therapies and conduct personalized risk predictions through 
gathering massive amounts of epi/genomic data of cancer patients collected from multiple 
treatment centers, so called “bio-profiles”. High-dimensional issues arise as the number of 
genomic covariates from these datasets often far exceeded the sample size. Another 
challenge for survival analysis and feature selection is censored data are often observed 
rather than precisely measured time-to-event information.  In the past decades, a series of 
parametric and semi-parametric models were proposed to overcome these two challenges, 
including regularized Cox-regression models, regularized accelerated failure time models, 
supervised principal components, partial least squares, etc. Yet the efficiency of these 
models largely depends on the underlying assumptions. More recently, non-parametric 
machine learning algorithms became a focus of growing interest to deal with high-
dimensional issues. Ensemble based approaches, including boosting and random forests, 
are the most widely applied, albeit boosting with high dimensional censored data is not fully 
investigated. It was reported that a gradient boosting procedure fit smoothing splines to 
estimate proportional hazard models and identify non-linear effects of important variables 
(genes) from microarray data  that are correlated to the risk of any specific event (Li and 
Luan 2005).     
Since classical Cox regression method is used to select single biomarker, without 
considering strong correlation between those co-expressed genes, the network-based Cox 
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regression models (such as fastcox, AdaLnet and Net-Cox) were proposed to overcome 
such drawbacks, and permutation-based algorithms provided favorable validations on the 
selection of cancer signature genes involved in regulatory pathway/networks. (Iuliano, 
Occhipinti et al. 2016) Other regularization methods, including lasso and group lasso for 
sparse estimation were also designed for the sake of accurate prediction. In addition, these 
regularization algorithms demonstrated better performance when an additional simple 
procedure (e.g. Cox model) is initially applied to reduce the number of covariates.  
 
1.7.3 Feature selection for high dimensional regression using LASSO (Least Absolute 
Shrinkage and Selection Operator) algorithms  
High-dimensional data mining and feature selection are amongst the most challenging 
topics in modern statistics. The field of high-dimensional statistics spans a wide range of 
models including supervised methods in regression and classification models, as well as 
unsupervised approaches for clustering, multiple testing or graphical models (Buhlmann and 
van de Geer, 2011). One of the major statistical challenges with high-dimensional data 
mining is overfitting in regression where the number of variables far exceeds the number of 
observations (sample size). In these situations standard estimation methods, such as 
ordinary least square, failed in accurate prediction. Therefore, a wealth of efforts emerging 
to handle the high-dimensional regression, typically employing penalty based regularization 
for dimension reduction and/or feature selection. 
LASSO, proposed by Tibshirani in 1996, is the most popular method by far.  By 
construction, the lasso not only fits the regression model, it simultaneously performs variable 
selection by shrinking regression coefficients of unimportant variables to zero. So it is 
suitable for prediction and model construction, by producing a sparse solution and 
consequently extracting most important variables. Shrinkage is performed by placing a 
constraint on the size of the regression coefficients and adding a penalty term to residual 
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sum of squares, where penalty Jλ (| β j |) depends on tuning parameter λ that regulate the 
extent of the shrinkage, which take on various forms, typically involving λ | β j |r, where r refer 
to different methods, including ridge regression with a penalty Jλ (|β j |) = λ| βj |r with r = 2, 
lasso by assigning r = 1. All regularization methods depend on one or more tuning 
parameters controlling the model complexity including the number of variables preselected 
in subset selection, the number of derived inputs to use in principal components regression 
or the amount of shrinkage in shrinkage methods. It is critical to determine tuning 
parameters for model fitting and obtaining right balance between bias and variance to 
minimize prediction errors.  
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However, standard lasso regression model may be less efficient when underlying 
patterns of dataset are more complex. For instance, the effects of the covariates might 
deviate from linearity, or they might interact with each other or additional measurable 
quantities outside the data, confounding the prediction. In many situations, or given 
assumptions arising from relevant (biological) knowledge, the standard lasso might not be 
adequate to solve high dimensional problems. Consequently the standard lasso has been 
extended and modified to deal with more complex data structures that are hidden in high-
dimensional data sets. The adaptive LASSO, group LASSO and Elastic Net are the most 
prevalent methods developed in this regard.   
The adaptive LASSO (ALASSO) penalty applied a weighted penalty term that was 
introduced via the least - angle regression (LARS) algorithm; it yields consistent estimations 
on the parameters while keeping the convexity property of the lasso. The motivation is to 
favor predictors with univariate strength on regression coefficients and to avoid spurious 
selection of noise predictors, it uses univariate regression coefficients in place of full least 
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squares estimates when the number of features is far beyond the sample size. It recovers 
the correct model under milder conditions than does the lasso. The major advantage of 
ALASSO is the penalty terms are assigned to regression coefficients adaptively according to 
the importance of the corresponding covariates and it relies on neither censoring distribution 
nor baseline survival function.(Dai, Koutrakis et al. 2016, Raeisi Shahraki, Pourahmad et al. 
2016) 
In some statistical scenarios of regression with categorical predictors, the predictors 
belong to different pre-defined groups (e.g. genes functioning in the same biological 
pathway). The group lasso was designed to solve this problem by shrinking and selecting 
the elements from a group together. Standard group lasso algorithms use coordinate 
descent, and assume that the design matrix in each group is orthonormal and use simple 
soft-thresholding. If the size of each group is 1, it is exactly equivalent to the regular lasso 
solution. While the group lasso generates a sparse set of groups, when a group is included 
in the model, all coefficients in that group will be nonzero. For predictors with few levels it is 
reasonable to use the group lasso - sparsity within group is unnecessary as groups are 
small. As the number of levels per predictor rises, the sparse-group lasso show best 
performance by setting the coefficients for many levels equal to 0 even in nonzero groups, to 
reduce the predictors whose levels are less informative. (Liu, Wu et al. 2014, Wang and Xue 
2015) 
There are common situations with distinct correlations among the variables (e.g. co-
expression of genes belonging to the same molecular networks). The lasso penalty works 
less sensitively to those strong but correlated variables. Ridge algorithms are proposed to 
shrink the coefficients of correlated variables towards each other. The elastic net penalty is a 
compromise of both lasso and ridge solutions, in the form where the front term favors a 
sparse solution for coefficients of averaged features, the back term favors highly correlated 
variables to be averaged, consequently more than min (N, p) coefficients can be nonzero. 
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1.8 Fusion genes as an emerging target for precision medicine  
Genomic instability, structure rearrangement of the genome, in particular translocations, as 
well as non-structural rearrangement mechanisms (such as transcription read-through of 
neighboring genes or mRNA trans-splicing or cis-spicing), could lead to the formation of a 
large proportion of gene fusions, which collectively played important roles in tumor-initiating 
process. Therefore fusion genes could serve as potential biomarker for both diagnostic tools 
and therapeutic targets, due to their inherent expression in a subset of tumors. In general, 
the frequency of gene fusions varies between different cancer types and appears inversely 
correlated with the frequencies of other somatic mutations at both per cancer types and 
tumor samples. Kinase, DNA-binding domain and chromatin modifiers are often involved as 
one of the partners of chimeric genes, with many fusion genes fusing with only one other 
partner (Yoshihara, Wang et al. 2015). While the distributions of fusion events vary largely 
amongst different cancer types, delineation of fusion genes and their genomic features in 
multiple cancer types will provide more precise perspectives for precision therapies for those 
cancer patients.  
The rapid development of next generation sequencing (NGS) accompanied with 
novel computational models has exponentially facilitated the discovery of fusion genes in 
solid tumors, which include sarcoma, carcinoma and tumors in central nervous system, 
besides hematologic malignancies (Parker and Zhang 2013). Knowledge regarding the 
prevalence and function of gene fusions has been revolutionized, coinciding with the 
advances of NGS technology, bioinformatics algorithms and large-scale computational 
biology, though raising the issues in terms of driver oncogenic or passenger events encoded 
by these predicted fusions for cancer development. Several lines of studies have highlighted 
the fusion-driven oncogenesis that enriched with certain combinations of functional domains 
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encoded by fusion transcripts (Ortiz de Mendibil, Vizmanos et al. 2009) (Frenkel-
Morgenstern, Lacroix et al. 2012). The genomic hallmarks of oncogenic fusion genes 
revealed by public databases include the expression changes in fusion transcripts due to 
untranslated region (UTR)/ promoter swapping, protein-protein interaction interfacing with 
novel oncogenic functions, as well as other genomic features associated with replication 
timing, which could serve as the foundation for predicting oncogenic drivers of novel fusion 
events by referring to their common features with known fusions (Shugay, Ortiz de Mendibil 
et al. 2012).  
It is also important to explore the mechanisms through which fusion transcripts or 
proteins are precisely targeted for the sake of potential drug development. Prediction of the 
function of fusion products is non-trivial, through inferring the secondary structure/ domain 
architectures and regulatory elements of the parent protein and the interaction of the 
functional domains in chimeric proteins. Based on the structural features of fusion proteins 
revealed by a series of studies, those proteins form fusions tend to present fewer domains 
than other proteins, while fusion transcripts encode more domains than expected by chance; 
fusion proteins are more enriched at specific domains than randomly permuted arrangement 
would suggest; and increased intrinsic reorder in fusion proteins promotes viable joining of 
different constituent domains into flexible proximity for internal interactions.  
Identification of both common and rare gene fusions has numerous impacts on 
personalized clinical care. For example, the TMPRSS2-ERG fusion transcript functions were 
established as a urinary biomarker for prediction of localized prostate cancer recurrence 
after surgery (Leyten, Hessels et al. 2014) and KIF5B-RET gene fusions are discovered as 
a potential target for existing TKIs (vandetanib) in lung cancer (Kohno, Ichikawa et al. 2012).  
Fusion genes involving kinase gene fusions served as promising therapeutic targets due to 
their susceptibility to kinase inhibitors (Stransky, Cerami et al. 2014). And fusion genes 
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harboring histone methyltransferases were discovered as other attractive drug targets (Helin 
and Dhanak 2013).  
Yet there is still room to increase the specificity and sensitivity of fusion gene 
prediction, as well as functional characterization of these frequently oncogenic mutations, 
which will play important roles in elucidating disease processes across diverse tumor types. 
The pivotal advances in targeting therapy against fusion proteins harboring kinases and 
chromatin modifiers (Chen and Tseng 2014) (Kannan, Coarfa et al. 2015), pave a way for 
fusion transcripts as promising targets for future therapeutic avenues in genomic era.  
 
1.9 Motivations and Rationale of the studies in this thesis  
The sole purpose for cancer genomics is to advance personalized medicine through NGS 
sequencing and characterize the patient tumors based on genetic alterations associated 
with featured biological phenotypes, in order to develop more efficient prevention, diagnosis 
and treatment strategies corresponding to these genetic variables. Such study for future 
iterations will fuel more efficient designs of clinical trials in which patients are eligible for 
novel treatments based on their genomic profiling, molecular classification and predicted 
outcomes.  
However the accuracy of applying NGS data for risk prediction and patient 
stratification has been largely constrained due to many limitations, such as clinical sample 
detection, filter and annotation of the variants, computational and statistical algorithms, etc. 
For example, due to molecular heterogeneity and anatomic diversity of cholangiocarcinoma 
(CCA), the subtypes of cholangiocarcinoma show various epidemiological behaviors and are 
correlated with inconsistent prognostic risks, various tissue origins, which render the CCA 
molecular classifications prone to ambiguity, consequently preventing the precise 
identification of functional mutations, biomarkers, and target therapies in basic research and 
clinical setting.  Since CCA often develops an inflammatory milieu including cirrhosis and 
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cholangitis, the tumor microenvironments (TME) are likely to promote the progression of the 
malignancy, contributing to phenotypical heterogeneity in terms of genomic alterations, 
cellular morphology and resistance to therapy (Raggi, Invernizzi et al. 2015).   
A wealth of studies have been carried out to elucidate the mechanisms for radiation 
resistance of GBM, some studies reported glioma cells undergoing Epithelial-Mesenchymal 
Transition (EMT) involving in GBM recurrence (Kubelt, Hattermann et al. 2015), while other 
studies reported only a subset of proneural  patient-derived glioma sphere cultures (GSCs) 
differentiated to MES state mediated by TNF-α/NF-κB, accompanied with CD44 
subpopulations enrichment  and radio resistant phenotypes, while some GBM cases present 
constitutive MES signatures upon removing from the microenvironment, implying cell 
intrinsic mechanisms could also sustain MES network (Bhat, Balasubramaniyan et al. 2013). 
These observations invoked different hypothesis, whether there is co-existence of proneural 
and mesenchymal GSC within individual tumor, and Mes-like radiation-resistant cells 
preferentially survive and emerge as dominant population, or intrinsic transition from 
proneural to mesenchymal occur upon GBM recurrence. And IHC analysis revealed that 
proneural and mesenchymal markers co-exist in the same tumor region, indicating    
transcriptomic plasticity in GBM samples.  And MES GBMs exhibit high content of necrosis 
(Cooper et al., 2012) and macrophages/microglial infiltration (Engler et al., 2012; Li et al., 
2012). Given the impact of tumor microenvironment on molecular classification and 
contradictory interpretation of clinical outcomes in each distinct tumor subtype, it is important 
to systematically investigate the confounder factors associated with ambiguities of molecular 
classification established in previous TCGA network study of GBM (Brennan, Verhaak et al. 
2013), so I have deciphered the effects of tumor microenvironment on transcriptomic 
dynamics of GBM and revealed the tumor associated microenvironment mimic 
mesenchymal phenotype of GBM, which is described in Chapter 2.          
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Integrative analysis on around 600 glioma patients from TCGA and several lines of 
other studies revealed significant prolonged survival in glioma patients harboring 1p/19q 
codel, with median survival for ~115 months, while we observed that distinct variations in 
these patients with relatively favorable outcome also present in terms of clinical behaviors 
including timing of tumor progression, response to therapy and consequent survival. 
(Cancer Genome Atlas Research, Brat et al. 2015) Approximately 85% of the gliomas with 
1p/19q codels in the TCGA cohort are comprised of oligodendroglial components, which 
could be divided into low grade (grade II) and high grade (grade III) glioma based on WHO 
classification criteria, yet we also found that the clinical outcome doesn't show significant 
concordance with grade, suggesting other factors might determine the clinical status. 
Moreover a series of clinical trials reviewed that combined chemotherapy with procarbazine, 
lomustine (CCNU), and vincristine (PCV) following standard radiation therapy delayed 
glioma development and favorable clinical outcomes in patients diagnosed of anaplastic 
oligodendroglioma, and additional chemotherapy only exhibit benefits to those patients 
harboring 1p/19q co-deletion, yet the advantage to adjuvant chemotherapy only observed in 
part but not all amongst these patient cohort (Buckner, Gesme et al. 2003). In addition, an 
independent study indicated that some patients diagnosed with glioblastoma harboring 
1p/19q co-deletion do not show improved survival outcomes (Boots-Sprenger, Sijben et al. 
2013). As a matter of fact, contemporary management of low-grade glioma is still 
controversial, including the necessary components of the diagnostic strategies, the role of 
“wait-and-see” criteria, the nature of surgical intervention and radio/chemo therapeutic 
regimens (Zadeh, Khan et al. 2015). Although putative molecular markers, such as IDH 
mutant, TP53 mutation, MGMT methylation were applied for the prediction of LGG, there are 
further biological signatures that could distinguish glioma with 1p/19qcodel into subgroups, 
which will impact the risk of malignant progression and clinical outcome, in order to 
discriminate low-risk patients within glioma harboring 1p/19q co-deletion for whom intensive 
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adjuvant chemotherapy might be ignored, I have developed the gene signature applying 
machine learning algorithms and evaluated its predictive performance in independent 
datasets, which is presented in Chapter 3.               
Though gene fusions have been proved to serve as important drivers of cancer 
progression and target therapy, our understanding of the prevalence and associated 
genomic features for gene fusions in different cancer types is still insufficient, since the 
recurrence rate for fusion events are relatively lower than that for somatic mutations, fusion 
genes are not fully discovered due to limited sample size, bias due to RNAseq library and 
diverse computational frameworks, and fusion transcripts in rare cancer types are less 
appreciated in the past decades. Therefore taking advantage of massive RNA-Seq data 
generated from TCGA project, I performed fusion transcripts detection across 33 TCGA 
cancer types using the PRADA pipeline and discovered numerous novel gene fusions as 
well as known fusion events in never reported cancer types. And I have explored the 
associated genomic features with these fusion genes and predicted their oncogenic 
properties based on their context in protein networks, functional domains. My study will 
allow the clinicians and biologists to further explore these gene fusions datasets with a few 
mouse clicks and get the world’s most comprehensive gene fusions from major cancer types, 
fusion frequencies across each cancer type, fusion association with genomic rearrangement 
as well as fusion mRNA expression level and predictive protein domains in the fusion 
transcripts leading activation or inactivation of the coding products, elucidating possible 
causal factors of the cancer, decode the pathways that are perturbed by different fusions, 
and predict of potential targets for drug development and patient stratifications, as discussed 
in Chapter 4.    
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CHAPTER 2 
Tumor microenvironment associated with transcriptomic subtype 
plasticity during glioma evolution 
(The methods and results in this chapter have been published in biorxiv, Qianghu Wang*, 
Xin Hu*, Baoli Hu, Florian Muller, Hoon Kim, Massimo Squatrito, Tom Mikkelsen, Lisa 
Scarpace, Floris Barthel, Yu-Hsi Lin, Nikunj Satani, Emmanuel Martinez-Ledesma, Edward 
Chang, Adriana Olar, Guocan Wang, Ana C. deCarvalho, Eskil Eskilsson, Siyuan Zheng, 
Amy B. Heimberger, Erik P. Sulman, Do-Hyun Nam,  Roel G.W. Verhaak,“Tumor evolution 
of glioma intrinsic gene expression subtype associates with immunological changes in the 
microenvironment”. According to the journal policy, the author retains the right to include the 
submitted and published article in full or part in a dissertation.)    *Co-first authors 
 
2.1 Introduction 
The intrinsic capacity of glioblastoma (GBM) tumor cells to infiltrate normal brain impedes 
surgical eradication and predictably results in high rates of early recurrence. To better 
understand determinants of GBM tumor evolution and treatment resistance, The Cancer 
Genome Atlas Consortium (TCGA) performed high dimensional profiling and molecular 
classification of nearly 600 GBM tumors (Cancer Genome Atlas Research 2008, Noushmehr, 
Weisenberger et al. 2010, Verhaak, Hoadley et al. 2010, Brennan, Verhaak et al. 2013, 
Ceccarelli, Barthel et al. 2016). In addition to revealing common mutations in genes such as 
TP53, EGFR, IDH1, and PTEN, as well as the frequent and concurrent presence of 
abnormalities in the RB, p53 and receptor tyrosine kinase pathways. Unsupervised 
transcriptome analysis identified four clusters, referred to as classical, mesenchymal, neural 
and proneural, that were tightly associated with genomic abnormalities (Verhaak, Lintsen et 
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al. 2010). The proneural and the mesenchymal expression subtypes have been most 
consistently described in literature with proneural relating to a more favorable outcome and 
mesenchymal to unfavorable survival (Phillips, Kharbanda et al. 2006, Huse, Phillips et al. 
2011, Zheng, Chheda et al. 2012), but these findings were affected by the relatively 
favorable outcome of IDH-mutant glioblastoma which are consistently classified as proneural 
(Noushmehr, Weisenberger et al. 2010, Verhaak, Lintsen et al. 2010). Proneural to 
mesenchymal switching upon disease recurrence has been described as a source for 
treatment resistance in GBM relapse (Bao, Wu et al. 2006, Phillips, Kharbanda et al. 2006, 
Bhat, Balasubramaniyan et al. 2013, Ozawa, Riester et al. 2014), but the relevance of this 
phenomenon in glioma progress remains ambiguous. 
 GBM tumor cells along with the tumor microenvironment create a complex milieu that 
ultimately promotes tumor cell plasticity and disease progression (Olar and Aldape 2014).  
The presence of tumor-associated stroma results in a mesenchymal tumor gene signature 
and poor prognosis in colon cancers. (Isella, Terrasi et al. 2015) Furthermore, the 
association between a mesenchymal gene expression signature and reduced tumor purity 
has been identified as a common theme across cancer (Yoshihara, Shahmoradgoli et al. 
2013, Martinez, Yoshihara et al. 2015).  Tumor-associated macrophages/microglia in GBM 
have  been proposed as regulators of proneural-to-mesenchymal transition through NF-kB 
activation (Bhat, Balasubramaniyan et al. 2013) and may provide growth factor mediated 
proliferative signals, which could be therapeutically targeted (Pyonteck, Akkari et al. 2013, 
Patel, Tirosh et al. 2014, Yan, Kong et al. 2015).  
 In this study we explored the properties of the microenvironment in different GBM 
gene expression subtypes and characterized the transition between molecular subtypes 
before and after therapeutic intervention. In doing so, we improved the robustness of gene 
expression subtype classification through revised gene signatures and proposed analytical 
methodology. Our results suggested that the tumor microenvironment interferes with 
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expression based classification of GBM, both at the primary disease stage as well as at 
disease recurrence, and suggest a role for the macrophage/microglia in treatment response. 
 
2.2 Methods  
2.2.1 Data sources for multiplatform classification comparison 
U133A array profiles for 543 primary GBM, and RNA-Seq data for 166 primary and 13 
recurrent GBM (part of GBM samples were measured by both U133A array and RNA-Seq) 
were obtained from TCGA portal https://tcga-data.nci.nih.gov/tcga/. Mutation calls and DNA 
copy number profiles were obtained for all samples, where available. All raw data from non-
TCGA resources (either microarray profiles or RNA-Seq) were retrieved from GEO. 
Processed primary/recurrence expression data was analyzed using 
GlioVis http://recur.bioinfo.cnio.es/.  
Tissues from 20 initial GBM and matched recurrent tumors were obtained from 
Henry Ford Hospital (n = 9) in accordance with institutional policies and all patients provided 
written consent, with approval from the Institutional Review Boards (Henry Ford Hospital IRB 
protocol #402). All RNA samples tested were obtained from frozen specimens. All of the 
recurrent GBMs had been previously treated with chemotherapy and radiation. Three cases 
were diagnosed with lower grade astrocytoma prior to primary GBM (HF-2869/HF-3081/HF-
3162). Tumors were selected solely on the basis of availability. RNA-Seq libraries were 
generated using RNA Truseq reagents (Illumina, San Diego, CA, USA) and paired-end 
sequenced using standard Illumina protocols. Read length was 76 base pairs for cases 
sequenced by TCGA and from Henry Ford hospital. RNA-Seq data on frozen tissue from 44 
patients with initial and recurrent GBM that received resection at Samsung Medical Center 
and Seoul National University Hospital were provided by Dr. Nam’s lab. Surgery specimens 
were obtained in accordance to the Institutional Review Board (IRB) of the Samsung 
Medical Center (No. 2010-04-004) and Seoul National University Hospital. (No. C-1404-056-
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572) Affymetrix CEL files of 39 pairs of initial and recurrent glioma were retrieved from the 
Gene Expression Omnibus (GEO accession GSE4271, GSE42670, GSE62153) (Phillips, 
Kharbanda et al. 2006, Joo, Kim et al. 2013, Kwon, Kang et al. 2015). The expression 
profiles of the 23 pairs from GSE4271 were determined using Affymetrix HG-U133 
GeneChips, the 1 pairs from GSE42670 were analyzed using the Affmetrix HuGene-1-0-st 
platform, the 15 pairs from GSE62153 were analyzed using Illumina Human HT-12 V4.0 
expression BeadChip. The RNA sequencing data of 14 and 5 pairs of primary and recurrent 
low grade glioma were from TCGA LGG cohort and EGAS00001001255 (Mazor, Pankov et 
al. 2015), respectively. Genome wide DNA copy number profiling and exome sequencing on 
thirteen TCGA tumor pairs and nine of ten Henry Ford tumor pairs were performed and data 
was analyzed using standard protocols and pipelines as previously described (Kim, Zheng 
et al. 2015).  
RNA sequencing data was available for 162 primary GBMs (Brennan, Verhaak et al. 
2013) for which an Affymetrix HT-U133A gene expression profile was also available. We 
observed a low Pearson Correlation Coefficient (< 0.15) between RNA sequencing based 
reads per kilo base of transcript per million reads (RPKM) and Affymetrix HT-U133A profiles 
in eighteen cases and these were removed from further analysis. In summary, in order to 
assess the concordance between classification results of the new 70-gene signatures and 
previously published 210-gene signatures (Verhaak, Hoadley et al. 2010), 144 GBMs which 
were profiled in both RNA sequencing and Affymetrix U133A platforms were used in our 
further analyses. 
 
2.2.2 Transcriptome data processing 
The latest version custom CDF files (Version19, http://brainarray.mbni.med.umich.edu) (Dai, 
Wang et al. 2005, Sandberg and Larsson 2007) were used to map probes from the 
Affymetrix HG-U133A and HuGene-1_0-st GeneChip platforms to the Ensemble transcript 
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database, combined in one probe set per gene and normalized using the AROMA package 
with default parameters, resulting in RMA normalized and log transformed gene expression 
values (Bengtsson, Ray et al. 2009). All RNA sequencing data was processed by the 
PRADA pipeline (Torres-Garcia, Zheng et al. 2014). Briefly, reads were aligned using BWA 
against the genome and transcriptome. After initial mapping, the aligned reads were filtered 
out if their best placements are only mapped to unique genomic coordinates. Then quality 
scores are recalibrated using the Genome Analysis Toolkit (GATK), and duplicate reads are 
flagged using Picard. Mapped features were quantified and normalized per kilobase of 
transcript per million reads (RPKM) and were converted to a log2 scale to represent a gene 
expression level. RPKM values measuring the same gene that mapped to the Ensemble 
transcript with longest size were selected to obtain one expression value per gene and 
sample. The statistical environment R was used to perform all the statistical analysis and 
graph plots.  
 
2.2.3 Identification of gene signatures for refined GBM subtype   
A pair-wise gene expression analysis identified 5,334 genes which are significant higher 
expressed in glioma bulk samples compared to their derivative glioma stem cells (GSCs). 
These genes were excluded from the gene list for developing tumor-specific molecular 
subtypes. Consensus non-negative matrix factorization (CNMF) clustering method identified 
three distinct subgroups among the 369 IDH-wt primary GBMs. A set of 270 GBMs was 
selected as core samples based on a positive silhouette width. The gene expression values 
of each subtype were compared with those from the other two subtypes combined (Verhaak, 
Hoadley et al. 2010). Signature genes per cluster were selected based on the differences in 
gene expression level and were considered significant if they reached the cut-off value with 
t-test p-value< 1E-3 for higher expressed in this class, while also showing a significant lower 
expression with t-test p-value<1E-3 in the other two classes. In the original gene signatures, 
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both down and up-regulated genes were included, while only up-regulated genes (n=70 per 
gene signature) were selected for revised gene signatures. Only genes measured on both 
RNAseq and U133A platforms were included, and the U133A data from 162 GBM samples 
measured on both platforms (which included the 144 cases used to compare U133A and 
RNAseq platform) was used in the final comparative analysis. 
 
2.2.4 Molecular classifications based on ssGSEA enrichment scores 
Single sample gene set enrichment analysis was performed as follows. For a given GBM 
sample, gene expression values were rank-normalized and ordered based on their ranks. 
The Empirical Cumulative Distribution Functions (ECDF) of the signature genes and the 
remaining genes were calculated. Then the statistic was deduced by integration of the 
difference between the ECDFs, the method is similar to GSEA but based on absolute 
expression value rather than differential expression (Barbie, Tamayo et al. 2009). Since the 
ssGSEA test is based on the ranking of genes by expression level, the uncentered and log-
transformed U133A and RPKM expression levels were used as input for ssGSEA. Since the 
scores of the three signatures were not directly comparable, we performed a resampling 
procedure to generate null distributions for each of three subtypes. First we generated a 
virtual sample matrix V(s, g) (numbers of permutation, Ns >1,000,000) to simulate the gene 
expression by randomly selecting an expression value of the same gene (gj) in the 
remainder of the samples (s1, s2…sn…..si-1). Then ssGSEA scores of three signatures in 
each sample (s) were calculated to generate a large number (>1,000,000) of random 
ssGSEA scores for each subtype, and build the null distribution of ssGSEA scores for 
simulated samples, from which we derived empirical p-values (the numbers of ssGSEA 
scores in simulated samples higher than the one in original sample in each subtype adjusted 
by the number of permutations) corresponding to the raw ssGSEA scores for each sample. 
By testing on multiple datasets with different sample sizes, we found the resampling 
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generated distribution could be replaced with student-t distribution (sample size > 30) or 
normal distribution (sample size > 50) to obtain similar results.  
 
2.2.5 Evaluate the heterogeneity of GBM subtype  
For each sample, first we reversely rank the empirical p-values for each subtype to generate 
ordered statistics as 𝑅𝑁−1,𝑅𝑁−2  … 𝑅1,𝑅0. In particular, 𝑅0 equals to the minimum empirical 
p-value and corresponding to the dominant subtype (top activated subtype). The 
accumulative distance to the dominant subtype (ADDS) was defined as: 
𝐴𝐷𝐷𝑆 = �(𝑅𝑖 − 𝑅0)𝑁−1
𝑖=1
 
Similarly, the accumulative distance between non-dominant subtypes (ADNS) as: 
𝐴𝐷𝑁𝑆 = � (𝑅𝑗𝑗 − 𝑅𝑖)
𝑗𝑗>𝑖>0
 
Thus the values of ADDS and ADNS are positively and negatively correlated with single 
activated subtype, respectively. Hence, we defined the simplicity score by combining ADDS 
and ADNS together and adjusted with a constant (𝑅𝑁−1−𝑅0)
𝑁−1
 as follows: 
𝑆𝑎𝑎𝑎𝑎𝑝𝑙𝑎𝑎𝑐𝑎𝑎𝑡𝑦𝑦 𝑠𝑐𝑜𝑎𝑎𝑒 = [𝐴𝐷𝐷𝑆 − 𝐴𝐷𝑁𝑆] × (𝑅𝑁−1 − 𝑅0)
𝑁 − 1  
2.2.6 Tumor purity assessment  
The ESTIMATE package was used to evaluate tumor purity on the basis of the expression 
level of marker genes in stromal and immune cells (Yoshihara, Shahmoradgoli et al. 2013), 
where the fraction of stromal cells and immune cells in each sample were represented by 
stromal score and immune score respectively, and the mixed fraction of both stromal and 
immune cells was represented by estimate scores. The ABSOLUTE package was used to 
confirm the tumor purity on the basis of chromosome copy number and allele fraction ratios 
on samples for which SNP array data were available (Carter, Cibulskis et al. 2012). 
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2.2.7 Establish glioma neurosphere cultures (GSCs)  
Upon approval from the institutional review board of The University of Texas M.D. Anderson 
Cancer Center, glioblastoma tumor tissues were collected and labeled in the order that they 
were acquired. Each tissue was enzymatically and mechanically dissociated into single cells 
and grown in DMEM/F12 media supplemented with B27 (Invitrogen), EGF (20 ng/ml), and 
bFGF (20 ng/ml), resulting in neurosphere growth. All cell lines were tested to ensure 
mycoplasma infection negative. To minimize any batch effect the downstream molecular 
analyses were performed on identical cell culture batches. Total RNA from formalin fixed, 
paraffin embedded tumor tissues and matching neurospheres was prepared using the 
Masterpure complete DNA and RNA isolation kit (Epicenter) after proteinase K digestion per 
to the instructions from the manufacturer. Paired-end Illumina HiSeq sequencing assays 
were performed resulting in a medium number of 50 million 75bp paired end reads per 
sample. We employed the PRADA pipeline to process the RNA sequencing data (Torres-
Garcia, Zheng et al. 2014). Briefly, Samtools, Burroughs-Wheeler alignment and Genome 
Analysis Toolkit (GATK) were used to align short reads to the human genome (hg19) and 
transcriptome (Ensembl 64). RPKM gene expression values were generated for 135,994 
transcripts consist of 21,165 protein coding genes in Ensembl database. 
 
2.2.8 Western blotting 
Lysates were prepared from fresh frozen sections using RPPA lysis buffer (1% Triton X-100 
50mM HEPES pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na 
pyrophosphate, 1mM Na3VO4, 10% glycerol, plus protease and phosphatase inhibitors 
cocktails from Roche Applied Science #05056489001 and 04906837001), with sonication 
and clearing by centrifugation at 10,000g. Protein concentration was measured using the 
BCA kit (Thermo Scientific -Pierce #23225). SDS-PAGE and western blotting was performed 
using Midi gel system (Life Technologies - #WR0100) and NuPage-Novex 4-12% Bis-Tris 
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Midi (20-well) Protein Gels (Life Technologies - #WG1402) using the following antibodies: 
ITGAM (CD11B) (Sigma Aldrich – #HPA002274), IBA1 (AIF1) (Sigma Aldrich – 
#HPA049234), GFAP (Cell Signalling – #3670), YKL40 (CHI3L1) YKL40 (CHI3L1, Santa 
Cruz Biotechnology - #sc-30465) a-actinin (Sigma Aldrich A5044) and Tubulin (Sigma 
Aldrich T9026). 
 
2.2.9 Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections (4 µm thick) were produced on super-
frost plus slides. Briefly, tissue sections were deparaffinized with xylene and ethanol and re-
hydrated with 95, 70 and 50% ethanol. Sections were antigen unmasked using citrate buffer 
(Vector Labs #H-3300) and heating. Peroxidase block was conducted with 3% H2O2 and 
blocking was with 5% goat serum (Vector Labs #S-1000). Primary rabbit polyconal antibody 
against IBA1 (AIF1) (WAKO #016-20001) at 1:400 was used overnight. Secondary antibody 
was done using with the Rabbit-on-Rodent HRP-Polymer (Biocare #RMR622L) for 1 hr at 
room temperature. The slides were developed with Nova-red (Vector Labs #SK-4800) and 
counterstained with haematoxylin, mounted and scanned with Pannoramic 250 slide 
scanner (Caliper Life Sciences). Unbiased quantification of microglial (IBA1+) percentage in 
primary and recurrent GBMs was performed using the Caliper Vectra image system and 
InForm analysis software. Thirty scan fields were automatically selected on from entire 
tumor section. Nineteen scan fields were select from the primary tumor of patient #2 due to 
the small size of tumor section. Percentages of the median and high levels (2+, 3+) of IBA1 
were used for the comparison.  
 
2.3 Results  
2.3.1 Harnessing glioma sphere-forming cells identifies GBM specific inter-tumoral 
transcriptional heterogeneity 
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We set out to elucidate the tumor-intrinsic and tumor associated microenvironment 
independent transcriptional heterogeneity of GBMs. We performed a pairwise gene 
expression comparison of independent set of GBMs and the derivative glioma sphere-
forming cells (GSCs) (n = 37) (Galli, Binda et al. 2004).  In total, 5,334 genes were found to 
be significantly higher expressed in parental GBMs relative to derived GSCs that could be 
attributed by the tumor associated GBM microenvironment (Figure 2.1A). To focus the 
analysis on the tumor-intrinsic transcriptome, these genes were filtered from further analysis, 
given that this step may additionally exclude genes exogenously expressed in activated 
glioma cells. GBMs with IDH mutations have distinct biological properties and favorable 
clinical outcomes compared to IDH wild-type GBMs (Noushmehr, Weisenberger et al. 2010, 
Brennan, Verhaak et al. 2013, Cancer Genome Atlas Research, Brat et al. 2015, Ceccarelli, 
Barthel et al. 2016). Using the filtered gene set, we performed consensus non-negative 
matrix factorization clustering (CNMF) to identify three distinct subgroups amongst 369 GBM 
samples with IDH wild type, then we further selected 270 core samples with positive 
silhouette width of each cluster (CL: n=97, MES: n=94, PN: n=79)   (Figure 2.1B; Figure 
2.1C). When comparing the clustering result with the previously defined proneural (PN), 
neural (NE), classical (CL) and mesenchymal (MES) classification (Verhaak, Hoadley et al. 
2010, Brennan, Verhaak et al. 2013), three subgroups were distinctly enriched for CL, MES 
and PN GBMs, respectively (Figure 2.2). Consequently, we labeled the groups as CL, MES 
and PN. None of the three subgroups was enriched for the NE class, suggesting the neural 
phenotype is non-tumor specific. The NE group has previously been related to the tumor 
margin where normal neural tissue is more likely to be present (Sturm, Witt et al. 2012, Gill, 
Pisapia et al. 2014) and such contamination might explain why the neural subtype was the 
only subtype lack of distinct gene abnormalities (Brennan, Verhaak et al. 2013, Verhaak, 
Tamayo et al. 2013). 
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 Figure 2.1 Selection of gene signature for molecular classification of IDH-WT GBMs 
(A) Exclude genes specifically expressed in tumor associated microenvironment.  
(B) Exclude GBM samples associated with IDH mutation/ G-CIMP+.  
(C) Selection of signature genes based on NMF clustering.   
[* Courtesy of Erik Sulman, Qianghu Wang] 
 
Figure 2.2 Comparison between GCIMP- GBM specific classification and previously TCGA 
defined GBM subtypes 
New assignment Class1: Classical; Class2: Mesenchymal; Class3: Proneural 
In order to classify external GBM samples, we implemented a single sample gene set 
enrichment analysis (ssGSEA) based equivalent distribution resampling classification 
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strategy using 70-gene signatures with significantly differential gene expression (p-value< 
1E-3, t-test) and up-regulated for each subgroup (Table 2.1)(Figure 2.3), to assign each 
sample with three empirical classification p-values derived from ssGSEA on which we 
determined the significantly activated subtype(s) in each GBM sample.  
 
Figure 2.3 Gene signatures applied for GBM classification  
Heatmap of 70-gene signatures by gene expression subtype was developed based on 270 core 
samples of GBMs. Selected ten genes are listed for each subtype.  
 
 
 
 
 
Table 2.1 Gene signatures applied for transcriptomic classification of GBM  
Gene expression value was normalized cross samples. 
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Applying this method we found that the overall concordance of cluster assignments on 144 
TCGA GBM samples profiled using both RNA sequencing and Affymetrix U133A 
microarrays was 95.14% (Figure 2.4). This was an improvement over the 77% subtype 
concordance determined using previously reported methods (Verhaak, Hoadley et al. 2010). 
 
Figure 2.4 Concordance of transcriptional classification of GBMs cross multiple platforms 
Through TCGA, the expression profiles of 144 GBM were analyzed using both Affymetrix U133A 
gene expression arrays and RNA sequencing. The empirical –log (P-value) of raw ssGSEA 
enrichment scores at each signature are shown as heatmaps, with dark blue representing no 
activation and bright red as highly activated. For each panel, the first row shows U133A based 
classification, and the second row indicates RNA-seq subtype classification. 
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2.3.2 Multi-activation of subtype signatures associated with intra-tumoral 
heterogeneity 
We observed that 34/369 (9.2%) samples showed significant enrichment of multiple 
ssGSEA scores (empirical classification p-value<0.05), suggesting these cases activate 
more than one transcriptional subtype. To quantify this phenomenon, a score ranging from 0 
to 1 was defined to quantitatively evaluate the simplicity of subtype activation based on 
order statistics of ssGSEA score. Samples with high simplicity scores activated a single 
subtype and those with lowest simplicity scores activated multiple subtypes. All multi-
subtype TCGA samples showed simplicity scores of less than 0.1 (Figure 2.5). 
 
Figure 2.5 Multi activation of transcriptional subtypes associated with intra-tumoral 
heterogeneity  
The expression profiles of 369 IDHwt GBMs were analyzed using Affymetrix U133A. The 
empirical -log(P-value) of raw ssGSEA enrichment scores at each signature are shown as 
heatmaps, with dark blue representing no activation and bright red as highly activated. Yellow 
star indicates the secondary activated subtype (empirical p-value<0.05).  For each panel, the 
first row shows simplicity score, and the second row indicates transcriptional subtype.  
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Then we evaluated the distribution of somatic variants across these three molecular 
subtypes (Figure 2.6) and confirmed the strong associations between transcriptomic 
subtypes and genomic abnormalities in previously reported driver genes (Fisher’s exact test) 
(Verhaak, Hoadley et al. 2010, Brennan, Verhaak et al. 2013).  
 
 
Figure 2.6 Genomic alteration patterns for each subtype  
(A) The most prominent GBM somatic events. In the upper panel, the first row shows the 
simplicity score for each sample, the second row shows primary subtypes of each samples 
determined by ssGSEA using U133A array expression data. The third row shows the secondary 
subtype of each sample. In the bottom panel, mutations and copy number alterations in key 
GBM genes are shown. Missing values i.e. when exome data or SNP array data was not 
available are labeled in gray. 
(B) Frequency of subtype related somatic genomic alterations.  
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To determine whether transcriptional heterogeneity associated with genomic intra-tumoral 
heterogeneity, we correlated simplicity scores, total mutation rates and subclonal mutation 
rates. Included in the analysis were 224 TCGA GBMs with available whole exome 
sequencing data (Kim, Zheng et al. 2015) and ABSOLUTE (Carter, Cibulskis et al. 2012) 
determined high tumor purity (> 0.8) to equalize the mutation detection sensitivity (Aran, 
Sirota et al. 2015). Although not significant (Wilcoxon rank test p-value=0.143), the total 
mutation rate was less in the bottom 30% with lowest simplicity scores versus the top 30% 
samples with highest simplicity scores. The subclonal mutation rate was significantly higher 
(p-value=0.024) in samples with lowest simplicity scores (Figure 2.7), suggesting that 
increased intra-tumoral heterogeneity associates with increased transcriptional 
heterogeneity.  
 
Figure 2.7 Association between genomic and transcriptomic intratumoral heterogeneity 
Comparison of mutation rate, subclonal mutation rate and subclonal mutation fraction between 
IDHwt GBMs with high and low simplicity scores, P-values were calculated using Wilcoxon rank 
test and shown at the top of each panel.  
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We compared outcomes amongst the three transcriptional groups and observed no 
significant differences. However, when restricting the analysis to samples with high simplicity 
scores, a distinct trend of MES showing worst survival and PN the most favorable outcome 
became visible. For example, Kaplan-Meier analysis of 88 samples with simplicity 
scores >0.99 showed a median survival of 11.4, 14.7 and 16.7 months were detected in 
MES, CL and PN, respectively, which was significantly different (log rank test, p=0.048) 
(Figure 2.8).  
 
Figure 2.8 Impact of intratumoral heterogeneity on overall survival between different 
transcriptional subtypes  
The Kaplan-Meier survival curves for each transcriptional subtype are shown. The patients were 
selected based on increased simplicity score as threshold from panel A, B (>0.9), C (>0.99), D 
(0.999). 
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In addition, higher simplicity scores correlated with relative favorable outcome within the PN 
set, non-significant in the CL subtype, and correlated with relatively unfavorable survival in 
the MES class (Figure 2.9). 
 
Figure 2.9 Impact of intra-tumoral heterogeneity on patient survival in each transcriptional 
subtype 
The Kaplan-Meier survival curves for each transcriptional subtype are shown. The patients were 
grouped based on their simplicity scores. The blue curve denotes the patients with 30% high 
simplicity scores, the red curve denotes the patients with 30% low simplicity scores.  
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Single GBM cell RNA sequencing recently suggested that GBMs are comprised of a 
mixture of tumor cells with variable GBM subtype footprints (Patel, Tirosh et al. 2014). We 
used this data to classify 502 single GBM cells in addition to the bulk tumor derived from five 
primary glioblastomas. All bulk tumor samples showed simplicity scores less than 0.05 
suggesting high transcriptional heterogeneity compared to 45 of 369 TCGA GBM samples 
with simplicity scores below 0.05. In four of five cases (MGH26, MGH28, MGH29 and 
MGH30), the bulk tumor samples were classified in the same primary subtype as the 
majority of their single cells (Figure 2.10).  Our analysis suggests that the heterogeneity 
observed at the single cell level is captured in the expression profile of the bulk tumor, and 
that the five GBM samples studied at the single cell level represented samples with relatively 
high transcriptional heterogeneity. 
 
Figure 2.10 Transcriptome classification of five bulk tumor samples their derived 502 
single GBM cells 
The top two row of each panel show the dominant and secondary subtype of the GBM tumor 
bulk. The heatmap of each panel shows the empirical -log(P-value) of  the ssGSEA scores of the 
derived single GBM cells on each of the three subtype signatures. The bottom row shows the 
subtype distribution of derived single GBM cells within the same GBM tumor of origin. 
 
2.3.3 Transcriptional subtypes differentially activate the immune microenvironment  
Despite restricting the cluster analysis to genes exclusively expressed by GBM cells, we 
found that tumor purity predictions based on ABSOLUTE were significantly reduced in GBM 
classified as MES (Student T-test p-value < 10e-14; Figure 2.11A). This was concordant by 
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gene expression based predictions of tumor purity using the ESTIMATE method (Student T-
test p-value < 10e-32; Figure 2.11B) (Yoshihara, Shahmoradgoli et al. 2013) . The 
ESTIMATE method has been optimized to quantify tumor-associated fibroblasts and 
immune cells (Yoshihara, Shahmoradgoli et al. 2013) and the convergence of a decreased 
ABSOLUTE and decreased ESTIMATE tumor purity confirmed previous suggestions on the 
increased presence of microglial and neuroglial cells mesenchymal GBM (Bao, Wu et al. 
2006, Engler, Robinson et al. 2012, Ye, Xu et al. 2012, Gabrusiewicz, Rodriguez et al. 2016). 
The mean simplicity score of samples classified as MES was 0.53 which was significantly 
lower than in PN (Wilcoxon rank test p-value < 0.019) and CL subtypes (Wilcoxon rank test 
p-value < 0.0001), confirming increased transcriptional heterogeneity.  
 
Figure 2.11 Transcriptional subtypes differentially activate the immune microenvironment 
Tumor purity of 364 respectively 369 TCGA IDHwt GBM samples was determined by ABSOUTE 
(A) and ESTIMATE (B) The difference in tumor purity between subtypes was evaluated using 
two-sample heteroscedastic t-test.  
 
In order to identify genomic determinants of macrophage/microglia chemo-attraction, 
we compared genomic alterations between mesenchymal class samples with high (n=51) 
and low (n=51) ABSOLUTE based tumor purity. GBM carrying heterozygous loss of NF1 or 
somatic mutations in NF1 showed reduced tumor purity compared to GBM with wild type 
NF1 (Wilcoxon rank test p-value=0.0007) and this association was similarly detected when 
46 
 
limiting the analysis to MES samples (Wilcoxon rank test p-value=0.017) (Figure 2.12). 
Formation of dermal neurofibromas in the context of Nf1 loss of heterozygosity has been 
reported to be context and microenvironment dependent (Le 207 et al., 2009). Further 
functional studies may clarify whether NF1 deficient GBM are able to recruit cells that 
provide them with a proliferative advantage, or whether NF1 loss provides that proliferative 
advantage in a specific tumor-associated microenvironment context. 
 
Figure 2.12 Comparison of tumor purity and immune cell fraction between GBMs with 
different NF1 genomic status 
P-values were calculated using Wilcoxon rank test between samples carrying NF1 
deletion/mutation versus NF1 WT and carrying amplification.       [* Courtesy of Qianghu Wang]  
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To determine the cellular components of the tumor microenvironment across 
different transcriptional subtypes, we used the CIBERSORT in silico cytometry (Newman, 
Liu et al. 2015) method to evaluate absolute immune cell fractions. We evaluated 22 
different immune cell types in 69 PN, 137 CL and 96 MES samples, after filtering samples 
with classification simplicity scores less than 0.1. Microglia is the resident macrophages in 
the central nervous system. Peripheral blood monocytes also give rise to tumor associated 
macrophages. These innate immune cells can be broadly classified as the proinflammatory 
M1 type and the alternative tumor promoting M2 type(Hambardzumyan, Gutmann et al. 
2015). The M2 macrophage gene signature showed a greater association with the MES 
subtype (13.4%) relative to the PN (4.6%) and CL (6.0%)(Figure 2.13), consistent with 
previous analysis of the TCGA database(Doucette, Rao et al. 2013, Gabrusiewicz, 
Rodriguez et al. 2016). In addition to the M2 macrophage gene signature, there was also a 
significantly higher fraction of MES samples that expressed M1 macrophage (Student T-test 
p-value 3.20E-5) and neutrophil (Student T-test p-value 1.30E-9) gene signatures. In 
contrast, the activated natural killer T-cell gene signature (Student T-test p-value 4.91E-2) 
was significantly reduced in the MES subtype and resting memory CD4+ T cells (Student T-
test p-value 5.40E-7) were less frequently expressed in the PN subtype.  
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 Figure 2.13 Comparison of immune cell fraction among different subtypes of GBM 
Purple, blue and green boxplots indicate PN, CL and MES subtype, respectively. Immune cell 
fraction was estimated using CIBERSORT and corrected using ABSOLUTE purity scores. 
Difference of cell fraction between subtypes was evaluated using Mood’s test.  
 
To confirm the association of macrophages/microglia with the MES GBM subtype, 
we assessed protein expression levels of the ITGAM (alternatively known as CD11B) and 
IBA1 (also known as AIF1) macrophage/microglial markers in a set of 18 GBM for which we 
also characterized the expression subtype (Figure 2.14). 
 
 
Figure 2.14 Presence of macrophages/microglia in MES GBM  
The upper panel shows ssGSEA enrichment scores and associated expression subtype 
classifications. Bottom panels display protein expression of the microglial markers integrin alpha 
M (ITGAM) and allograft inflammatory factor 1 (IBA1), astrocyte marker glial fibrillary acidic 
protein (GFAP) and the loading control vinculin and tubulin.              [* Courtesy of Florian Muller] 
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We confirmed the tumor associated microenvironment as the main source for 
ITGAM/IBA1 transcription by comparing transcriptional levels in 37 GBM-neurosphere pairs 
used for gene filtering, which showed that neurospheres do not express ITGAM/IBA1 
(Figure 2.15). The association of the MES GBM subtype with increased level of M2 
microglia/macrophages may suggest that in particular MES GBM are candidates for 
therapies directed against tumor-associated macrophages(Pyonteck, Akkari et al. 2013). 
Activated dendritic cell signatures (Student T-test p-value 7.36E-3)(Figure 2.13) were 
significantly higher in the CL subtype, suggesting this subtype may benefit from dendritic cell 
vaccines (Palucka and Banchereau 2012). Dendritic cells may require an activated 
phenotype in order to direct the immune system. A previous study suggested that MES GBM 
patients treated with dendritic cells were more likely to benefit (Prins, Soto et al. 2011).   
 
         
 
Figure 2.15 Characterization of the source of microglia in GBM  
(A) Generation of neurosphere cells that deprived of microglia from tumor associated 
microenvironment  
(B) Comparison of ITGAM and IBA1 gene expression levels between GBM patients and their 
derived neurosphere models. 
[* Courtesy of Erik Sulman, Qianghu Wang]  
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2.3.4 Phenotypic plasticity upon GBM recurrence 
Glioblastoma has long been hypothesized to progress along a proneural to mesenchymal 
axis (Phillips, Kharbanda et al. 2006). First we evaluated the subtype classification and 
tumor contents of 22 primary GBM and their matching recurrence case. When considering 
subtype classifications based on the maximum ssGSEA score, the molecular subtypes 
remained consistent after disease recurrence for 19 of 22 patients. 3 of 22 tumor samples 
that switched primary subtypes showed a relative decrease in tumor purity after recurrence. 
In contrast, of the remaining 19 pairs with different primary-recurrent subtype classifications 
only 5 showed a decrease in tumor purity at time of recurrence. A remarkable shift away 
from the EGFR associated classical subtype was observed, with only a single case retaining 
this classical status. Then we evaluated whether the previously reported genomic 
associations between tumor subtype and genomic abnormalities persisted after disease 
recurrence, using 22 pairs for which genome wide DNA copy number levels and exome 
sequencing data were available in The Cancer Genome Atlas (TCGA) or generated by 
ourselves and reported elsewhere(Kim, Zheng et al. 2014). Although limited by sample size, 
we observed an overall trend in genomic associations that was consistent with what we 
found previously in primary GBM, such as two recurrences that retained the IDH1 mutation 
status and the proneural phenotype, three of three recurrent classical GBM with focal EGFR 
amplification and/or EGFR mutations, and three of nine recurrent mesenchymal GBM with a 
non-synonymous mutation in NF1(Brennan, Verhaak et al. 2013)(Figure 2.16). 
To further determine the relevance of this transition process in IDH wildtype glioma 
evolution, we performed a longitudinal analysis of the subtype classification and tumor-
associated microenvironment in sample pairs obtained at diagnosis and first disease 
recurrence from 124 glioma patients. The cohort included 96 initial GBM and first recurrence, 
eight pairs of primary low grade glioma and matching secondary GBM, and 20 pairs of 
primary and recurrent low grade glioma. Gene expression profiles of 78 tumor pairs were 
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analyzed through transcriptome sequencing, and remaining pairs were generated using 
Affymetrix (n = 31) and Illumina (n = 15) microarray, respectively. To facilitate exploration of 
this dataset we have made it available through the GlioVis portal http://recur.bioinfo.cnio.es/.  
 
Figure 2.16 Integrative views of molecular classification and genomic alterations across 
molecular subtypes in paired primary and recurrent glioblastoma 
The molecular classifications, tumor purity and genomic alteration landscape of 22 pairs of 
primary and recurrent GBM. In the upper panel, ssGSEA enrichment scores are shown and the 
yellow dots indicate subclass, green dots represent the secondary activation scores. In the 
middle panel, tumor purity based on ABSOLUTE scores is shown, light pink represent primary 
samples, dark pink represent recurrent samples. Bottom panel displays molecular alterations; 
mutations are indicated by a brown cell, with synonymous substitution labelled with pink triangle, 
a different base mutated labelled with green squares. copy number events are illustrated in blue 
for homozygous deletions, light blue for hemizygous deletions, beige for copy number neutral, 
orange for low level amplification, and dark red for high level amplifications. A single case with a 
history of low grade glioma is denoted with a red asterisk (*). The samples are sorted first by 
primary tumor grade, then by recurrent tumor subtype, and then by primary tumor subtype. 
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We used a gene expression signature (Baysan, Bozdag et al. 2012) to determine 
that 33 of 124 cases were IDH-mutant/GCIMP at presentation and recurrence. We used the 
renewed gene signatures and classification method to determine molecular subtype of the 
91 pairs of IDH wild type cases and found that expression class remained consistent after 
disease recurrence for 48 of 91 IDH-wildtype cases (52%). The MES subtype was most 
stable (64%) while the CL (47%) and PN (43%) phenotypes were less frequently retained. 9, 
16 and 18 post-treatment tumors switched subtypes to become CL, MES and PN at disease 
recurrence, respectively, indicating that PN and MES increased in higher frequency after 
recurrence while the CL subtype was least frequently found (Figure 2.17A). The CL 
expression class was previously found to be most sensitive to intensive therapy and it is 
possible that therapy provides a competitive advantage for non-CL cells, which could 
explain the reduced post-treatment incidence (Verhaak, Hoadley et al. 2010). Our results did 
not identify enrichment for proneural to mesenchymal transitions.  
 
Figure 2.17 Comparison between transcriptional subtype of primary and paired recurrent 
tumors  
(A) Rows and columns of the cross table represents subtype distribution frequency of primary 
and paired recurrent tumors, respectively.  
(B) Violin plots show the distribution of simplicity scores of pairs with (left) and without (right) 
subtype transition.  
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 We observed a significant difference in transcriptional simplicity between primary 
GBM retaining their expression class, versus those that switched to a different phenotype 
upon their recurrence (Figure 2.17B). GBMs with a primary tumor simplicity score greater 
than 0.5, with lower transcriptional heterogeneity, were classified as the same subtype in 31 
of 48 (64.5%) cases, compared to 15 cases classified as the same subtype out of 41 (36.6%) 
cases with primary tumor simplicity scores less than 0.5. (Fisher exact test p-value=0.01)  
 
2.3.5 Tumor microenvironment transitions upon GBM recurrence 
Debulking surgery, radiotherapy and chemotherapy provide therapeutic intervention but 
nonetheless induce tumor evolution, including impact on their tumor infiltrated 
microenvironment. We explored this hypothesis by comparing the tumor associated 
microenvironment in primary and recurrent GBMs using CIBERSORT (Newman, Liu et al. 
2015). A comparison between 91 primary and recurrent IDH-wild type tumors revealed a 
decrease in monocyte gene signature expression at recurrence, suggesting relative 
depletion of circulation derived monocytes (Figure 2.18A). Next, we dissected 
microenvironment fluctuations between primary and recurrent tumors across different 
subtype combinations. Primary non-MES (CL or PN) tumors showed relatively high tumor 
purity and consequently, recurrent tumors classified as non-MES demonstrated a relatively 
global decrease of immune cells while cases transitioning to MES at recurrence represented 
a trend towards increased immune cell fractions. Gene signatures of immunosuppressive 
regulatory T cells showed an increase in gene expression at recurrence across several 
primary-recurrence subtype combinations although the inferred cellular fractions are 
relatively small (Figure 2.18B). 
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 Figure 2.18 Microenvironment transition between primary and paired recurrent tumors 
(A) Red and blue boxplots represent the immune cell fraction distribution of each immune cell 
type. Immune cell fraction was calculated using CIBERSORT and adjusted using ESTIMATE 
purity scores. Difference between cell fraction of primary and paired recurrent tumors was 
calculated using Wilcoxon rank test.  
(B) The blue-to-red heat-map represents changes of immune cell fraction upon tumor recurrence 
per subtype transitions labeled on the left of the heat-map.  
 
In contrast to the trend of monocyte depletion, the imputed M2 macrophage 
frequency was significantly higher at recurrence in cases transitioning to MES (Figure 2.19). 
This observation converges with the higher predicted fraction of M2 macrophages in primary 
MES GBM relative to primary non-MES GBM. M1 macrophages and neutrophils also 
correlated with primary MES GBM, but these associations were not confirmed for recurrent 
GBM.  
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 Figure 2.19 Comparison of M2 Macrophage fractions between MES and none-MES 
subtypes during tumor evolution 
Each dot represents M2 macrophage cell fraction in a pair of primary and recurrent GBM. Red 
dots denote samples transit from none-MES to MES upon recurrence; blue dots denote samples 
transit from MES to non-MES upon relapse.   
 
We validated the increase in macrophages using immunostaining of IBA1 expression 
in two primary-recurrent GBM pairs which were classified as CL to MES. IBA1 immune 
straining signal restricted to macrophages/microglia, cells exhibiting either globular or 
filamentous/spidery morphology, with no expression in glioma tumor cells. Quantitative 
analysis of microglia frequency using inform software for automated pathology imaging 
processing confirmed a significantly higher presence (p value = 2.25e-11 and 2.12e-13 for 
patient #1 and #2, respectively) of at MES recurrence (Figure 2.20). These findings further 
solidify the association between MES GBM and macrophage/microglia and extend this 
mutual relationship to disease recurrence. MES tumors at recurrence compared to primary 
MES tumors showed an increase in transcriptional activity associated with non-polarized M0 
macrophages, which has been previously described (Gabrusiewicz, Rodriguez et al. 2016), 
but also dendritic cells which is potentially motivated by the increased levels of neoantigens 
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at disease recurrence (Kim, Zheng et al. 2015). In contrast, primary PN GBM were found to 
contain significantly higher fractions of five immune cell categories compared to recurrent 
PN GBM, indicating a relative absence of immune infiltration in PN GBM upon recurrence. 
 
 
Figure 2.20 Comparison of M2 macrophage cell fractions in primary and matched 
recurrent tumors  
(A) Representative images of IBA1 immunohistochemistry staining and corresponding score map 
obtained by Inform image analysis in two matched pairs of primary and recurrent GBM. Scale 
bar, 25 μm.  
(B) Unbiased quantification of IBA1+ percentage in primary and recurrent GBMs. 
[* Courtesy of Baoli Hu, Qianghu Wang]  
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 We evaluated the effect of transcriptional class on patient survival. The analysis was 
performed in 50 cases for whom annotation on overall survival (OS) time and time to 
disease progression (PFS) were available and with high simplicity scores, indicating low 
transcriptional heterogeneity. We confirmed the worse prognosis for patients whose primary 
tumor was classified as MES on overall survival (logrank test p=0.029 with HR=1.97) 
(Figure 2.21 AB). This pattern was retained in patients whose secondary glioma was 
classified as MES (logrank test p=0.09 with HR=1.71) (Figure 2.21 CD). Consequently, 
cases for whom both primary and recurrent tumor were classified as MES subtype showed 
the least favorable outcome, suggesting an additive effect of transcriptional class at different 
time points (Figure 2.21 EF and Figure 2.22)  
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 Figure 2.21 Survival analysis of paired IDH wild type GBM 
(A, B) OS and PFS analyses between samples with difference primary subtype (C) Difference of 
survival time after secondary surgery between patients with non-MES and MES in primary 
tumors. (D) Survival analysis of time after secondary surgery between patients with non-MES 
and MES in recurrent tumors. (E, F) OS and PFS analyses between samples with different 
recurrent subtypes 
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 Figure 2.22 Survival analysis on MES versus non-MES patients   
(A, B) Overall and progression free survival analysis between samples in different recurrent 
subtypes of MES versus non-MES. (C) Survival after secondary surgery comparison between 
different transition types. 
 
2.3.6 Treatment-induced immunological microenvironment changes upon GBM 
recurrence 
Temozolomide treatment of gliomas can induce hyper-mutation (Hunter, Smith et al. 2006, 
Kim, Zheng et al. 2015). Missense mutations may generate neoantigens that can be 
recognized by CD8+ T lymphocytes (Schumacher and Schreiber 2015). Using matching 
exome data we classified five recurrent gliomas underwent hypermutation at (>=400 SNVs). 
The predicted frequency of CD8+ T cells was significantly increased at recurrence in 
comparison to their primary tumors (median 7.7% vs 1.9%; Wilcoxon rank test p-
value=0.008) (Figure 2.23A). This observation was further validated by comparing 7 
hypermutated primary GBMs to 238 non-hypermutated GBMs (median 7.0% vs 0%; 
Wilcoxon rank test p-value=0.031) (Figure 2.23B). The majority (61%) of non-hypermutated 
primary GBMs showed predicted CD8+ T cell fractions equal to zero. This observation 
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suggests that patients with hyper-mutated tumors are more likely to benefit from CD8+ T cell 
antitumor immunity. 
 
Figure 2.23 Comparison of CD8+ T cell fraction associated with gain of hyper-mutation 
induced by chemotherapy    
(A) Blue and red diamond indicates individual primary and recurrent tumors. Dash line connects 
paired primary and recurrent tumors.  
(B) Blue and red cycle indicates non-hyper-mutated and hyper-mutated primary samples.  
 
 Preclinical studies suggested radiation may increase the recruitment of T cells in the 
tumor microenvironment (Zeng, See et al. 2013, Deng, Liang et al. 2014). We compared the 
microenvironment of primary GBM treated with radiation therapy and separated short term 
relapse (PFS > 6 months, n = 27) from late relapse (PFS > 12 months, n = 21). Evaluating 
the presence of M2 macrophages and CD4+ T cells (CD4+ T memory resting and CD4+ 
follicular helper cells) based on gene signatures in 75 IDH-WT GBM patients who received 
radiotherapy, we observed no significant difference between their primary tumors with short-
term and long-term relapse but found a significant increase at recurrence post radiation 
therapy (Figure 2.24). M2 macrophages have been speculated to play a role in resistance 
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to radiotherapy(Meng, Beckett et al. 2010, Ruffell and Coussens 2015) and macrophage 
targeting immunotherapy (Pyonteck, Akkari et al. 2013, Ries, Cannarile et al. 2014) may 
boost the radio-sensitivity. The increased level of CD4+ T cells at recurrence for short term 
relapse tumors implying the blockage of CTLA-4 as adjuvant therapy with radiation. 
 
 
Figure 2.24 Comparison of immune cell fractions in paired samples upon relapse after 
different period of radiation   
Sky blue/dark blue and orange/red boxplots indicate short- and long- term relapsed patients. The 
cell fraction of M2 macrophage(A), CD4+ T memory resting cells(B), CD4+ follicular helper cells 
(C) are calculated based on gene signatures implemented in CIBERSORT. 
  
2.4 Discussion 
Transcriptome profiling of tumor samples is a commonly used modality for interrogating 
pathway functionality and phenotype based patient classification. The transcriptional 
footprint left by the tumor microenvironment, which may constitute 10-80% of cells in a 
tumor biopsy (Yoshihara, Shahmoradgoli et al. 2013), can obscure the true activity of the 
signaling network (Isella, Terrasi et al. 2015, Kim and Verhaak 2015). Here, we employed in 
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silico methods to integrate mRNA expression profiles from glioma samples and glioma cell 
culture models to provide insights into glioma-intrinsic pathway activities and classification, 
and to deconvolute the glioma associated stroma into its immunological cellular components.  
GBM expression subtype classification has emerged as an important concept to 
better understand the biology of this devastating disease (Huse, Phillips et al. 2011, Dunn, 
Rinne et al. 2012, Sturm, Bender et al. 2014). Robust classification of new GBM tumors is 
therefore critical to ensure consistency in reporting between different studies. The 
transcriptional glioma subtypes we discovered using tumor-intrinsic gene expression values 
strongly overlapped with the proneural, classical and mesenchymal subtypes but identified 
the neural class as normal neural lineage contamination. Our updated methods, released 
through a R-library, were found to be highly robust and provide the community with a 
standardized strategy for classification of gliomas. 
 Through re-classification of primary GBM samples from TCGA and despite using 
tumor-only transcripts, we observed that the mesenchymal GBM subtype associated with 
the presence of tumor-associated glial and microglial cells. Mesenchymal glioma cell 
differentiation status has been found to correlate with enrichment of macrophages/microglia 
(Kreutzberg 1996, Bhat, Balasubramaniyan et al. 2013). Through in silico cell type 
identification we additionally detected enrichment of various adaptive immunity cell types, 
including CD4+ T lymphocytes.  
Longitudinal analysis of tumor samples is complicated by the lack of tissue 
collections including such pairs. Through aggregation of existing and novel datasets we 
compiled a cohort of 124 glioma pairs, including 91 pairs of IDH wild type tumors. 
Comparison of pairs of initial gliomas and first disease recurrence did not identify the trend 
of proneural GBM transitioning to a mesenchymal phenotype that has often been suspected 
(Phillips, Kharbanda et al. 2006). Mesenchymal subtype at diagnosis and at disease 
recurrent correlated with relatively poor outcome. The recurrent IDH wild type GBM immune 
63 
 
system showed fewer blood derived monocytes which may reflect lower penetration through 
the blood brain barrier. While the frequency of M2 macrophage/microglia was increased in 
recurrent mesenchymal GBM compared to primary non-mesenchymal GBM, the overall 
fraction of M2 macrophage/microglia remained stable. This possibly suggests that the 
majority of these cells are derived from resident CNS macrophages than through active 
recruitment from the circulation.  
  In summary, our study defines a new strategy to determine transcriptional subtype, 
and associated expression classes to the tumor-associated immuno-environment. Our 
findings may aid in the implementation of immunotherapy approaches (Blank, Haanen et al. 
2016) in a disease type with very limited treatment options. Collectively, our results have 
improved our understanding of determinants of GBM subtype classification, the critical 
impact of the tumor microenvironment, and provide new handles on the interpretation of 
transcriptional profiling of glioma.  
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CHAPTER 3 
 
Multi-Gene Signature for Predicting Prognosis of 
Patients with 1p19q Co-deletion Diffuse Glioma 
 (The methods and results in this chapter have been accepted by Neuro- 
Oncology, November, 23, 2016: Xin Hu, Emmanuel Martinez-Ledesma, Siyuan Zheng, Kim 
Hoon, Floris Barthel, Tao Jiang, Kenneth R. Hess, Roel G.W. Verhaak, “Multi-Gene 
Signature for Predicting Prognosis of Patients with 1p19q Co-deletion Diffuse Glioma”. 
According to the journal policy, the first author retains the right to include the published 
article in full or part in a dissertation.) 
 
 
3.1 Introduction 
According to current guidelines for brain tumors, the diagnosis of grade II-III adult diffuse 
glioma is assessed primarily by histopathological examination (Weller, van den Bent et al. 
2014), while molecular abnormalities have been evolving as supportive markers to facilitate 
diagnostics and management of these patients. Diffuse gliomas with mutations in 
IDH1/IDH2 may represent an entirely different type of disease than those with wild type 
IDH1/IDH2, known as IDH-wildtype glioma (Cancer Genome Atlas Research, Brat et al. 
2015, Eckel-Passow, Lachance et al. 2015, Ceccarelli, Barthel et al. 2016). Within the group 
of IDH-mutant glioma, presence of 1p/19q co-deletion (IDH-mutant-codel glioma) may 
present an additional prognostic marker, separate from IDH-mutant glioma with intact 
1p/19q chromosome arms (IDH-mutant-non-codel glioma). The unique characteristics of 
IDH-mutant-codel glioma led to recognition of this subtype in the 2016 World Health 
Organization Classification System of Tumors in Central Nervous System (Louis, Perry et al. 
2016). A series of clinical trials revealed that standard radiation therapy followed by adjuvant 
chemotherapy with procarbazine, lomustine, and vincristine (PCV) delayed disease 
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progression and increased survival in patients diagnosed with anaplastic oligodendroglioma. 
Interestingly, patients harboring the 1p/19q co-deletion demonstrated better response to 
additional chemotherapy than patients whose tumor was 1p and 19q wildtype (Cairncross, 
Wang et al. 2013, van den Bent, Brandes et al. 2013, Dubbink, Atmodimedjo et al. 2015, 
Buckner, Shaw et al. 2016). Approximately 85% of diffuse gliomas with the 1p/19q co-
deletion in the TCGA cohort have an oligodendroglial component and could be classified as 
either grade II (low-grade) or grade III (high-grade) glioma according to the World Health 
Organization (WHO) system. Patients with histologically and molecularly similar glioma may 
show heterogeneous clinical characteristics and response to treatment, which suggest that 
additional factors may determine clinical behavior and prognosis. The management of low-
grade diffuse glioma, including the components necessary for diagnosis, the role of 
surveillance, and the nature of surgical intervention, radiation therapy, and chemotherapy, 
lacking conclusive evidence to support best practices, remains controversial (Zadeh, Khan 
et al. 2015). Phenotypic and genomic inter-tumor heterogeneity of 1p/19q co-deleted 
gliomas may account for inconsistency between clinical observations.(Figarella-Branger, 
Mokhtari et al. 2014, Alentorn, Dehais et al. 2015, Zadeh, Khan et al. 2015) Understanding 
of the biological components associated with clinical and phenotypic heterogeneity will aid 
improved disease staging before treatment and tailoring of appropriate therapeutic regimens.  
Molecular markers such as IDH1/2 mutation, promoter methylation of MGMT, ATRX  
and EGFR gene mutations, and BRAF fusion transcripts or point mutations are increasingly 
recognized as an integral aspect of the clinical management of adult diffuse glioma patients 
(Siegal 2015). There may be a role for molecular markers in risk classification of 1p/19q co-
deletion glioma patients. High-risk patients could receive aggressive treatment with adjuvant 
chemotherapy, whereas low-risk patients might forgo intensive adjuvant chemotherapy. 
Several independent studies have demonstrated that gene expression profiling can be 
applied to identify biomarkers and molecular subtypes of glioma associated with certain 
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clinical outcomes.(Freije, Castro-Vargas et al. 2004, Yan, Zhang et al. 2012)  However, the 
prognostic profiles these studies identified have few genes in common, and the reported 
gene signatures are based on survival information and gene expression patterns from 
histopathological glioma classes. Such gene signatures might not accurately predict survival 
for patients whose gliomas harbor the 1p/19q co-deletion, as the mRNA expression patterns 
and underlying biological characteristics of this subgroup may be intrinsically different from 
those gliomas without the 1p/19q co-deletion, as is implied by its distinct favorable clinical 
outcomes (Huang, Hsu et al. 2015).  
In an integrative analysis of newly diagnosed diffuse glioma patients, we observed 
that glioma patients harboring the 1p/19q co-deletion exhibit heterogeneous clinical 
outcomes (Cancer Genome Atlas Research, Brat et al. 2015),(Ceccarelli, Barthel et al. 
2016). In the present study, we sought to identify molecular markers associated with the 
diverse clinical outcomes in this subset of glioma patients.  
 
3.2 Methods 
3.2.1 Process of the datasets 
Our approach to perform gene signature selection and validation for classification 
using normalized gene expression datasets is summarized in Figure 3.1. We curated gene 
expression and sample information from five publicly available glioma datasets whose 
tumors were assessed with microarrays (Gravendeel, Kouwenhoven et al. 2009, Madhavan, 
Zenklusen et al. 2009, Yan, Zhang et al. 2012) or RNA-Seq (Bao, Chen et al. 2014, Cancer 
Genome Atlas Research, Brat et al. 2015), summarized in Table S1. Normalized RSEM 
values for TCGA glioma samples were retrieved from the LGG-GBM project data portal 
(https://tcga-data.nci.nih.gov/docs/publications/lgggbm_2015). RPKM values for CGGA1 
RNA-seq data (Bao, Chen et al. 2014) were calculated using in house software 
(PRADA)(Torres-Garcia, Zheng et al. 2014). We used Affymetrix Human Genome U133 Set 
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annotation data provided by the Bioconductor library hgu133plus2.db hgu133a.db, and 
Illumina HumanHT-12 WG-DASL to convert microarray probe signals to gene expression 
levels. Multiple probe sets were mapped to a single gene by averaging the signals. In 
addition, we curated and combined two gene expression datasets measured by microarrays 
and used this as a second validation dataset (Guan, Vengoechea et al. 2014, Weller, Weber 
et al. 2015) (Table 3.1). Affymetrix CEL files in training- and first validation dataset but not 
the second validation dataset were normalized together. Overall survival time (OS) was 
defined as time from diagnosis to death; the patients who were alive by the end of each 
study period were censored at the time of last follow-up. Tumor grade was also established 
at primary diagnosis.   
The microarray expression values as retrieved from GEO and the RPKM/RSEM 
values resulting from RNA-sequencing were log2 transformed, respectively. Since each 
expression dataset contained a slightly different set of genes, we merged the expression 
datasets and retained the genes commonly present in all datasets, then fit elastic net to 
perform feature (i.e., gene) selection. Each dataset was globally scaled across all the 
samples and genes and to obtain a mean of 0 with standard deviation of 1 and an empirical 
Bayes framework (combat) was applied to adjust for batch effects on the merged dataset 
(Johnson, Li et al. 2007). Using random sampling, we then assigned glioma samples with 
the 1p/19q co-deletion to the training dataset or the validation dataset.  
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Figure 3.1 Workflow for identification and validation of prognostic gene signatures using 
the elastic net 
Each gene expression data set was scaled separately and batch effects were calibrated using 
ComBat after merging of the five data sets. The gene signature was selected based on the 
optimal value of the regularization parameter λ determined from cross-validation in the training 
model.  The training model was applied to the validation dataset to derive the risk scores, which 
classified the patients in the validation dataset into high- and low- risk groups for assessment of 
prognostic power. 
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Table 3.1  Clinical characteristics of glioma patients harboring 1p/19q co-deletion  
 
Characteristic       No. of patients  
Age, years   (range =17, 87; median = 43)  
  < 43   175 
  > 43    179  
 
 
 
     43   13 
Not available   
 
7 
Gender  
  Male  217 
  Female  148 
  Not available  9 
Time to death/last follow-up for event-free subjects: median  22.7months, range 0-182.3 
months 
Kaplan-Meier estimated median survival time : 75.7 months (range 1-248 months) 
 WHO grade  
  II  179 
  III  159 
  IV  16 
  Not available  20 
Histologic subtype  
  Oligodendroglioma  217 
  Astrocytoma  32 
  Oligoastrocytoma  96 
  GBM  9 
  Not available  13 
 
Table 3.1 Clinical characteristics of glioma patients harboring the 1p/19q co-deletion  
Abbreviations: WHO, World Health Organization; GBM, glioblastoma multiforme. 
Note: The dataset of glioma patients with the 1p/19q co-deletion was curated and selected 
based on  copy number variation information from The Cancer Genome Atlas (15 death events / 
151 patients), the Chinese Glioma Genome Atlas (22 death events / 81 patients), Gravendeel et 
al. (35 death events / 40 patients), and Rembrandt et al. (49 death events/61 patients),Weller et 
al. (4 death events / 31 patients) (Weller, Weber et al. 2015) and Guan et al (1 death event / 10 
patients)(Guan, Vengoechea et al. 2014).   
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3.2.2 Predicting 1p/19 status using gene expression 
DNA copy number profiles determining 1p/19q status were available for a subset of the 
cohort (Table 3.2). For cases described below where copy number profiles were absent, we 
applied a Gaussian window smoothing algorithm on the expression dataset to infer the 
pattern of chromosome arm sized copy number variations (CNVs). Using the expression 
values of the genes located at Chr-1p and Chr-19q sorted by their genomic locations from 
start to end, we used a sliding 100 gene window to determine chromosome arm wide 1p/19q 
expression levels. We applied the following equation to the resulting gene-specific 
expression patterns to determine 1p/19q status: where (𝑎𝑎) is the estimated copy number 
(relative value) of sample k at ith gene in genomic-ordered gene list, g𝑗𝑗 is the jth gene in the 
genomic-ordered gene list, and (g𝑗𝑗) is the relative gene expression value of that gene in 
sample k. Note that the estimated 1p/19q status is often consistent with the chromosome 
centromere borders, with increased or decreased values within specific chromosomes, 
suggesting that it accurately represents chromosomal changes. We then applied 
hierarchical cluster analysis to CNVk (i) values to assign all the samples from each dataset 
into a group reflecting 1p/19q co-deletion, and another group with 1p/19q wild type copy 
number.  
 
Table 3.2 Data sources for gene expression and CNV in glioma patients harboring 1p/19q co-
deletion  
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3.2.3 Correlation of somatic mutations and clinical outcome 
We applied the Kaplan-Meier estimator to assess the prognostic value of the most prevalent 
mutations in glioma, CIC, FUBP1, NOTCH1, and PIK3CA mutations, on overall survival 
(OS). Two-sided log-rank tests were applied to examine the differences of overall survival 
(OS) between the patients with and without any of these mutations. P values < 0.05 were 
considered statistically significant. We conducted this analysis using the TCGA dataset, 
which included mutation information. Although OS might be affected by treatment bias at the 
time of tumor progression, OS data are generally more accurate than PFS data; therefore, 
we used OS to represent clinical outcomes that more accurately reflect disease 
aggressiveness in each glioma patient. 
 
3.2.4 Gene signature selection and risk based classification 
Using the training set, we first pre-filtered the genes based on Wald p-values generated 
from univariate Cox models and selected the 1,000 most significant genes, then applied the 
Cox proportional hazards model with elastic net penalty for variable selection. The univariate 
and multivariable Cox models were built using the R package “survival”; the elastic net 
regression (i.e., the combination of L1 regularization and L2 regularization) was performed 
using R package “glmnet.”(Friedman, Hastie et al. 2010, Hughey and Butte 2015) The 
penalty parameter λ was chosen based on 3-fold cross validation within the training set, 
which produced the minimum mean cross validated error for the Cox model. Thus, we used 
shrinkage-based regularization combined with a univariate Cox model to obtain the gene 
signature.  
Using the training dataset, we fit a multivariable Cox proportional hazards model with 
the genes identified using the above penalty-based method. We then computed a prognostic 
index for each individual patient in the validation set through multiplying their gene 
expression values by the corresponding regression coefficients estimated from the training 
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data. This resulted in a risk score for each patient in the validation dataset according to a 
linear combination of the mRNA expression level from the validation data weighted by the 
multivariable Cox model–derived regression coefficients from the training data. We 
calculated the concordance index (C-index) and its standard error for the gene signature, 
age, grade, and gene signature combined with age and grade, using the R package 
“survcomp” (Schroder, Culhane et al. 2011) We also calculated the hazard ratios (HR) and 
their 95% confidence intervals between two groups of patients with risk scores above and 
below the median risk score computed from the training dataset. 
 
3.2.5 Association of risk classification and clinical outcome 
We divided the patients from the validation dataset into high- risk and low-risk groups based 
on their risk scores derived from the linear prediction, using the median risk score in the 
training set as cut-off value. We used the Kaplan–Meier estimator and the two-sided log-
rank test to evaluate the differences in overall survival (OS) between the high- and low-risk 
patients. To examine the robustness of the risk-based classification using selected genes, 
we divided the patients into subgroups using a series of different risk scores as cut-off 
values and evaluated the difference of OS between high- and low-risk groups using the 
Kaplan–Meier estimator and hazard ratio (HR). To further investigate the trend of the OS 
pattern to align with the predicted risk scores, we fit a smoothing spline to ascertain the 
association of risk scores with the OS of the patients in the validation dataset.  
 
3.2.6 Gene Set Variation Analysis of Associated Genes and Top Gene Ontology Terms 
We first used a Student’s t-test to identify the genes differentially expressed between the 
high- and low-risk groups, only including genes with a p-value of less than 0.05 and an 
absolute difference in median gene expression of 0.4. We then mapped the gene ontology 
(GO) terms of the corresponding 260 genes that present the most variance in expression 
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between the two risk groups. We applied gene set variation analysis (GSVA)(Hanzelmann, 
Castelo et al. 2013) to obtain the enrichment scores for each gene set that corresponding to 
the GO terms containing those genes in all the patients.  
 
3.2.7 Evaluation of Tumor Purity with ESTIMATE gene signatures 
We inferred tumor purity of each sample using ESTIMATE (Yoshihara, Shahmoradgoli et al. 
2013), which reflects the enrichment of stromal and immune cell gene signatures in a 
transcriptional profile.  
 
3.3 Results 
3.3.1 Effects of somatic mutations on patient outcome 
Recent studies by TCGA and others have revealed genes frequently mutated in IDH-mutant 
and 1p/19q co-deleted glioma, including the 1p gene FUBP1 and the 19q gene CIC. 
Mutations in these genes fulfill the classic Knudson tumor suppressor two-hit model in which 
one allele is lost and the second is inactivated through somatic mutation. Thus, gliomas 
carrying CIC/FUBP1 mutations are candidates for further progressing disease. To test this 
hypothesis, we performed univariate survival analyses of 151 diffuse IDH-mutant-codel 
gliomas from TCGA. We found significant correlation between overall survival (OS) and the 
presence of the FUBP1 mutation (n = 40 of 151; log-rank test p-value = 0.05) but not the 
CIC mutation (n = 71 of 151; log-rank test p-value = 0.71). No associations were observed 
for other gene mutations frequently detected in IDH-mutant-codel gliomas such as in 
NOTCH1 (23/151; log-rank test p-value = 0.46), or PIK3CA (20/151; log-rank test p-value = 
0.06). Despite the relatively small numbers of death events in the TCGA dataset (15 of 151), 
our results suggest that these mutations do not significantly affect disease progression or 
clinical outcomes in IDH-mutant-codel glioma patients.  
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3.3.2 Constructing a gene expression data set of 1p/19q co-deleted glioma 
Since only FUBP1 somatic point mutations showed a significant association with patient 
outcome, we set out to identify a gene expression signature with the potential to identify 
high-risk IDH-mutant-codel patients. We curated gene expression and clinical information 
from seven publicly available datasets of adult diffuse glioma patients whose tumors were 
assessed by microarray or RNA-Sequencing. Where available, we used annotation on 
1p/19q co-deletion available per the respective publications or data from genome-wide DNA 
copy number profiling to identify IDH-mutant-codel cases. As this data was unavailable on 
some data sets, we applied a Gaussian window smoothing algorithm to infer the signal of 
large scale CNVs for each sample. By suppressing individual gene-specific expression 
patterns, and averaging relative expression values over large genomic regions, we selected 
the samples that harbor the 1p/19q co-deletion based on the hierarchical clustering of the 
CNVs estimated from each dataset (Figure 3.2). We found that our method could predict 
1p/19q codel status with high accuracy in the TCGA data set (sensitivity=0.97, 
specificity=0.97, Mathews correlation coefficient (MCC) = 0.94). Using the window sliding 
method in the Weller et al dataset, which included CGH-based 1p/19q status, we obtained a 
specificity of 0.91.  We found 411 of 2,231 gliomas to contain the 1p/19q co-deletion and 
retained those samples with survival data, resulting in two combined datasets consisting of 
374 (n = 333 for first dataset, n = 41 for second dataset) clinically annotated 1p/19q codel 
IDH mutant glioma gene expression profiles (Table 3.1). The patient characteristics of the 
1p/19q co-deletion glioma cohort are summarized in Table 3.1. The patients’ median age at 
diagnosis was 43 years (range, 17-87 years) with Kaplan-Meier estimated median survival 
time of 75.7 months (range, 1-248 months), including 121 events. Amongst censored cases, 
the median follow up was 22.7 months.  
After performing scale normalization using the 13,345 genes common to all data sets, 
we found no distinct clustering in any of the 5 gene expression datasets in the training- and 
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first validation set, suggesting that any platform or batch variance across the different 
datasets had been mostly eliminated (Figure 3.3).  
 
 
Figure 3.2 Co-deletion of 1p/19q inferred by gene expression profiling  
Normalized gene expression levels of chromosome 1 and chromosome 19. The top panel shows 
the Rembrandt glioma dataset (n = 69 with co-deletion, n = 550 total). The bottom panel shows 
the TCGA dataset. The top bar denotes the CODEL status based on SNP6 DNA copy number 
arrays, the bottom bar denotes the CODEL status inferred by our method using gene expression 
data (n = 162 with co-deletion, n = 667 total). The green bar denotes the samples classified as 
CODEL, the yellow bar denotes the samples classified as non-CODEL. The averaged 
expression level is shown in red-white-blue scale.  
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 Figure 3.3A Distribution of normalized gene expression datasets from different data 
sources  
The density plot represents the transformed and merged datasets of gliomas with the 1p/19q co-
deletion used for featured gene selection and prediction modeling. Datasets were curated from 
TCGA_RNAseq (151, events = 15), Gravendeel et al (GSE16011, NETH) (40, events = 35), 
Rembrandt et al (REMB) (61, events = 49), CGGA1_RNAseq (63, events = 15), 
CGGA2_Microarray (18, events = 7). 
 
Figure 3.3B The Principal Component Analysis (PCA) of transformed datasets 
All samples in the transformed gene expression dataset were plotted using the top principal 
components (PCs) which captured the majority of the variance in the input dataset. Each sample 
is denoted by a single dot. And each colored symbol represents a data source as labelled on the 
right. The inertia ellipses represent 95% of the inertia of the corresponding dataset.  
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3.3.3 Identification of a 35-gene signature associated with overall survival   
We divided 333 patients from the first combined dataset including five original datasets 
(Table 3.1) into training and validation datasets by event-frequency matched random 
sampling, so that each consisted of comparable numbers of astrocytic, oligodendrocytic, 
and mixed histological tumor subtypes. We also balanced for chemotherapy and 
radiotherapy treatment. Through the controlled randomized sampling process, the training 
dataset (n=170, death events = 64) included 105 samples with treatment annotation of 
whom 26 patients received radiotherapy and 26 patients received chemotherapy, with 
eleven of those cases undergoing both radio- and chemo-therapy. The remainder of the 105 
patients (n = 64) were surgically debulked without further treatment. The first validation 
dataset (n=163, death events = 57) consisted of 84 samples with treatment information of 
whom 22 patients received radiotherapy and 18 patients received chemotherapy. To build 
the training model, we selected the 1,000 genes with the most significant linear correlation 
with overall survival (OS). We then applied a linear regression function that fits the Cox 
model regularized by elastic net penalty (Figure 3.4), to select 35 genes as active 
covariates of the Cox model to assess the prognostic index in the validation sets (Table 3.3).  
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hgnc_symbol entrezgene band start_position end_position P.value_Diff_Expression 
ADIG 149685 q11.23 38581195 38588463 8.97E-01 
ARHGEF15 22899 p13.1 8310241 8322516 1.28E-01 
CCDC58 131076 q21.1 122359591 122383231 1.36E-03 
CCKAR 886 p15.2 26481400 26490462 2.28E-05 
CDC37 11140 p13.2 10391134 10420121 1.25E-03 
CRYBA2 1412 q35 218990189 218993421 4.51E-01 
DOCK4 9732 q31.1 111726110 112206411 1.83E-03 
EGR1 1958 q31.2 138465490 138469315 2.91E-03 
EGR3 1960 p21.3 22687659 22693302 2.49E-06 
EXOC8 149371 q42.2 231332753 231337852 5.86E-05 
FBXO36 130888 q36.3 229922302 230013109 2.28E-02 
FOXD2 2306 p33 47436017 47440691 1.40E-05 
FRZB 2487 q32.1 182833275 182867162 4.48E-05 
GAS2 2620 p14.3 22625642 22813055 1.29E-08 
GATA4 2626 p23.1 11676959 11760002 3.24E-02 
GRK5 2869 q26.11 119207589 119459742 1.54E-03 
GSTO2 119391 q25.1 104268873 104304945 1.83E-02 
HSD17B2 3294 q23.3 82035004 82098534 9.55E-04 
IARS2 55699 q41 220094102 220148041 1.25E-02 
IFT88 8100 q12.11 20567069 20691437 4.13E-05 
IL32 9235 p13.3 3065297 3082192 1.11E-06 
ITIH3 3699 p21.1 52794768 52809009 3.41E-02 
LHCGR 3973 p16.3 48686775 48755730 1.15E-09 
MAP9 79884 q32.1 155342658 155376970 2.25E-03 
MIPEP 4285 q12.12 23730189 23889419 2.40E-02 
MTMR6 9107 q12.13 25246201 25288009 5.34E-04 
PF4V1 5197 q13.3 73853189 73854155 1.10E-02 
POU4F2 5458 q31.22 146638893 146642474 3.91E-06 
PTGDR 5729 q22.1 52267713 52276724 1.75E-03 
RPS8 6202 p34.1 44775251 44778779 2.48E-06 
SDHC 6391 q23.3 161314257 161375340 3.66E-02 
TFAP2B 7021 p12.3 50818723 50847613 5.33E-03 
TRAT1 50852 q13.13 108822698 108855005 8.93E-04 
TRH 7200 q22.1 129974305 129977938 8.91E-04 
TRPA1 8989 q21.11 72019917 72075617 1.17E-06 
 
Table 3.3 Annotation of 35 gene signature for prediction    
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Figure 3.4 Partial likelihood deviances as function of regularization parameter λ for 3-fold-
cross validation in the training dataset 
The penalization criteria cross-validated error rates in the training dataset were plotted. Each red 
point represents a λ value along regularization paths for Cox model; with error bars in gray lines 
representing confidence intervals for the cross-validated error rate (Partial Likelihood Deviance). 
The left vertical line in green marks the minimum error while the right vertical line denotes the 
largest value of λ so that the error is in one standard deviation from the minimum. The top 
number of the plot labeled the size of each model upon shrinkage and selection based on linear 
regression. The bottom panel illustrates the zoom in plot.   
 
To assess the performance of the signature genes as classifiers, we computed a 
linear combination of the 35 genes using the coefficients of multivariable Cox regression 
derived from the training dataset to calculate the risk scores for the patients in the first 
validation dataset. Using median risk score amongst samples from the training dataset as 
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the cutoff value to divide the first validation dataset into high risk and low risk groups, we 
found a significant difference in OS time between the two groups (log-rank test p-value = 
0.014) (Figure 3.5A).The high risk group associated with HR of 2.03 (95% confidence 
interval, 1.14-3.60).  The median OS duration was 75.2 months for the patients (n=84) with 
high-risk prognostic indices and 118.2 months for those (n=79) with low-risk indices. We 
also found a significant difference in OS when dividing the first validation set using the upper 
and bottom quartile risk scores (log-rank test p-value = 0.0085; HR = 2.9 (95% confidence 
interval, 1.3- 6.6), Figure 3.5B).  
 
Figure 3.5 Kaplan-Meier survival analysis of glioma patients harboring 1p/19q co-
deletion according to 35-gene signature derived risk scores 
(A) Kaplan-Meier cumulative survival curves for first validation set glioma patients with 1p/19q 
co-deletion tumors, classified in two groups based on 35-gene signature derived risk scores. The 
survival of the high-risk patients (solid line) was significantly worse than that of the low-risk 
patients (dashed line; p-value = 0.014, log-rank test; hazard ratio = 2.02).  
(B) Kaplan-Meier survival curves for the top and bottom quantile of glioma patients with the 
1p/19q co-deletion in the first validation dataset based on 35-gene signature derived risk scores 
are shown. Patients in the first validation dataset were divided into high- and low-risk subgroups 
according to the risk scores derived from the multivariable Cox model. The survival of the high-
risk patients (upper quartile, red line) was significantly worse than that of the low-risk patients 
(bottom quartile, green line; P = 0.0085, log-rank test).  
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We evaluated several different arbitrary risk score cutoffs to define high- and low-risk 
patient groups and found that regardless of cutoff value chosen, the overall survival of the 
low-risk group show significantly better than that in the high-risk group (Figure 3.6 and 
Figure 3.7).  
 
 
Figure 3.6 Consistent prediction of prognosis in high- and low-risk groups 
Patients were divided into high- / low-risk groups using different risk scores (prognostic index) 
after adjustment for age and stratification by grade. The cut-off value (0, 0.5, 1, 1.5, 2, and 2.5) 
was assigned to each test respectively. Survival curves for the high-risk patients (red) and low-
risk patients (purple) are shown. The log-rank P values and HRs for each subgroup are labeled 
in each plot.  
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 Figure 3.7 Hazard Ratios (HR) with 95% CIs for gene signatures in high- versus low-risk 
groups 
The x-axis indicates the risk scores (derived from 15-year survival probabilities) used as cutoff 
values. The pink bars (bottom) indicate the proportion of patients in the high-risk group from the 
first validation dataset; blue diamonds (top) denote HRs adjusted for clinical risk based on 15-
year survival probability and the blue vertical lines denote the corresponding 95% CIs.  
 
We then computed risk scores on 41 samples with predicted 1p/19q co-deletion from 
two datasets that were not included in the training set (Table 3.1). There was no significant 
difference in overall survival between the two resulting groups in this second validation set 
(log-rank test p-value=0.25, HR = 2.7) which is likely due to the low number of death events 
(n = 5) (Figure 3.8A). Combining both validation sets into a single analysis showed a highly 
significant difference in survival between high and low risk classes (log-rank test p-value= 
0.00058, HR = 2.65) (Figure 3.8B).  
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Figure 3.8 Kaplan-Meier survival analysis of co-deletion glioma according to 35-gene 
signature derived risk scores 
(A) Kaplan-Meier survival curves for the glioma patients with 1p/19q co-deletion an independent 
dataset compiled from publications by Guan et al and Weller et al. predicted according to gene 
expression in an independent second validation dataset based on the median cut-off of 35-gene 
signature derived risk scores are shown. Patients in the second validation dataset were divided 
into high-risk (red line) and low-risk (green line) subgroups according to the risk scores and 
cutoff based on the median value in the training cohort. (P = 0.25, log-rank test; hazard ratio = 
3.30).  
(B) Kaplan-Meier survival curves for 1p/19q co-deletion glioma patients from combined first and 
second validation dataset, separated into two groups based risk score. The survival of the high-
risk patients (red line) shown significantly worse than that of the low-risk patients (green line; P = 
0.00058, log-rank test; hazard ratio = 2.65).  
                                               
In addition, we examined scaled Schoenfeld residuals to verify the proportional 
hazards assumption (Figure 3.9) and analyzed martingale-residuals (Figure 3.10) to verify 
linearity, as well as Variance Inflation Factor (VIF) analysis on 35 genes included in the final 
multivariable Cox model to assess the potential for multi-collinearity on those 35 signature 
genes (Table 3.4). The results of residual analysis with overall VIF were acceptable without 
high correlation, with all VIF values being less than ten in the training dataset. These results 
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suggest that the 35-gene signature is significantly associated with the survival of 1p/19q 
codel patients.  
 
 
 
Figure 3.9 Schoenfeld residual plots to evaluate the proportional hazard assumption of 
signature genes 
The X-axis represents the overall survival time for each patient; Y-axis represents 
scaled Schoenfeld residuals, the black dots represent the Schoenfeld residuals for each 
predictor in the model. The horizontal red line refers to Schoenfeld value as zero on the 
individual plots. The solid black curve is a cubic split fit to the data and the dashed black lines 
represent upper and lower approximate 95% confidence limits. 
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Figure 3.10 Martingale residuals to evaluate the linearity of log hazard on signature genes 
The X-axis represents the expression value of each signature gene in all the patients; Y-axis 
represents martingale residuals, the green dots represent the martingale residuals for each 
predictor (covariates) in the hazard model. The horizontal red line refers to a nonparametric 
loess regression line on the individual plots.  
 
 
When we examine the association between risk scores and overall survival time, we 
observed a trend for the high risk group towards reduced survival compared to the low risk 
group (Figure 3.11). 
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Table 3.4 Variance inflation factors (VIF) of 35 gene signature for prediction in the training 
dataset    
Gene Signature 
Variance Inflation 
Factor (VIF) 
PF4V1 2.144599 
GAS2 2.774342 
TRAT1 2.836738 
CRYBA2 3.037724 
CCKAR 3.254183 
IL32 3.264624 
EGR1 3.347227 
ITIH3 3.353768 
CCDC58 3.379878 
MTMR6 3.395117 
CDC37 3.404695 
TRH 3.525869 
TFAP2B 3.573467 
ARHGEF15 3.621795 
ADIG 3.635986 
MAP9 3.702387 
RPS8 3.713787 
GRK5 3.76141 
SDHC 3.836232 
DOCK4 4.013433 
EXOC8 4.109896 
FOXD2 4.131283 
GSTO2 4.212632 
FBXO36 4.245492 
EGR3 4.420287 
TRPA1 4.536422 
POU4F2 4.666415 
HSD17B2 5.37498 
LHCGR 5.83129 
GATA4 5.871038 
IFT88 6.036097 
PTGDR 6.606242 
FRZB 7.335438 
IARS2 7.560403 
MIPEP 9.128166 
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Figure 3.11 Correlation between gene signatures derived risk scores and overall survival 
time.  
The purple dots represent low-risk patients (negative risk scores), and the red dots represent 
high-risk patients (positive risk scores). The soft dots represent living patients; the solid dots 
represent dead patients. The green line plots a smooth, nonparametric estimation of the quantile 
distribution of overall survival (OS) as a function of patients’ risk scores. 
 
3.3.4 Multivariable analysis shows prognostic power of 35-gene signature 
Using prognostic index (risk score) as a continuous covariate, we determined the predictive 
accuracy by computing the C-index of the gene signature, age and grade. We also 
examined the C-index value of the gene signature combined with age and grade. Both 
analyses were performed in the joint validation set restricted to the patients whose age and 
grade information is available. The C-index of the gene signature (0.626 ± 0.044) was 
comparable to that of age (0.640 ± 0.048), or grade (0.640 ± 0.073) alone (Table 3.5). The 
highest C-index was achieved in when combining the three variables (0.663 ± 0.041). These 
results suggest that risk prediction is most accurate when combining the 35-gene signature 
with age and tumor grade.  
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 Table 3.5 Performance of Multivariable Analysis in Validation Dataset 
 
Predictor 
Gene 
signature  Age Grade Age + Grade 
Gene signature + Age + 
Grade 
C-Index ± 
SE 0.626±0.044 0.640±0.048 0.640±0.073 0.656±0.041 0.663 ± 0.041 
C-
Index(CI) 0.540, 0.712 0.545, 0.734 0.497, 0.785 0.574, 0.737 0.583, 0.743 
HR (95% 
CI) 
1.78 
(1.02 - 3.11) 
1.71 
(0.99 - 2.97)  
1.26  
(0.74 - 2.15)  
2.06 
(1.18 - 3.60) 3.23 (1.73 - 6.04) 
 
Abbreviations: C-index, concordance index; HR, hazard ratio; CI, confidence interval 
Estimates are based on data from patients in the combined validation dataset (n=191,1st 
validation dataset + 2nd validation dataset), with both age and grade information available. The 
hazard ratios (HR) and their 95% confidence intervals between two groups of patients in the 
validation dataset were calculated based on their risk scores above and below the median risk 
score computed from the training dataset.  
 
3.3.5 Functional Annotation of 35 Gene Signatures  
We compared gene expression between the high- risk and low- risk groups and found that 
32 out of 35 signature genes showed a significant difference (Figure 3.12, Table 3.3).   
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 Figure 3.12 mRNA differential expression patterns of 35 signature genes in two risk 
groups 
The normalized level of mRNA expression was plotted, with genes labelled on the left along with 
their corresponding p-values on the right, asterisks indicating the significance of differential gene 
expression (t-test) between two groups with predicted high risk (right part) and low risk(left part) 
(***P < 0.001, **P < 0.01 and *P < 0.05). The dendrogram on the left showed the cluster by 
genes. The top bar show each patient’s predicted risk scores (green indicates low risk and brown 
indicates high risk) and its source dataset. (TCGA=red, Gravendeel=purple, Rembrandt=cyan, 
CGGA1_microarray=yellow, CGGA2_RNAseq=pink).  
 
Gene set variation analysis revealed that the gene ontology (GO) terms which mapped to 
the genes that were differentially expressed in high- and low-risk groups were associated 
with acetylation activity, response to copper ions, prostaglandins and inflammation (Figure 
3.13). The corresponding biological functions of protein acetylation, inflammatory response 
and copper homeostasis may contribute to these patients’ high risk and poor clinical 
outcomes.  
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Figure 3.13 Association of risk groups with gene ontology (GO) function   
Risk scores for each patient (top bar; in ascending order, from left to right) were derived from a 
multi-variable Cox model. Gene set variance analysis (GSVA) was used to calculate gene set 
enrichment scores (bottom). The P-values on the right were obtained using a t-test of enrichment 
scores from high-risk and low-risk groups for each GO term.  
 
The presence of the inflammation category amongst the differentially activated GO 
terms suggested differences in the tumor microenvironment between high-risk and low-risk 
groups. We applied the ESTIMATE algorithm to predict tumor purity using the gene 
expression profiles (Yoshihara, Shahmoradgoli et al. 2013) and found a significant increase 
in ESTIMATE scores in the high risk group (Figure 3.14), suggesting that a greater 
presence of inflammatory microenvironment components is associated with progressive 
tumorigenesis. 
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 Figure 3.14 Comparison of ESTIMATE scores in high- and low-risk group in the first 
validation dataset of 1p/19q codel  
(A) Scores computed by the ESTIMATE tumor purity algorithm were plotted for the high-risk (red) 
and low-risk group (blue) from the first validation dataset, with p-values indicating the 
significance of the difference between ESTIMATE scores (t-test) between two groups (***P < 
0.001).  
(B) The correlation of ESTIMATE scores (X-axis) and risk scores (Y-axis) are plotted. The 
LOESS curve in green fitted to ESTIMATE scores from risk scores. The confidence intervals of 
loess regression are in yellow. 
 
 
3.3.6 Applying the 35-Gene Signature across Glioma 
We asked whether the 35-gene signature model is also associated with patient survival in 
patients with IDH-wildtype or IDH-mutant-non-codel gliomas. From TCGA, we obtained the 
gene expression profiles from 223 IDH-mutant gliomas that were wild type for chromosome 
arms 1p and 19q, as well as the transcriptional profiles from 221 IDH-wildtype gliomas. The 
analysis was restricted to cases with available outcome data and expression data generated 
by RNA-sequencing. After computing risk scores for all samples we separated the two 
datasets into a low risk and high risk group based on median risk score respectively and 
observed significant differences in overall survival for both glioma categories (Figure 3.15).  
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 Figure 3.15 Prediction of outcome in non-codel IDH-mutant glioma and IDH-wildtype 
glioma   
Kaplan-Meier cumulative survival curves for TCGA diffuse glioma patients whose tumors carry 
IDH-mutation but not the 1p/19q co-deletion (left) and with IDH-wildtype tumors (right), classified 
into two groups based on 35-gene signature derived risk scores. p-value is the result of a log-
rank test between the two groups shown in each panel. 
 
To gain insight into the universal relevance of the 35-gene signature across different 
molecular subtypes of glioma, we also applied the ESTIMATE algorithm to compare tumor 
93 
 
purity between high- and low- risk groups. With IDH-mutant-codel gliomas, we found that 
ESTIMATE based tumor purity scores were significantly lower in the low-risk group of IDH-
wildtype glioma samples, compared to their high-risk counterpart. This was not the case for 
IDH-wildtype LGG, nor for IDH-mutant-non-codel gliomas regardless of grade (Figure 3.16 
A, B). The difference in microenvironment presence between high- and low-risk group of 
IDH-wildtype glioblastoma emphasizes the facilitating role that tumor-associated microglia 
play in promoting disease progression (Hanahan and Weinberg 2011). 
 
 
 
Figure 3.16 Comparison of ESTIMATE scores in high- and low-risk group of IDH-mutant-
non-codel and IDH-wildtype glioma 
(A) Scores computed by the ESTIMATE tumor purity algorithm were plotted for the high-risk (red) 
and low-risk (blue) groups from IDH-mutant-non-codel (left) and the IDH-wildtype (right) TCGA 
cohorts, with p-values reflecting the significance of the difference between ESTIMATE scores (t-
test) between two groups. 
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(B) Scores computed by the ESTIMATE tumor purity algorithm were plotted for the high-risk (red) 
and low-risk group (blue) from the IDH-wildtype-GBM, with p-values reflecting the significance of 
difference between ESTIMATE scores (t-test) between two groups. 
 
3.4 Discussion 
High-throughput gene profiling and sequencing have yielded new insights on the molecular 
aberrations underlying glioma progression.(Verhaak, Hoadley et al. 2010, Ceccarelli, Barthel 
et al. 2016). As our perspective on the optimal clinical and molecular marker based 
classification of adult diffuse glioma harboring 1p/19q co-deletion progresses, biomarkers for 
risk based classification may provide additional value. Our systematic analysis identified a 
35-gene signature, which classified 1p/19q codel glioma patients according to their overall 
survival. Remarkably, the median survival of the group of patients classified as high risk was 
75 months, as opposed to 45 months for non 1p/19q codel patients, confirming that 1p/19q 
codel patients have a favorable overall survival and suggesting a relatively homogeneous 
disease subtype. Our gene signature was derived from multiple data sources, representing 
patients from a mixture of diffuse glioma grades and histologies. We validated the 
prognostic performance in independent validation datasets and showed the signature to 
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have added predictive signal when combined with known prognostic markers such as age 
and grade. Due to the unavailability of some of the files needed, normalization of training 
and validation datasets could not be performed entirely separately. Patients in our cohort 
were treated using a variety of different modalities and treatment annotation was lacking for 
a substantial portion of the dataset. With the recent introduction of a potential standard of 
care for low grade glioma (Buckner, Shaw et al. 2016), it is important to repeat and validate 
the gene signature on a coherently treated patient data set, while considering additional 
prognostic factors such as tumor size, location, and extent of resection. In order to pursue 
validation studies, risk scores can be computed using the gene signature and regression 
coefficients derived from the training dataset. 
          The univariate Cox model alone is insufficient for feature selection through estimation 
of survival as clinical endpoints when solving regression problems with high dimensional 
data. To prevent overfitting, the ridge regression Cox model demonstrates the best 
performance in tested datasets (Bovelstad, Nygard et al. 2007). Therefore, we applied the 
univariate Cox model to select genes related to OS time and regularized regression 
coefficients calculated by an elastic net regression Cox model, which combined the 
algorithm of ridge and lasso regression, to improve the predictive performance in the 
independent datasets. Owing to the relatively small number of events (64 deaths /170 
patients in training dataset), we applied a 3-fold cross validation for Cox PH regression and 
selected the signature genes with optimized λ based on penalty regularization. While none 
of the individual genes showed an exceptionally high coefficient in our Cox model, multiple 
genes cumulatively exhibited an effect on survival prediction. Finally, we used multivariable 
Cox regression to adjust the selected genes for the clinical factors age and grade and to 
generate our prognostic index. As treatment information was unavailable for a considerable 
portion of our cohort (43%), we did not consider treatment variables in our statistical 
modeling.   
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             Pathway analysis suggested that N-terminal acetyltransferases (NATs), protein 
acetylation, response to copper ions, prostaglandins and inflammation may be involved in 
1p/19q glioma progression. Therapeutic agents including tamoxifen and cisplatin have been 
reported to demonstrate their anti-cancer effects through NAT inhibitory activity (Lu, Lin et al. 
2001, Lee, Lu et al. 2004, Ragunathan, Dairou et al. 2008, Kalvik and Arnesen 2013), 
suggesting targeting of NATs as a potential therapeutic strategy in high risk 1p/19q co-
deleted cases. In addition, copper depletion may act as an effective anti-angiogenesis 
strategy (Goodman, Brewer et al. 2004), and prostaglandins play an important role in cell 
adhesion, migration, and invasion during cancer development (Menter and Dubois 2012). 
Accordingly, the genes involved in protein acetylation and response to inflammation and 
copper are highly expressed in high-risk glioma patients (Di Cerbo and Schneider 2013). 
These data indicate that alterations in the expression levels of these signature genes might 
exert significant roles in glioma progression by promoting growth and conveying cell survival 
advantages. In addition to our pathway analyses, we noted that the stromal and immune 
related signals quantitated via ESTIMATE scores were significantly increased in the high–
risk group relative to the low–risk group of 1p/19q codel glioma as well as in IDH-wildtype 
glioblastoma. This observation implies an association between the survival risk predicted by 
our gene signature and the infiltration by tumor-associated normal cells, which play a crucial 
role in microenvironment regulation during tumor progression(Quail and Joyce 2013). Four 
genes (ITIH3, TRAT1, FRZB, IL-32) from 35 genes signature overlap with the stromal and 
immune gene signatures use to define ESTIMATE scores, further suggesting the tumor 
microenvironment as an potential risk factor for subsets of glioma patients.   
Collectively, our findings highlighted signature genes that might be involved in critical 
tumor progression and fundamental biological functions in gliomas with the 1p/19q co-
deletion. The lack of treatment standardization amongst our patient cohort means that 
further research is needed to determine whether this or other gene signatures are able to 
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serve as treatment biomarkers. Ideally, clinical decisions would be based on a predictive 
model integrating clinical variables, tumor phenotypic and molecular factors. While further 
and prospective validation is needed, the gene signature approach may provide a starting 
point to better understand prognostic risk factors in 1p/19q co-deletion glioma. The results 
described here provide a first report investigating the heterogeneity of the relatively novel 
entity of 1p/19q codel glioma.  
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CHAPTER 4 
Prediction of emerging fusion transcripts with oncogenic potential 
in The Cancer Genome Atlas pan- cancers 
 
4.1 Introduction 
Fusion transcripts are chimeric genes derived from partial DNA fragments of two previously 
independent gene partners. The prevalence of gene fusions varies widely between cancer 
types; gene fusions have been previously reported in 90% of all lymphomas, over half of 
leukemia, and one-third of soft-tissue tumors (Parker and Zhang 2013). Overall, recurrent 
fusion events occur at low frequencies; for example, KIF5B-RET fusion presents in 1%–2% 
of lung adenocarcinomas (Qian, Chai et al. 2014, Huang, Schneeberger et al. 2016).  
Fusion transcripts are a result of mechanisms such as genomic rearrangements, 
including chromosome translocations (Guarnerio, Bezzi et al. 2016) and interstitial deletions 
(Hermans, van Marion et al. 2006, Meyer, Brieger et al. 2009); transcriptional read-through 
of neighboring transcription units (Nacu, Yuan et al. 2011, Varley, Gertz et al. 2014); and 
trans- and cis-splicing of adjacent genes (Zhang, Gong et al. 2012, Velusamy, Palanisamy 
et al. 2013, Jividen and Li 2014, Qin, Song et al. 2015). Many fusion transcripts are 
associated with oncogenic potential, which is correlated with the chimera proportion of the 
transcripts, and thus fusion transcripts play a critical role as driver mutations in a wide 
spectrum of cancer types (Bos, Gardizi et al. 2013, Watson, Takahashi et al. 2013, Zhou, 
Yang et al. 2013). Most gene fusions exert their oncogenic impact by regulating a fusion 
protein with oncogenic activity (e.g., by triggering constitutive activation of tyrosine kinase, 
on which cancer cells become dependent through “oncogene addiction”), by disrupting a 
function (e.g., by truncating the coding sequence of tumor suppressor genes), or by 
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deregulating one of the partner genes (e.g., by gain or loss of ubiquitination sites that 
modulate the stability of the original proteins).  
Recent advances in bioinformatics have elucidated many aspects of oncogenic gene 
fusions, from the causative genomic features of fusion events to the structural and 
regulatory properties of fusion proteins. Gain in the understanding of both common and rare 
gene fusions have shown promising impact on clinical applications such as identifying 
molecular subtypes of cancers, stratifying patients according to fusion occurrence, 
monitoring residual disease after treatment, and predicting relapse (Eguchi, Faria et al. 2014, 
Wyatt, Mo et al. 2014). Fusion transcripts also have served as efficacious therapeutic 
targets in both solid and hematologic malignancies (Parker and Zhang 2013); for instance, 
the ALK inhibitor crizotinib emerged as an effective therapy for a subset of non–small cell 
lung cancer patients harboring EML4-ALK fusions (Sasaki, Rodig et al. 2010). 
Fusion genes have been recognized for over 30 years as critical drivers of cancer 
progression and effective therapeutic targets. However, the complexity of the cancer 
transcriptome, the high dynamic range of gene expression, and the unavoidable presence of 
sequencing errors confound computational fusion detection, and the gene fusions identified 
by different studies and in different cancer types show few distinct trends. Fusion rank 
algorithms could help biologists and clinicians prioritize putative fusion lists and predict the 
biologic functions of these fusions on the basis of their genomic features and protein 
structures. Using The Cancer Genome Atlas (TCGA) RNA sequence profiling, we have 
comprehensively characterized fusion transcripts across 33 tumor types and provided an 
integrative platform for the identification and annotation of both novel and known fusion 
genes that could serve as diagnostic tools and molecular targets for therapeutic 
interventions.  
 
4.2 Methods 
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4.2.1 Data resources  
TCGA DNA and RNA sequencing data were downloaded from the Cancer Genomics Hub 
(CGHub, https://cghub.ucsc.edu). Copy number segmentation data and gene expression 
data were downloaded from Firehose (https://gdac.broadinstitute.org/).  
Somatic mutation data were downloaded from UCSC Xena repository. 
(https://xenabrowser.net/datapages/?cohort=TCGA%20Pan-Cancer%20(PANCAN)) All data 
used in this study were summarized in Table S4.1. A panel of normal samples (n=689-22) 
were assembled as controls to filter out potential germline fusion events,  after  excluding 22 
normal samples that resembled tumor samples on the basis of unsupervised hierarchical 
clustering. The clustering was done within each cancer type using expression of all genes 
and ward’s method.   
 
4.2.2 Identification of fusion transcripts 
We applied PRADA (Torres-Garcia, Zheng et al. 2014) to all RNAseq samples for data 
preprocessing and fusion calling. In brief, RNA sequencing reads were aligned to a 
composite reference consisting of both genome (hg19) and transcriptome (Ensembl 64), 
followed by a remapping step that aligns transcriptome coordinates to the reference genome 
(Berger, Levin et al. 2010). GATK best practices were implemented in the pipeline, including 
marking duplication and base quality recalibration. More information about PRADA can be 
found at http://bioinformatics.mdanderson.org/main/PRADA:Overview.  
PRADA detects fusion transcripts based on discordant read pairs (reads mapping to 
different protein-coding genes) and junction spanning reads (reads mapping to the exon–
exon junctions). We required at least two discordant read pairs and one junction spanning 
read to call a fusion candidate. Multiple steps were applied to remove possible artifacts, 
including gene pairs with high sequence similarity (Blastn E-value > 0.001), low 
transcriptional allelic fraction (TAF, minimum 0.01 for both partner genes), and high partner 
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gene variety (PGV, maximum 10). TAF was calculated as the ratio of fusion supporting 
junction spanning reads to the total number of junction spanning reads. PGV was defined as 
the number of chromosomal arms where partner genes were localized for a fusion gene per 
cancer type. We excluded all fusions where any partner gene had a PGV more than 10. To 
test the stringency of this cutoff we ran 100,000 permutations and observed a less than 
0.001% chance by random to see such promiscuity, suggesting fusions involving these 
genes were highly unlikely to be bona fide. Finally we removed all fusions found in normal 
samples.  
 
4.2.3 Validation of fusion transcripts through integrating structure variants and copy 
number changes 
For cases where both copy number profiles and gene fusions were available, we aligned 
fusion points with copy number breakpoints allowing an extension of 100 Kb to the expected 
direction for both partner genes. We used Speedseq to detect structural variants (SVs) 
(Chiang, Layer et al. 2015) from whole genome sequencing (WGS) data. We filtered SVs 
requiring more than 3 supporting reads > 3, at least one split read and one discordant read 
pair. For fold-back inversions (BND on the same chromosome) we required more than 9 
supporting reads. We removed SVs with breakpoints falling in low-complexity regions (eg. 
repeat region DNA), or stacking across different tumor types. We further removed SVs with 
high sequence similarity of the 100bp window flanking the breakpoints. Germline events 
were filtered out by comparing with matched normal samples.  
We scanned the intersection between the edge of the confidence interval from the 
supported structure variants including large fragment duplication, deletion, insertion and 
inversion and truncated intron region flanking to the junction upon fusion events. First we 
assigned two partner genes into three categories based on their relative location to the 
adjacent break point of structure variants separately, (A,B,C,D definition  only consider 
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individual fusion junction that mapped to any break point of SV calls, here fusion Gene-A 
and Gene-B are calculated/ scanned separately) where category  A: a break point of 
structure variants fall into the exact intron region following the transcriptional orientation of 
adjacent junction point of the fusion; category B: a break point of structure variants fall into 
the maximum edge exon region of an entire gene depending on the transcriptional direction 
side expanded with 100Kb wiggle room; Next we assigned each fusion pair into four 
categories based on the fidelity supported by structure variants. High fidelity was defined 
when both partner genes are assigned with category A, middle fidelity was assigned for 
those fusion genes with one partner gene assigned with category A and another partner 
gene assigned as category B, low fidelity was defined when both fusion partner genes are 
assigned as category B; For those fusion pairs with only one partner gene supported by 
structure variants, we assigned as one-sided.  
 
4.2.4 Pathway and fusion centrality analysis 
Pathway enrichment of fusion genes was tested against Gene Ontology (GO) based on 
hypergeometric distribution. Fusion transcript centrality score was calculated based on 
domain-based fusion model, to predict the oncogenic driver in which partner genes act as 
hubs in a cancer pathway network. (Wu, Kannan et al. 2013)  We set the threshold value to 
0.37 for fusion degree centrality score, the fusion transcripts assigned with centrality score > 
0.37 were considered as prioritized cancer fusion drivers.   
 
4.2.5 Exon expression analysis 
We calculated the reads per kilobase per million mapped for exon expression based on 
Ensembl 64 annotation using realigned files generated from PRADA, and then we 
performed Z-score transformation for the expression of each exon across all the samples in 
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each cancer type. Welch’s t-test was used to compare the expressions of exons before and 
after the junction point of each partner gene. 
 
4.3 Results 
4.3.1 Distribution of fusion transcripts in different cancer types  
We analyzed mRNA sequencing data of 9968 tumors and 665 normal samples from 33 
cancer types available in TCGA (Table S4.1) and identified 56,198 candidate fusion events. 
After removing 35,263 potential artifacts with stringent filters and 862 fusions detected in 
normal samples, we obtained 20,112 somatic fusions for further analyses (Figure 4.1A). On 
average sarcoma and uterine carcinosarcoma harbored the most fusions whereas kidney 
cancers (papillary carcinoma, chromophobe carcinoma, clear cell and renal cell carcinoma), 
uveal melanoma, and thymoma harbored the least fusions, indicating the lower tail of the 
spectrum.  
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 Figure 4.1 Spectrum of filtered fusion transcripts across 33 cancer types  
The top panel shows the percentage of samples where at least one fusion transcript was 
detected per cancer type (dark blue). The middle panel shows total number of fusion transcripts 
detected in each cancer type. The bottom panel shows the number of fusions detected in each 
tumor sample. The brown horizontal marker indicates the mean number of fusions in each 
cancer type. The cancer types are sorted according to the percentage of samples detected with 
fusion transcripts.  
 
Breaking into chromosome arms, sarcoma presented a strong enrichment of fusions on 12q 
(Figure 4.2), a pattern reminiscent of focal chromothripsis in a subset of this malignancy 
(Nord Karolin et al., 2013, Human Molecular Genetics).  
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Figure 4.2 Counts of fusion transcripts supported by structure variants at different 
chromosome arms in 23 cancer types 
Dark red on the heat-map represents the counts of fusion transcripts. 
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By integrating copy number data we found 32% of fusions had both junctions close to a 
DNA breakpoint and ~58.5% of fusion transcripts had at least one partner gene in amplified 
or deleted regions. We next separated fusions into short (<1 Mb), intermediate (1-10 Mb) 
and long (>10 Mb) intra-chromosomal events and inter-chromosomal events per genomic 
localization of the two partner genes. We observed disparate association patterns between 
these categories and copy number profile. For instance, almost 50% of fusions were short 
intra-chromosomal events in high grade ovarian serous carcinoma (OV), and they were 
predominantly associated with copy number changes. In contrast, 70% of fusions detected 
in thyroid carcinoma (THCA) were copy number neutral inter-chromosomal events. Acute 
myeloid leukemia (AML), which also exhibited a quiet genome, displayed a similar 
percentage (65%) of copy number neutral inter-chromosomal fusions (Figure 4.3). A rare 
cancer, pheochromocytoma and paraganglioma (PCPG), demonstrated predominantly copy 
number associated inter-chromosomal fusions which might reflect frequent large segmental 
copy number alterations in this disease (Flynn, Benn et al. 2015). Other outliers included 
cervical cancer, which showed minimal copy number related fusions.  
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Figure 4.3 Distribution of genomic features among fusion transcripts across 33 cancer 
types   
The bar plots represent the fractions of different categories of fusions according to the distance 
between two partner genes and presence of DNA copy number variations within a 100-Kb 
window up-stream and down-stream of the junction point. CNV: copy number variation  
 
4.3.2 Gene fusion annotation and tight association with genomic structure alterations   
The finding of frequent copy number neutral interchromosomal fusions prompted us to 
investigate to what extent balanced translocations may drive fusion formation. Using 
speedseq, we realigned whole genome sequencing data of 971 pairs of tumor and matched 
germline samples, and detected 272,638 somatic structural variations (SVs). Speedseq 
categorized SVs into deletion (6.6%), duplication (9.2%), inversion (65.6%) and 
translocation (18.5%) events depending on the read alignment patterns. No SVs were found 
in 70 tumors, of which 35 were acute myeloid leukemia or thyroid carcinoma. Similar with 
gene fusion, SVs also showed a continuous spectrum across human cancers (Figure 4.4). 
Of the 272,638 SVs, 151,564 had both ends falling into genic regions. In comparison, we 
detected a total of 2,588 fusions in these WGS cases, suggesting WGS was more sensitive 
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in calling SVs, or the majority of the SVs were not expressed. Filtering parameters of both 
DNA and RNA SV analyses had an impact on the observed discrepancy but were unlikely 
the major factors. 
 
Figure 4.4 Counts of fusion transcripts and structure variants in each tumor sample 
Each dot denotes one sample, and each color represents a cancer type.  
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We next examined the DNA structure variants for mechanistic evidence of the observed 
fusion events. Overall we found supporting evidence for 717 fusions (28%) from all four 
categories of structure variants (Figure 4.5). 
 
 
Figure 4.5 Distribution of fusion transcripts associated with structure variants 
The number of fusion transcripts supported by different types of structure variants at different 
confidence levels. Each group was divided according to the distance of the chromosome location 
of two junction points from the fusion transcript (x-axis). Confidence level in stacked bar plot: 
high, breakpoints of structure variants in the intron region of adjacent fusion junction; middle, 
breakpoints of structure variants in the entire exon region of adjacent fusion gene; low, 
breakpoints of structure variants in the 100-Kb spanning region to the exon of adjacent fusion (y-
axis).  
 
Interestingly duplication explained the largest proportion of short intra-chromosomal fusions, 
and translocation accounted for all inter-chromosomal fusions. This pattern was 
independent of levels in supporting evidences. It should be noted that short intra-
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chromosomal fusion was likely underestimated in the deletion SV group because our tool 
discards discordant read pairs in short distance to exclude possible read through events.  A 
few examples are illustrated in Figure 4.6. Given the abundance of fusions supported by 
translocation, we will examine the translations in more detail.    
 
 
 
 
Figure 4.6A Fusion transcript derived from inversion in BLCA  
A somatic ADRBK2-AP1B1 fusion resulting from a balanced inversion (chr22: 26,089,092- 
29,748,825) in BLCA (TCGA-C4-A0F7) was measured by both whole-genome sequencing and 
RNA sequencing. The inversion is shown on the top (middle region in gray block truncated for 
visualization purposes). The partner genes ADRBK2 and AP1B1 formed the fusion transcript 
ADRBK2-AP1B1 shown on the bottom. The red vertical lines represent breakpoints of structure 
variants detected by SpeedSeq.  
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Figure 4.6B Fusion transcript derived from translocation in SKCM  
A somatic CDC27-BRAF fusion resulting from a balanced translocation (chr17:45,206,337– chr7: 
140,491,457) in SKCM (TCGA-FS-A1ZU) was measured by both whole-genome sequencing and 
RNA sequencing. The inter-chromosomal translocation is shown on the top (middle region in 
gray block truncated for visualization purposes). The partner genes CDC27 and BRAF formed 
the fusion transcript CDC27-BRAF shown on the bottom. The red vertical lines represent 
breakpoints of structure variants detected by SpeedSeq.  
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Figure 4.6C Fusion transcript derived from large fragment deletion in SARC  
A somatic PLXNC1-TXNRD1 fusion resulting from a large fragment deletion (chr12: 94,681,044- 
104,736,300) in SARC (TCGA-DX-A3U5) was measured by both whole-genome sequencing and 
RNA sequencing. The deletion is shown on the top (middle region in gray block truncated for 
visualization purposes). The partner genes PLXNC1 and TXNRD1 formed the fusion transcript 
PLXNC1-TXNRD1 shown on the bottom. The red vertical lines represent breakpoints of structure 
variants detected by SpeedSeq.  
 
4.3.3 Hotspot fusion transcripts are associated with genomic instability  
Among all the fusion transcripts detected across all cancer types, the most frequent fusion 
transcripts, containing kinase partner gene FRS2 (n=66 in 12 cancer types), were located at 
hotspots of chromosome 12q breakpoints, where most condensed fusion transcripts 
presented in sarcomas (n=39 for FRS2 fusions in sarcomas). The genomic hotspots for 
fusions overlapped with regions that were frequently amplified in sarcomas and were 
accompanied by complex genomic rearrangement with intra-chromosome inversion. Only 
genomic events detected in samples overlapping with fusion-positive samples are shown in 
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a circos plot (Figure 4.7), suggesting that these fusion events are derived from genomic 
rearrangement. The genomic hotspots for fusions are observed on chromosomes 12q15; 
these regions are coincident with frequent focal gains, chromosomal translocations, and 
inversions. Increased levels of local genomic instability were linked to concomitant higher 
frequency of complex genomic rearrangement and consequently to fusion formation where 
both fusion points were adjacent to genomic breakpoints detected with multiple segments 
between the two breakpoints. This finding suggests that unbalanced genomic 
rearrangements occur on high-density specific DNA double-strand breaks and rejoin into 
fusion transcripts.  
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Figure 4.7 Association between hotspots of recurrent fusion transcripts with 
chromosome rearrangement and copy number alterations in SARC  
A circos plot represents all the curated fusions identified in sarcomas from TCGA dataset. Fusion 
transcripts formed by FRS2 kinase in SARC are represented by thick arcs (n=39) and labeled in 
blue outside the ideogram. The green arcs represent intra-chromosomal fusions; the blue arcs 
represent inter-chromosomal fusions. The light red arcs show genomic translocations in SARC.  
The middle ring in orange shows the frequency of fusion genes in a density histogram at the 
given genomic location. The next ring shows structure variants of inversion (purple), duplication 
(tomato), and deletion (olive-green) detected in SARC, and the outermost ring shows the copy 
number alterations of amplification (red) and deletion (green) in sarcomas. The frequencies of 
structure variants and copy number alterations are presented by the color density. Only samples 
detected with FRS2 fusions are calculated for the frequency of structure variants and copy 
number alterations.   
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4.3.4 Prioritizing functional fusions 
We observed 476 recurrent fusions across 33 cancer types, including those found in one 
cancer type or multiple cancer types. The former included TMPRSS2-ERG in prostate 
cancer, PML-RARA and RUNX1-RUNX1T1 in leukemia, PTPRK-PSPO3 in colorectal 
cancer, FGFR2-BICC1 in cholangiocarcinoma, EML4-ALK in lung cancer and FGFR3-
TACC3 in glioblastoma, cervical cancer, head and neck cancer (Figure 4.8). We also 
identified less characterized recurrent fusions UBTF-MAML3 in pheochromocytoma and 
paraganglioma. 
 
Figure 4.8 Frequency of recurrent fusion transcripts across 33 cancer types  
The most recurrent (n≥2) fusion transcripts are shown, and the most prevalent fusion transcripts 
are labeled in red. The fusion frequency was defined as the number of samples detected with 
the number of recurrent fusions divided by the total number of samples analyzed in each cancer 
type.  
 
Gene wise, FGFR3 and TACC3 represented the most frequent genes involved in recurrent 
fusions, followed by BRAF, RARA, RET and PML (Figure 4.9). Recently Pan FGFR 
inhibitors have been under test in phase I-II clinical trials (Shaw, Hsu et al. 2013), which may 
lead to targeted inhibition of tumors with FGFR fusions.  
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Figure 4.9 Most frequent partner genes in recurrent fusion transcripts across 33 cancer 
types  
The distributions of partner genes that form the fusion transcripts are shown. The y-axis 
represents the number of patients found to have partner genes that form fusion transcripts in 
each cancer.  
 
We applied two approaches to systematically nominate possible functional fusions, and we 
employed a network based approach to assign a centrality score to every fusion (Wu, 
Kannan et al. 2013). The underlying hypothesis is derived from the empirical observation 
that at least one of the partner genes of most known cancer fusions are hub genes in a gene 
network; thus the fusion centrality score (a multi-gene-based centrality metric) may reflect 
the functional significance of a fusion. We found thyroid cancer and acute myeloid leukemia 
distinguished from other cancers for high centrality scores, and both cancer types were 
known for fusion genes (TCGA, unpublished data). The third lead cancer type was 
cholangiocarcinoma, in which frequent FGFR fusions manifested a distinct molecular 
subtype (TCGA, unpublished data). Using an arbitrary cutoff (centrality score > 0.37), thyroid, 
acute myeloid leukemia and cholangiocarcinoma were the top three cancer types with 75%, 
68%, and 67% of fusions being predicted to have functional roles in these malignancies 
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(Figure 4.10). Using the same cutoff, we were able to find 6,175 in-frame fusion transcripts. 
In addition to established driver fusions such as BCR-ABL (0.396), MLL-MLLT4 (0.395), 
PML-RARA (0.39), ETV6-NTRK3 (0.39), SND1-BRAF (0.389), CCDC6-RET (0.387), and 
NCOA4-RET (0.388), we  also identified novel recurrent fusions with high centrality scores, 
such as AFF1-PTPN13 (0.372) in bladder cancer, BUB1B-EIF2AK4 (0.376) in breast cancer, 
UBTF-MAML3 (0.373) in pheochromocytoma and paraganglioma, HIPK2-PARP12 (0.384), 
SRGAP3-LHFPL4 (0.370) in uterine corpus endometrial carcinoma.    
 
 
  
Figure 4.10A Centrality scores of fusion partner genes across 33 cancer types 
The centrality distributions of all the cancer fusion partner genes after the filter procedure (6,175 
in-frame fusion transcripts including 6,528 partner genes) in each cancer type are shown in a 
violin plot. The gray horizontal bars in the boxplot represent the mean centrality scores in each 
cancer type. The numbers of potential fusion drivers (centrality scores of >0.37) in each cancer 
type are labeled in red on the top.   
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 Figure 4.10B Proportion of driver fusions among all fusion transcripts across 33 cancer 
types  
The numbers and distributions of partner genes that form the fusion transcripts are shown. The 
y-axis represents the number of patients found to have partner genes that form fusion transcripts 
in each cancer type.  
 
We also accessed the predicted fusion transcripts derived from oncogenes and 
tumor suppressor genes. Based on the cosmic database of cancer gene census and cancer 
genome landscapes (Vogelstein, Papadopoulos et al. 2013), we found 412 in-frame fusion 
transcripts involved in tumor suppressor genes (TSGs) and 481 in-frame fusion genes 
comprised of oncogenes (OGs) in either partner genes. (Figure 4.11) The percentage of in-
frame fusion transcripts involved in OGs is highest in THCA (29.9%) and LAML(19.2%), 
which is consistent with the proportion of driver genes in each cancer type (Figure 4.10B), 
implying fusion transcripts might play a dominant role in tumor progression in a subset of 
THCA and LAML, which could be applied for molecular classification and prognosis markers.  
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 Figure 4.11 Number of fusion transcripts composed of tumor suppressor genes and 
oncogenes across 33 cancer types  
The counts of fusion transcripts comprised of tumor suppressor genes or oncogenes in either 
gene partner are represented in the bar plot. The percentage of tumor suppressor 
gene/oncogene–formed fusions dominated by total fusion transcripts in each cancer type are 
denoted in yellow circles, with the circle size proportional to the ratio of oncogenes or tumor 
suppressor genes to all fusion transcripts in each cancer type. The in-frame and out-of-frame 
fusion transcripts were counted separately.  
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In addition, we sought to examine the effects of fusion transcripts on gene 
expression level of their partner genes. Using distance based outlier clustering; we have 
detected 1,723 fusion transcripts with significantly altered expression compared with that of 
remaining tumor samples in each cancer type, indicating the potential regulatory effects on 
the transcriptional level upon fusion events. Applying Kernel density functions, we found 
2,835 fusion transcripts (75% quantile as critical value for outlier detection) displaying 
deviated expression level of their partner genes compared with their expression in those 
samples without corresponding fusion transcripts detected. For example, we observed the 
altered gene expression of partner genes in resulted fusion transcripts positive samples 
versus those samples without specific fusion transcripts detected. For example, in tumor 
samples detected with fusion gene C10orf68-CCDC7 from multiple types of cancers 
including BLCA, BRCA, COAD, KIRC, LUAD, PRAD, UCEC, both partner genes C10orf68 
and CCDC7 exhibited increased expression compared with their expression levels in 
samples without C10orf68-CCDC7 fusion events(Figure 4.12A), while accompanied with 
overexpression of exons flanking to fusion junction points in several samples (Figure 4.12B), 
indicating the potential of those fusion events associated with overexpression and 
dysregulation of their partner genes.  
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Figure 4.12A Increased transcription levels in recurrent fusion transcripts of C10orf68-
CCDC7 in multiple cancer types  
The expression levels (log2RPKM) of the C10orf68-CCDC7 fusion transcript in multiple cancer 
types (number of fusion transcripts in each cancer type: BLCA: n=3, BRCA: n=11, COAD: n=11, 
KIRC: n=4, LUAD: n=12, PRAD: n=2, UCEC: n=4) are shown. The dots show the expression of 
the partner genes C10orf68 and CCDC7 in each sample, the triangle shows the expression 
levels of C10orf68 and CCDC7 in the samples with C10orf68-CCDC7 fusion transcripts, and the 
cyan smoothing lines show the kernel density estimation of transcript expression levels of 
partner genes with C10orf68 and CCDC7 in all samples with C10orf68-CCDC7 fusion (n=45).  
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Figure 4.12B Z-normalized exon expression of C10orf68-CCDC7 in multiple cancer types 
Blue and red represent relatively low and high level of expression based on the reads per 
kilobase per million mapped (RPKM) value of each exon. 
 
4.3.5 Recurrent fusion transcripts in normal tissues  
To explore the germline events of chimeric fusions, we have detected the fusion transcripts 
in 23 normal samples from the same patients that match to tumor samples applying the 
same fusion call method followed by filtering. We have identified 779 fusion transcripts in 
742 normal tissue samples. Of these, 95% are fusion transcripts whose junction of either 
partner genes mapping to the region with germline copy number alterations based on the 
database of genomic variants, indicating that most fusion transcripts detected in normal are 
originated from the breakpoints located between the functional elements of two genes. We 
found a few recurrent fusion transcripts in different cancer types, such as CHST5-TMEM231 
in READ and CRHR1-KIAA1267 in BLCA, HNSC, KIRC, PRAD, THCA, and these highly 
recurrent fusions also frequently occur in multiple cancer types, therefore are considered as 
germline events. Since these fusions are also implicated in previous GWAS analysis (Leslie, 
O'Donnell et al. 2014), indicating the germline events occur at both genomic and 
transcriptomic level (Figure 4.13).    
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Figure 4.13 Frequency of recurrent fusion transcripts in normal tissue across 12 tissue 
types  
The most recurrent (n≥2) fusion transcripts are shown, and the most prevalent fusion transcripts 
are labeled in red. The fusion frequency was defined as the number of samples with each 
recurrent fusion divided by the total number of normal samples analyzed in each tissue type. 
 
4.3.6 Recurrent fusion transcripts are mutually exclusive with somatic mutations  
We selected the samples with both fusion and mutation data sets available to compare the 
mutation frequency between the samples with or without fusion transcripts constitute the 
specific gene. The emerging patterns of mutual exclusivity between gene fusions and 
somatic mutations in their partner genes are observed across multiple cancer types. For 
example, TYK2 kinase was detected to be fused with 42 different partner genes in 17 
cancer types, based on the presence of TYK2 constitute fusion, we have divided the 
samples from different cancer types into two groups, notably the overall mutation frequency 
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is significantly lower in fusion positive group than that in fusion negative group, (Welch’s t-
test, p-value =0.0055), and there are few somatic mutations occurring in those samples with 
TYK2 containing fusions (Figure 4.14A), similar phenomena in EIF2AK2 comprised fusion 
pairs (Welch’s t-test, p-value =0.0071), (Figure 4.14B), this finding has set the framework to 
unravel the genomic basis of fusion transcripts. The common trend between recurrent, in-
frame fusion transcripts and reduced number of somatic mutations in the same patients is 
seen in many cancer types, implying the properties of fusion events occurring in those 
patients drive cancer growth and progression instead of somatic mutations.   
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Figure 4.14A Recurrent TYK2-containing fusion transcripts are mutually exclusive with 
somatic mutation events in multiple cancer types  
The TYK2-containing fusion transcripts in multiple cancer types are shown. (ACC: n=2, BLCA: 
n=2, BRCA: n=8, DLBC: n=1, ESCA: n=1, HNSC: n=2, KICH: n=1, KIRC: n=5, KIRP: n=2, 
LAML: n=4, LGG: n=3, PAAD: n=3, PRAD: n=1, SARC: n=1, THCA: n=2, THYM: n=3, UCS: 
n=2.) The top panel represents the mutation frequencies of the somatic mutations; Welch’s t-test 
was performed to compare the mutation frequency between samples with or without fusion 
transcript–containing TYK2 kinase. The bottom panel illustrates the fusion and somatic 
mutations detected with TYK2 and its partner fusion genes in the samples with and without TYK2 
fusion transcripts detected.   
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Figure 4.14B Recurrent EIF2AK2-containing fusion transcripts are mutually exclusive with 
somatic mutation events in multiple cancer types  
The EIF2AK2-containing fusion transcripts in multiple cancer types are shown. (BLCA: n=6, 
BRCA: n=2, CESC: n=1, COAD: n=1, KIRC: n=3, KIRP: n=2, LGG: n=3, LIHC: n=1, LUAD: n=5, 
LUSC: n=4, PAAD: n=1, PCPG: n=1, READ: n=1, SKCM: n=2, STAD: n=4, THCA: n=2.) The top 
panel indicates the mutation frequencies of the somatic mutations; Welch’s t-test was performed 
to compare the frequency between the samples with or without fusion transcript–containing 
EIF2AK2 kinase. The bottom panel illustrates the fusion and somatic mutations detected with 
EIF2AK2 and its partner fusion genes in the samples with or without EIF2AK2 fusion transcripts 
detected.   
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4.3.7 Perturbed pathways associated with fusion formation 
The fusion transcripts largely triggered pathway perturbations through which the functional 
domains in partner genes were truncated by fusion formation or recombined with regulatory 
domains donated by their partner genes. We explored the enriched gene ontology terms 
and reactome pathways of all fusion transcripts in each cancer type. We found that the 
perturbed pathways were enriched for kinase activity and small GTPase signaling pathways 
and for transferase and transmembrane receptors in most cancer types (Figure 4.15).   
 
 
Figure 4.15 Most represented ontological categories in gene ontology analysis of fusion 
transcripts in 33 cancer types 
The perturbed gene ontology terms enriched at fusion transcripts in each cancer type are shown 
in dots; the colors of the dots represent the adjusted p value of gene ontology terms from partner 
genes of fusion transcripts, and the size of the dots represents the number of genes annotated in 
each gene ontology term.  
 
VEGF-VEGF receptor pathways and axon guidance and PDGF/NGF pathways, as well as 
chromatin remodeling pathways, were predominantly perturbed in urothelial bladder 
carcinoma, breast cancer, lung cancer, and head and neck cancer, suggesting that similar 
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pathways are perturbed in association with tumor genesis in these cancer types. In 
sarcomas, only a few pathways were disrupted, including SUMOylation, TGF-beta receptor, 
and ECM interaction pathways, despite the high frequency of fusion formations in sarcomas, 
indicating the heterogeneous effects of fusion events in different cancer types (Figure 4.16).                
 
 
Figure 4.16 Perturbed pathways from fusion transcripts across 33 cancer types  
The reactome pathways of fusion transcripts enriched in each cancer type are shown in dots; the 
colors of the dots represent the adjusted p-value of the enriched pathway from partner genes of 
fusion transcripts, and the size of the dots represents the number of genes annotated in each 
pathway.  
  
4.3.8 Cancer type–specific fusion gene networks and hubs 
Some fusion transcripts lead to biologic perturbations in which partner genes recombine with 
a large number of alternative partner genes, and a mutual fusion partner may link such 
genes, resulting in the clusters of interrelated fusion transcripts. We built the occurrence of 
degree in each cancer type to determine empirical hub genes. In cancer types with 100 to 
1000 fusion transcripts detected, we observed several common hub genes shared by 
multiple cancer types, such as STAT6 and EEF2 (Figure 4.17).  
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Figure 4.17 Network of gene fusions in multiple cancers 
All the unique fusion pairs that include more than three partner genes in 16 cancer types are 
plotted. The nodes (circles) indicate genes, and edges (gray lines) indicate the occurrence of a 
fusion transcript between genes. Node size indicates the number of partner genes with which the 
node/gene fuses. The hub genes that are interconnected with more than three partner genes are 
labeled in red.  
 
In the cancer types with a high frequency of fusion transcripts, we observed an intertwined 
network of fusion transcripts, with FRS2 as central hub gene predominantly fused with 
multiple partner genes in sarcoma and BRCA. FRS2 is a tyrosine kinase adaptor protein in 
FGFR pathway, inducing downstream activation of Ras-MAPK pathway (Luo, Kim et al. 
2015), suggesting its oncogenic potential upon fusion events. We also found that RARA and 
BCAS3 were hub genes in BRCA; BCAS3 (breast cancer anti-estrogen resistance gene 3) 
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was reported to be involved in estrogen resistance through its intracellular signal 
transduction domain, which causes estrogen-independent proliferation in breast cancer 
(Guo, Canaff et al. 2014). It is plausible that BCAS3-involved fusions contribute to cancer 
progression though constitutive activation (Figure 4.18).  
 
 
Figure 4.18 Network of gene fusions in cancer types with high frequency of fusion 
transcripts 
All the unique fusion pairs that include more than four partner genes in BLCA, BRCA, LUAD, 
LUSC, PRAD, and SKCM are plotted. The nodes (circles) indicate genes, and edges (gray lines) 
indicate the occurrence of a fusion transcript between genes. Node size indicates the number of 
partner genes with which the node/gene fuses. The hub genes that are interconnected with more 
than four partner genes are labeled in red. 
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Among 717 fusion transcripts comprising 1,259 unique partner genes detected in liver 
cancer, only five genes (ST7, STAT6, CCNA2, PCCA, and RAD51B) recombined with at 
least four partners, while there were few interconnected networks, and 1,151 (91.4%) of the 
partner genes were not part of any network (Figure 4.19).  
 
 
Figure 4.19 Network of gene fusions in liver cancer (LIHC) 
All the unique fusion pairs including all of their partner genes in LIHC are plotted. The nodes 
(yellow circles) indicate genes, and edges (gray lines) indicate the occurrence of a fusion 
transcript between genes. Node size indicates the number of partner genes with which the 
node/gene fuses. The hub genes that are interconnected with more than four partner genes are 
labeled in red.   
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A similar pattern was found in stomach adenocarcinoma, with only a few genes, such as 
MLL5, DNM2, and DDX21, fused with multiple partners (Figure 4.20). Fusion-triggered 
network alteration may also occur via node loss or changes of regulatory functions in the 
context of loss or a shift in protein functional domains.      
 
 
Figure 4.20 Network of gene fusions in stomach adenocarcinoma (STAD) 
All the unique fusion pairs including all their partner genes in STAD are plotted. The nodes 
(green circles) indicate genes, and edges (gray lines) indicate the occurrence of a fusion 
transcript between genes. Node size indicates the number of partner genes with which the 
node/gene fuses. The hub genes that are interconnected with more than four partner genes are 
labeled in red.   
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4.3.9 Altered tyrosine kinase domains in predicted fusion transcripts may deregulate 
oncogene functionality 
Tyrosine kinase fusion genes consist of a subset of therapeutic relevant oncogenes 
associated with both circulating and solid tumors (Medves and Demoulin 2012). In some of 
these kinase fusions, the kinase domains in the fusion oncogenes fuse with partner genes 
harboring regulatory domains and consequently loss of response to ligand and become 
constitutively activated through ligand-independent dimerization and/or oligomerization 
induced by their fusion partners. In other cases, the kinase domains are fused with their 
partner genes, leading to intracellular delocalization of the kinase domains, and the 
properties of crossing the cell membrane is needed for therapeutic antibodies against the 
original kinase targets. Using as references the Swiss-Prot Protein database 
(http://www.uniprot.org/docs/pkinfam), the Human Protein Reference Database 
(http://www.hprd.org/), and the Pfam database (http://pfam.xfam.org/), we identified 1,969 
fusion transcripts harboring a protein kinase, including 752 in-frame protein kinase fusions. 
Most in-frame kinase fusions belonged to the Ser/Thr protein kinase family, followed by the 
tyrosine kinase family. We identified 152 in-frame fusion transcripts harboring a kinase in 
either partner gene whose kinase domains remained intact upon fusion events, suggesting 
potential oncogenic functions under modulation by their partner genes. Interestingly, we 
identified PDGFRA-USP8 in sarcomas (Figure 4.21), in which tyrosine kinases from 
platelet-derived growth factor receptor (PDGFRA) flanked adjacent to the coiled-coil domain 
and Rho-related GTP-binding domain (RHOD) domain from USP8. Charged residues in the 
coiled-coil domain may function as a hinge that allows the N-terminal kinase domains to 
interact with C-terminal RHOD, a sulfurtransferase involved in cyanide detoxification, and 
coiled-coil interactions may mediate constitutive multimerization, mitochondrial binding, 
and kinase activity of its adjacent protein kinase. Notably, the expression level in exons of 
the PDGFRA-USP8 fusion transcript was significantly higher than that in their parental 
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exons, indicating that the novel fusion PDGFRA-USP8 may trigger structural and functional 
alterations in PDGFRA, whose oncogenic properties have critical implications in cancer 
(Velghe, Van Cauwenberghe et al. 2014).  
 
 
 
 
Figure 4.21 Novel fusion transcript PDGFRA-USP8 harboring kinase domains in sarcomas 
The top panel showed the partner genes PDGFRA and USP8 are illustrated in the top panel. 
The red frame represents the remaining fragment of two transcripts that recombined into the 
PDGFRA-USP8 fusion protein. The protein structure domains are illustrated in the bottom panel, 
with the tyrosine kinase domain from PDGFRA flanked closely to the coiled-coil domain from 
USP8. The bottom panel showed Z-normalized expression for each exon of PDGFRA and USP8 
in sarcomas. Red and blue represent relatively high exon expression and low exon expression, 
respectively.  
 
Another intriguing kinase fusion, composed of protein kinase C beta (PRKCB), which is 
reported to promote mammary tumorigenesis in the tumor microenvironment (Wallace, 
Pitarresi et al. 2014), was fused with different gene partners in multiple types of cancer 
including PRAD, LUSC, LUAD, LGG, and GBM. Thus, this fusion was predicted to truncate 
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at the N-terminal part of PRKCB harboring an auto-inhibitory domain and consequently to 
cause constitutive activation of PRKCB. The exon expressions of PRKCB-containing fusions 
displayed a similar pattern, with higher expression levels in fusion regions than in parental 
exons (Figure 4.22). Taken together, these findings reveal a set of fusion genes with kinase 
domains conferring critical roles in tumor progression in multiple types of cancers.    
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Figure 4.22 Novel fusion transcript involved kinase PRKCB in different cancer types  
The protein structure of PRKCB and its partner genes in five cancer types are illustrated in the 
top panel. The TCGA sample ID, cancer type, and coding protein domains in fusion genes, as 
well as nucleic acid and amino-acid sequences, are annotated for each predicted PRKCB kinase 
fusion protein. The 5′ partner genes are denoted in the purple segment, and the 3′ partner gene 
is denoted in the gold segment. In addition, the fusion breakpoints are denoted by red arrows. 
Serine/threonine protein kinase (S_TKc) domains and kinase extension domains are in cyan; the 
transmembrane domains (TM) are in blue rectangles, C1 and C2 conserved regulatory domains 
are in green polygons, and other domains are in yellow. Other SMART Domain annotation: AAA, 
ATPases; CYCc, guanylate cyclases that catalyze the formation of cGMP from GTP; VHS, 
membrane targeting/cargo recognition; C1/2, protein kinase C conserved region domains.  
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4.3.10 Loss of epigenetic modification domains in predicted fusion transcripts may 
deregulate activity of tumor suppressor genes 
Chromatin remodeling proteins function as gatekeepers and constitute a major determinant 
for transcriptional regulation, triggering a wide repertoire of biologic functions. Loss or gain 
of chromatin remodeling domains confers a unique ability to reprogram the cancer genome 
to alter oncogenic phenotypes (Muntean and Hess 2009) (Nair and Kumar 2012). Applying 
the epigenetic modifier database dbEM (http://crdd.osdd.net/raghava/dbem/), we found that 
2,688 (13.4%) fusion transcripts constituted epigenetic modifiers in one of the partner genes. 
There were 26 in-frame fusion transcripts involving chromatin modification domains with 
potential loss of functions in tumor suppressor genes. A typical novel fusion transcript, 
MANF-SETD2, could lead to loss of the SET domain in SETD2 in BRCA, and several lines 
of study have shown that SETD2 acts as an epigenetic modifier with tumor suppressor 
properties (Li, Duns et al. 2016). In addition, SETD2 plays important roles in maintaining 
genome integrity, and its loss of function could foster branched evolution through impaired 
DNA repair and replication stress in renal cancer (Kanu, Gronroos et al. 2015). Notably, the 
significantly increased expression of SETD2 in exons flanking the resulting fusion junction 
point was observed in several samples, demonstrating the potential of MANF-SETD2 as a 
potential oncogenic driver (Figure 4.23). Eight in-frame fusion transcripts involved chromatin 
modification domains with oncogenic properties, and the function and stability of these 
onocogenic domains are potentially modulated by the domains donated from its partner 
genes. 
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Figure 4.23 Novel fusion transcript affects chromatin remodeling domain (SET) in BRCA 
The top panel showed both transcriptomic (upper) and protein (bottom) structures of parent 
genes and the fusion gene MANF-SETDD2 are shown. The SET domain of SETD2 is depleted 
in the predicted fusion sequence. Ensembl transcript ID and genomic and protein coordinates 
are indicated. The bottom panel showed the exon expression of MANF-SETD2 in BRCA. 
 
Another example of chromatin modifier involved fusion is tumor suppressor gene ARID1B, 
which codes an A/T-rich interaction domain as a subunit of SWI/SNF complex, as a 5′ 
partner gene. Upon fusing with multiple partner genes in BRCA, BLCA, LUAD, UCEC, LGG, 
GBM, and SKCM, ARID1B lost the ARID domain upon the fusion event, accompanied by 
reduced expression of ARID1B at both the exon and the transcript level. Its loss of function 
is implicated in multiple types of cancers (Aso, Uozaki et al. 2015), indicating that ARID1B 
fusion confers bona-fide tumor suppressor properties (Figure 4.24).   
MANF                       SETD2                            
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Figure 4.24 Novel fusion transcripts ARID1B-EZR in Uterine Corpus Endometrial 
Carcinoma (UCEC)  
The top panel showed both transcriptomic (upper) and protein (bottom) structures of parent 
genes and the fusion gene ARID1B-EZR are shown. The ARID domain of ARID1B is depleted in 
the predicted fusion sequence. Ensembl transcript ID and genomic and protein coordinates are 
indicated. The bottom panel showed the exon expression of ARID1B-EZR in Uterine Corpus 
Endometrial Carcinoma (UCEC). 
  
4.3.11 Gain or loss of post-translational modification sites in fusion may deregulate 
oncogenes and tumor suppressor genes 
Post-translational modification sites play important roles in regulatory switches in protein 
functions and pathways. Frequent mutations in ubiquitination sites are implicated as novel 
driver mechanisms involved in carcinogenesis, including angiogenesis, and post-
translational modification–specific mutations are associated with decreased patient survival 
140 
 
(Narayan, Bader et al. 2016). We explored the loss or gain of ubiquitination sites in fusion 
transcripts composed of oncogenes or tumor suppressor genes, which could upregulate 
oncogene activity or downregulate tumor suppressor gene activity owing to the role of 
ubiquitination sites in mediating protein stability and degradation (Mani and Gelmann 2005, 
Kirkin and Dikic 2011). Taking advantage of ubiquitination site predictor CKSAAP_UbSite 
(http://protein.cau.edu.cn/cksaap_ubsite) (Chen, Zhou et al. 2014, Chen, Zhou et al. 2015), 
we found that four fusion proteins constitute oncogene NET1 loss ubiquitination sites in 
PRAD, TGCT, STAD (5′ partner gene), and BLCA (3′ partner gene). As a typical example, 
the specific pattern of segment retention in ATP11B-NET1 fusion proteins leads to 
ubiquitination site loss at the N-terminal of neuroepithelial cell transforming 1 (NET1), which 
may confer increased stability of NET1, a RhoA guanine exchange factor, to exert its 
oncogenic function of promoting motility and metastasis (Bennett, Sadlier et al. 2011) 
(Figure 4.25).  
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Figure 4.25 Fusion-induced ubiquitination binding site losses in oncogene 
The top panel showed both transcriptomic (upper) and protein (bottom) structures of parent 
genes and the fusion gene ATP11B-NET1 are shown. NET1 showed loss of four ubiquitination 
sites at its N-terminal upon fusion with ATP11B in BLCA. The bottom panel showed the exon 
expression of ATP11B-NET1 in BLCA.  
 
Conversely, we found that four fusion transcripts formed by tumor suppressor genes in 
sarcoma, SKCM, BRCA, and ESCA gain ubiquitination sites upon fusion events. A typical 
example of ubiquitination site gain adjacent to a tumor suppressor gene is HKR1-CEACAM7, 
which may trigger the amalgamation of a ubiquitinated segment from HKR1 with a short 
portion of the CEACAM7 tumor suppressor domain, leading to fusion-mediated loss of 
immunoglobulin-like C2-type domain function in CEACAM7, which mediates numerous 
cellular functions, including proliferation, differentiation, tumor suppression, immunity, and 
142 
 
infection through self-multimerization or multimerization with other family members (Bonsor, 
Beckett et al. 2015, Chang, Huang et al. 2016) (Figure 4.26).   
 
 
 
Figure 4.26 Fusion-induced ubiquitination binding sites gained in tumor suppressor 
genes from fusion HKR1-CEACAM7 in esophageal carcinoma (ESCA) 
The top panel showed both transcriptomic (upper) and protein (bottom) structures of parent 
genes and the fusion gene HKR1-CEACAM7 are shown. CEACAM7 gained four ubiquitination 
sites at its N-terminal upon fusion with HKR1 in ESCA. The bottom panel showed the exon 
expression of HKR1-CEACAM7 in ESCA.  
 
4.4 Discussions 
Our study has prospectively provided an integrated gene fusion database with 20,905 fusion 
transcripts detected from 9,964 paired-end RNA sequencing tumor samples. We 
comprehensively characterized the genomic features of fusion transcripts across 33 tumor 
types, and we found that certain fusion transcripts were associated with somatic mutations, 
complex genomic rearrangements, and copy number variation.  
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Notably, we observed significant mutual exclusion between fusion transcripts and 
somatic mutations per sample in most tumor types. Although the detailed mechanisms 
remain to be explored, this mutual exclusion suggests a compensatory process of genetic 
alterations acquired during tumorigenesis. The vast majority of fusion events were 
accompanied by increased expression in the posterior exons flanking the breakpoint 
detected in fusion transcripts, suggesting that fusion events affect transcriptional level. 
Importantly, there was substantial overlap between fusion transcripts and the breakpoints of 
complex genomic rearrangements, suggesting that these fusion events are caused by 
chromosomal rearrangement in a complicated fashion.       
Since genomic instability can produce passenger fusions and since fusion 
preferentially affects highly central, widely varying interaction-prone elements, the observed 
density of interaction-mediating features in parent proteins is in accordance with their 
centrality in interaction networks (Wu, Kannan et al. 2013). Many parent genes serve as 
essential genes, which dovetails with the concept of “edge” manner perturbations in cancer, 
(i.e., in-frame mutations or causal non-synonymous single-nucleotide polymorphisms disrupt 
specific interactions or edges of proteins rather than the entire node), and fusion events may 
perturb the functionality of or rewire specific interactions of only a portion of essential 
proteins. Therefore we implemented centrality scores to predict network disruptions that may 
be involved in oncogenesis triggered by fusion events. Expectedly, the centrality scores for 
predicted driver fusions aligned with a high proportion of fusion transcripts harboring 
oncogenes in THCA, LAML, and CHOL, suggesting the fidelity of centrality scores predicting 
most novel fusions that exhibited validated oncogenic relevance. Using cut-off values based 
on centrality scores to select predicted driver fusions from the passenger events, we not 
only observed the most prevalent fusion transcripts but also revealed new cancer types 
harboring known fusions, such as RUNX1-RUNX1T1, PML-RARA and MLL-MLLT10 in 
LAML; FGFR2-BICC1 in CHOL; FGFR3-TACC3 in BLCA and GBM; CCDC6-RET in THCA; 
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and PTPRK-RSPO3 in READ and COAD. These fusions were also detected in other types 
of cancers with low frequency and supported by previous reports (Brandimarte, Pierini et al. 
2013, Suzuki, Makinoshima et al. 2013, Williams, Hurst et al. 2013, Storm, Durinck et al. 
2016) (Arai, Totoki et al. 2014). The novel fusion UBTF-MAML3 frequently occurred in 
pheochromocytoma and paraganglioma; the nucleolar transcription factor UBTF fused with 
MAML3, the transcriptional coactivator, might confer altered transcript activity and could be 
used as biomarker for patient classification.  
Notably, our explorations uncovered a set of a set of fusion events that cause 
tumorigenesis through constitutive or modulated activation of kinase proteins. One such 
protein is the receptor tyrosine kinase PDGFRB, which serves as the receptor for platelet-
derived growth factors and plays important roles in wound healing, atherosclerosis, fibrosis, 
and regulation of tissue oncotic pressure. RHOD domain in USP8, which is involved in 
endosome dynamics and coordinates membrane transport with reorganization of actin 
cytoskeleton and focal adhesion dissolution, is also involved in internalization and trafficking 
of activated tyrosine kinase receptor PDGFRB (Moroncini, Paolini et al. 2010, Nehru, 
Voytyuk et al. 2013). When fused to the membrane-spanning region of PDGFRB through 
the hinge provided by coiled-coil domain, RHOD could lead to dimerization of PDGFRB and 
activation of its kinase activity. It is plausible that the constitutive signaling from PDGFRB-
USP8 drives cell proliferation. Since PDGFRB could be inhibited by imatinib, PDGFRB-
USP8 represents a potential therapeutic target. We also found that protein kinase C beta 
(PRKCB) fused with several partner genes in different cancer types, including ABCC1 in 
PRAD, ADCY9 in LUSC, SPNS1 in LUAD, GGA2 in LGG, and TNRC6A in GBM. Depletion 
of the N-terminal inhibitory domain of PRKCB could cause constitutive activation of PRKCB, 
which is known to mediate angiogenesis, immunity, fibroblast function, and adipogenesis 
(Wallace, Pitarresi et al. 2014). Therefore, targeted therapy using enzastaurin against 
PRKCB in patients harboring PRKCB fusions could be of benefit as precision treatment.   
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Importantly, we discovered a dozen fusion transcripts involving loss of epigenetic 
reader domains. For instance, MANF-SETD2 was identified in breast cancer, with the SET 
domain completely depleted upon fusion events, and with loss of SETD2, a histone-lysine 
N-methyltransferase that plays an important role in tumor progression and chemotherapy 
resistance through attenuation of DNA damage response in multiple cancers (Huang, 
McPherson et al. 2015, Kanu, Gronroos et al. 2015, Parker, Rose-Zerilli et al. 2016). As 
another example, ARID1B, a subunit of chromatin remodeling complex SWI/SNF, which 
function as tumor suppressor in human cancer (Aso, Uozaki et al. 2015), was identified with 
loss of ARID domains upon fusion to different gene partners. Therefore, both SETD2 and 
ARID1B fusions could serve as attractive biomarkers to predict clinical outcomes and stratify 
patients based on the presence of the involved fusions.  
In addition to the impact of fusion events on parental protein structure, post-
translational and co-translational modification sites on retained sequences of fusion proteins 
could regulate protein stability (e.g., by ubiquitination) or subcellular localization (e.g., N-
myristoylation) as well. We identified loss of ubiquitination sites at the N-terminal of 
oncogene NET1, a RhoA guanine nucleotide exchange factor that contributes to cancer cell 
motility and invasion (Carr, Zuo et al. 2013). The loss of ubiquitination sites confer the 
potential to promote NET1 activity by increasing its stability, as ubiquitin acts as a versatile 
cellular signal that governs various of biologic processes including transcription, DNA repair, 
endocytosis, protein degradation, autophagy, immunity and inflammation (Husnjak and Dikic 
2012). Fusion events altering ubiquitin binding sites adjacent to functional domains of 
parental proteins could trigger fundamental effects on their oncogenic properties.  
To our knowledge, the present study has produced the first repository of fusion 
genes identified in all major cancer types by unified criteria from RNA-Seq datasets 
(http://www.tumorfusions.org). Our study reflected the distinct genomic features of fusion 
composition in different cancer types and unraveled a series of common fusion hub genes 
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and fusion transcripts associated with potential tumorigenesis shared in multiple cancer 
types, including some less well-characterized fusion transcripts. Our findings not only build 
the foundation for clinical utility of various onco-fusion proteins but also facilitate thorough 
dive into the integrative molecular plateau driving cancers. Collectively, our findings could be 
instrumental to developing new prognostic and therapeutic strategies targeting onco-fusion 
proteins that have escaped from normal regulatory pathways in various tumor types. 
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CHAPTER 5 
Conclusions and future perspectives  
5.1 Summary   
In my dissertation, I have explored omics data and their clinical relevance in order to pave 
the way to precision medicine. Toward this goal, we performed studies through three 
aspects:1) We characterized how transcriptomic complexity was correlated with increased 
intra-tumoral heterogeneity and the contents of the tumor microenvironment, decoded  
cellular components contributing to the classification of GBM, and elucidated the clinical 
relevance towards therapeutic intervention in each subtype of the patients harboring distinct 
genomic patterns of both intrinsic tumor and infiltrated tumor microenvironments; 2) We 
identified gene signatures associated with inter-tumor heterogeneity and used this potential 
to stratify patients based on prognostic index in LGG; 3) We characterized fusion transcripts 
and their associated genomic features across different cancer types and identified some 
novel fusion events with oncogenic potential as diagnostic tools and/or therapeutic targets.  
 
5.2 Significance, pitfalls and perspective explorations  
5.2.1 Classification of glioma integrating transcriptomic profiling from both intrinsic 
tumor and infiltrated microenvironment 
Numerous studies have been carried out to elucidate the mechanism for radiation resistance 
of GBM. Some studies reported glioma cells undergoing Epithelial-Mesenchymal Transition 
(EMT) involving in GBM recurrence (Kubelt, Hattermann et al. 2015), while other studies 
reported only a subset of proneural GBM patient-derived glioma sphere cultures (GSCs) 
differentiated to MES state mediated by TNF-α/NF-κB, accompanied with CD44 
subpopulations showing enrichment for radiation resistant phenotypes (Bhat, 
Balasubramaniyan et al. 2013). These controversial findings led to our hypothesis that GBM 
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subtypes may change during tumor evolution. Is there an intrinsic transition from proneural 
to mesenchymal upon GBM recurrence, or do proneural & mesenchymal GSC co-exist 
within individual tumors and radiation-resistant Mes-like cells preferentially survive in 
recurrent cases and emerge as dominant populations? On the other hand, pathological 
examination revealed the neurosis exhibit higher content in mesenchymal subtype, yet no 
significant difference of overall survival between mesenchymal subtype and non-
mesenchymal subtypes, indicating other cellular components intertwined with mesenchymal 
signaling and phenotypic subtype, and differential expression of signature genes might 
reflect the molecular fluctuation signaling from both tumor and associated stromal or 
immune components. 
 To test this hypothesis, I dissected GBM intrinsic transcription phenotypes and their 
association with different cellular components of tumor immune environment, using RNA 
sequencing data derived from glioma patients and their derived glioma sphere cultures 
(GSC). I performed computational modeling on RNA sequencing data and integrated 
somatic mutation data to deconvolute the complex nature of stromal-tumor 
microenvironments and their association with established glioma subtypes. I also performed 
comparisons of molecular subtypes between matching primary and recurrent gliomas, and 
elucidated treatment-induced phenotypic tumor evolution. I found proneural to mesenchymal 
transitions occur only in a subset of GBM patients, while intra-tumoral heterogeneity acts as 
a predominant factor associated with subtype transition upon recurrence. Moreover 
decoding the components that infiltrate tumor microenvironment evolving different 
glioblastoma transcriptomic subtypes provided the rationale for more effective 
immunotherapy trials.  
 This study provided a more precise strategy to determine transcriptional subtype of 
GBM, revealed the tight association between intrinsic tumor transcriptome and dynamics of 
tumor-associated immuno-environment, and unraveled the essential contributions of 
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microenvironment to clinical outcomes. The alterations in cellular components of 
the immune system during GBM progression, such as reduced invading monocytes but a 
subtype dependent increase in M2 macrophages/microglia cells upon disease recurrence, 
implied that activated M2-macrophages may be potential targets for immunotherapy. Such 
therapies might include inhibition of macrophage recruitment, suppression of TAM survival, 
and blockage of M2-like tumor-promoting activity. Our work also sheds new light on how 
immune diversity in each patient contributes to inter-tumoral heterogeneity, which could 
explain the different responses to the same treatment regimen, indicating that therapeutic 
regimens should be determined through monitoring the state of both 
angiogenic and immune parameters in patients at different disease stages. In addition, this 
study has disputed the conventional wisdom that epithelial-to-mesenchymal transition (EMT) 
inducing signals drive glioblastoma progression in all subtypes and revealed that signaling 
from molecular classification is derived from complex mixed cellular traits rather than a 
single homogenous cell origin. Taken together this study has built significant foundation 
towards precision medicine through comprehensive characterization of transcriptional and 
cellular landscape of IDH wild type GBM during tumor evolution modulated by different 
treatments.  
Regarding future perspectives, given the significant contribution of tumor 
microenvironment to glioma-genesis and intra/inter tumor heterogeneity which is associated 
with clinical outcomes, I propose to develop novel immune/ stromal gene signatures to 
predict treatment response in GBM. In light of immune classification of GBM subtypes, I 
hypothesize that tumor subtypes are determined by two axes, inflammation and adaptive 
immunity, as shown in Figure 5.1. The tumor immunological environment contributes to 
clinical outcome along these two major axes, which could be applied to stratify tumor 
molecular subgroups. The adaptive anti-tumor immune response is associated with 
favorable outcomes, whereas pro-tumor inflammation leads to poor outcome. Therefore the 
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development of multiple markers regulated in different axes simultaneously is necessary to 
interpret the immune contexture of GBM and accurately predict prognosis and response to 
radio/chemo therapies. Characterization of interactions and crosstalk pathways between the 
immune system and bulk tumor will also facilitate targeting immunotherapeutic treatments. 
Developing computational modeling of single cell sequencing on specifically sorted cell 
types (based on cell surface markers) to discover signaling networks between cancer cells, 
stromal and immune cells involved in disease evolution and developing machine-learning 
and network analysis through single-cell transcriptomics profiling to decipher clonal 
evaluation and mechanisms mediating microglia/macrophage polarization to the 
immunosuppressive state in GBM.  
 
Figure 5.1 Clinically relevant transcriptomic subtypes determined by both inflammatory 
and adaptive immune components 
Transcriptomic predicted subgroups that correspond to GBM tumor based subtypes (proneural, 
classical, mesenchymal) are labeled in red rectangles. The smooth regression line and gray 
polygon represent the hypothetical trend of polarization of immune cells in tumor 
microenvironment. 
 
Taking advantage of single-cell technology, we could seek insights into unique 
subsets of immune cells that predict clinical outcomes, and sort out rare cell populations (i.e. 
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antigen-specific T cells) that confer protection or trigger the pathology of disease. We would 
then build system-level models to decipher the spatiotemporal and functional dynamics of 
intercellular interactions at single-cell resolution, so that we could evaluate the responses to 
antiangiogenic therapy in combination with immunotherapy. Based on the hypothesis that 
multipotent adipose-derived stromal cells (ASCs) could alter the tumor microenvironment in 
ways that facilitate the transition to more malignant status, I propose to qualify the ratio of 
stromal fibroblast to adipocytes, in order to predict the patients’ outcome based on their 
immune / stromal cell composition. As another arm of the project, we could quantify the 
intra-tumor heterogeneity based on single cell profiling of functionally distinct cell types in 
tumor associated microenvironment infiltration (TAM).  
 
5.2.2 Identify gene signatures associated with clinical outcomes in low grade glioma  
Given 1p/19q codel cohort only account for a small proportion of all intracranial gliomas in 
adults and  those patients usually exhibit prolonged survival with censored data (Figure 5.2), 
I have searched all over the public datasets to retrieve seven individual datasets of glioma 
with 1p/19q codel where both survival and gene expression data are available. Since the 
distributions of overall survival and death rates vary largely from one dataset to another, and 
are further confounded with measurement using different platforms including microarray and 
RNA-seq, different treatment options from different eras, combinations of two or three 
independent datasets failed to produce sufficient training data for penalty based feature 
selection or validation by standard Cox models.  
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 Figure 5.2 Subtype-specific molecular alterations and distinct clinical presentations in 
Lower-Grade Gliomas (LGG)  
The numbers of patients in each molecular subtype are shown. The molecular alterations and 
associated disease grade are shown on the right.    
(Cited from Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas  
The New England Journal of Medicine    June 25, 2015 vol. 372 no. 26) 
 
In order to accommodate the heterogeneous nature of the datasets and the limited 
number of events in some datasets, I have combined five major datasets through scaled 
normalization to reduce the batch effects, then I split the combined dataset evenly through 
random sampling so that the distributions of survival, treatment options, grade, age are 
similar for training and validation datasets respectively. First I used the training dataset 
(n=164) to perform feature selection applying the Elastic Net (3 fold cross-validation using 
glmnet), a regularized Cox model that is a robust hybrid of lasso and ridge regressions), 
then I made predictions for the validation dataset (n=170). The resulting C-index derived 
from gene signatures is similar to that from age and grade, with the hazard ratio (HR) for 
each gene predictor ranging between 0.5-1.5. I have assessed the linear correlation of each 
predictor and overall survival and found the effect of alteration of each gene expression on 
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overall survival is little, (Figure 5.3) indicating the individual predictors are weak, while the 
C-index is generated by the cumulative power of the entire gene signature (n=35).         
 
Figure 5.3 Partial plots for gene predictors from codel glioma  
The values on the y- axis represent the expected number of deaths for a given predictor, after 
adjusting for all other predictors. The values on the x-axis represent the relative gene expression 
values of each predictor. The red solid lines represent LOESS curves fitting gene expression 
versus death rate. 
 
In an attempt to develop an optimized gene signature, I have also explored different 
methods for feature selection through modeling the association of gene expression with 
overall survival, including L1 based feature selection (LASSO), Support Vector 
Machine (SVM), ensemble method (Survival Ensembles), Random Survival Forest 
(randomForestSRC) where ensemble estimates are derived for the cumulative hazard 
function, and Model-Based Boosting methods (Likelihood-based boosting for Cox 
models: CoxBoost). In ensemble algorithms, bagging process construct several instances of 
black-box estimators based on random sampling from training set and then aggregates each 
individual prediction into a final prediction. The goal is to make an ensemble by introducing 
randomization into its itinerary construction process and reduce the variance of decision tree 
as base estimator. Amongst these exploratory methods, LASSO outperforms the other 
methods through simultaneous estimation and variable selection, boosting exhibits 
intermediate performance, whereas Ensemble models generate poor predictions. The 
plausible explanation in terms of overfitting reduction is, bagging methods perform the best 
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on complex but strong models (fully developed decision trees), whereas boosting methods 
usually fit better with weak models. Of note, there is high overlap of top significant genes 
selected by the different methods, suggesting the selected gene signature is robust to 
certain extent. In addition, I combined two independent datasets to validate the predictive 
power of the gene signature. Though not significant due to extremely small sample sizes, 
there is a distinct trend between high and low risk groups based on their prognostic index.          
Interestingly my investigation revealed that some of these signature genes are 
associated with inflammatory response revealed by corresponding GO terms mapped to the 
signature genes. Moreover, I calculated the estimate score for each sample to infer their 
content of infiltrated immune signal and stroma components and found estimated scores in 
the high risk group are significantly higher than those in the low risk group. The risk scores 
deduced for each patient are positively correlated with their estimate scores, plus some 
selected signature genes are overlap with immune and stroma signature applied in 
ESTIMATE, suggesting inflammation and immune signal might contribute to increased risk 
in these patients. This is the first study tackling the source of heterogeneity in codel glioma 
patients.  
In terms of future directions, I will apply backward selection to reduce the number of 
signature genes to further reduce overfitting and the complexity of the model. I will fit a Cox 
model with current gene signatures, then dropped the least significant genes at some critical 
level, repeating the process by successively re-fitting reduced models and applying the 
same critical level until all remaining signature genes are statistically significant. I will also 
apply the adaptive lasso to fine-tune the gene signature selection process, where adaptive 
weights are used for penalizing different coefficients in the L1 penalty. Finally, I will look for 
newly generated datasets for independent validations of the potential predictions for 
application in clinical settings in the future.  
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5.2.3 Characterize distinct genomic patterns of fusion transcripts and identify novel 
fusion events conferring oncogenic potential in pan-cancers  
By investigating fusion transcripts of 33 different tumor types using TCGA RNAseq data, I 
have observed a large variance of fusion occurrence rates across fusion genes with distinct 
genomic features and cancer types. By integrating with multi-dimensional TCGA data, 
including WGS, WES and SNP array data, we have annotated a subset of fusion transcripts 
supported by corresponding structure variants in a gnomically coordinated manner. My 
study revealed common and diverse fusion spectrums with hotspot fusion events across 
different tumor types. We found a peak enrichment of fusion transcripts at 12q in sarcomas, 
which is coincident with structure variants and copy number alterations. The majority of 
fusion transcripts are associated with translocation at their adjacent regions followed by 
deletion, duplication and inversion.       
I have also explored the functional predictions on the fusion transcripts involving 
kinase activity, chromatin remodeling and post-translational modifications, demonstrating 
the potential functional relevance of transcripts in diverse biological and malignant contexts 
and nominating a set of novel fusion transcripts such as PDGFRB-USP8, MANF-SETD2, 
GGA2-PRKCB, etc with predicted functional associations for further study. This study will 
improve our understanding of fusion transcripts and their correlated genomic features, the 
oncogenic potential and perturbed pathways triggered by fusion transcripts, which will 
facilitate translational efforts in therapeutic target discovery and diagnostic tool development. 
The fusion database and annotation generated from this analysis are uploaded for public 
access. TCGA Fusion Gene Data Portal (www.tumorfusions.org). 
Since there is a distinct correlation between recurrent gene fusions and specific 
cancer types, we could develop the fusion gene detection for common tumor subtype 
screening, which will provide a roadmap for precision therapies. Some of the novel fusion 
transcripts identified in this study act as important drivers of malignancy, so they could serve 
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as potentially diagnostic markers in the clinical setting. These include recurrent fusions in 
PTPRK-RSPO3, TFG-GPR128 in READ, UBTF-MAML3 in PCPG, etc. In addition, this study 
provided integrative annotation of gene fusions associated with both balanced and 
unbalanced chromosomal rearrangements, as well as their association with copy number 
alterations, which lay the foundation for unraveling the complex nature of genomic structural 
aberrations. Collectively the fusion database detected from the world’s largest sample size 
and tumor types in uniform platform revealed fusion transcripts with clinical potential that 
have not been reported as yet. 
Regarding future directions, I will further explore the genomic features of hotspot 
fusion transcripts and elucidate the plausible elements that make those loci prone to fusion 
formation. I will also identify the fusion transcripts that trigger transcriptional alterations of 
their target genes by trans/cis-regulation. I will scan the fusion transcripts with gain or loss of 
sumoylation loci that are analogous to ubiquitination. I will decode the fusion genes that 
mediate rewiring of protein-protein interaction (PPI) networks in different cancer types, to 
address whether and how fusion transcripts disrupt the interactive networks, alter the 
regulatory sites and rewire the signaling that associated with tumor genesis. Collectively I 
will generate a comprehensive landscape revealing the molecular principles and 
heterogeneous patterns of fusion events across different types of cancers and their clinical 
association, with a subset of fusion transcripts as the classifier to stratify the patients.  
Insight into molecular heterogeneity, environmental risk factors, tumor plasticity and 
crosstalk between tumor and their associated microenvironments have laid the foundation 
towards potential novel strategies for early detection and efficacy therapy, while further 
basic and translational investigation to address heterogeneous nature and dynamics of 
cancer evolution are required. This will lead my study to dive into a promising continuation of 
efforts from the current thesis and demonstrate the contribution of my Ph.D. work to a series 
of biological and therapeutic perspectives towards precision medicine. 
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Supplementary Tables  
Table S4.1 Number of TCGA samples in 33 cancer types  
Cancer Tumor Normal 
ACC 79 0 
BLCA 414 19 
BRCA 1119 113 
CESC 306 3 
CHOL 36 9 
COAD 309 0 
DLBC 48 0 
ESCA 185 13 
GBM 170 5 
HNSC 522 44 
KICH 66 25 
KIRC 541 72 
KIRP 291 32 
LAML 179 0 
LGG 534 0 
LIHC 374 50 
LUAD 541 59 
LUSC 502 51 
MESO 87 0 
OV 428 0 
PAAD 179 4 
PCPG 184 3 
PRAD 502 52 
READ 95 10 
SARC 263 2 
SKCM 472 1 
STAD 414 37 
TGCT 156 0 
THCA 513 59 
THYM 120 2 
UCEC 185 24 
UCS 57 0 
UVM 80 0 
sum 9951 689 
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Table S4.2 Number of fusions filtered by each step in 33 cancer types  
Cancer Raw E.value > 0.001  PGV > 10 TAF > 0.01 No detection in normal 
ACC 448 394 335 247 240 
BLCA 2386 1971 1930 1159 1122 
BRCA 8460 6306 5413 4170 4060 
CESC 1242 900 790 445 426 
CHOL 103 83 83 64 61 
COAD 809 472 461 340 307 
DLBC 107 61 61 45 44 
ESCA 691 439 439 374 367 
GBM 684 360 360 295 289 
HNSC 5156 3959 1520 770 730 
KICH 190 137 125 57 47 
KIRC 1045 602 447 291 271 
KIRP 715 528 371 206 185 
LAML 279 174 174 127 112 
LGG 2277 1909 1367 851 785 
LIHC 2764 2154 1257 761 753 
LUAD 3551 2712 1962 1481 1451 
LUSC 3584 2531 2008 1426 1356 
MESO 445 208 197 141 136 
OV 790 675 675 419 416 
PAAD 989 482 378 201 192 
PCPG 532 473 225 125 119 
PRAD 4096 3361 2026 1441 1412 
READ 330 207 207 148 132 
SARC 3946 2906 2372 1764 1751 
SKCM 3844 3273 1869 1195 1170 
STAD 1313 960 946 784 768 
TGCT 311 155 144 101 82 
THCA 3094 2726 481 206 143 
THYM 169 96 96 58 55 
UCEC 1191 1004 981 787 780 
UCS 579 497 478 389 385 
UVM 78 57 57 37 33 
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